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ABSTRACT 
The purpose of this study was to explore and describe the determinant factors affecting 
adherence to antiretroviral therapy among HIV infected patients in Addis Ababa, Ethiopia. 
A cross-sectional study design was used and data were collected by interviewing 290 study 
participants from two health facilities using structured questionnaire. The research finding 
revealed 80.0% of the study participants had optimal combined adherence to dose, 
schedule and dietary instructions in the past three days. And, the non adherence rate was 
20.0%. In multivariate analysis only WHO clinical stage, change of ARV medication, 
knowledge about HIV disease and ART, and use of reminders were found to be 
independently associated with adherence to antiretroviral therapy. The most common 
reasons for missing HIV medications in the past one month were forgetfulness (35.1%), 
being busy with other things (17.5%), and running out of pills (10.5%). Adherence 
improving interventions should be emphasized to address multi-faceted problems. This 
study recommends setting of convenient appointment schedule, disclosure of one's HIV 
status, maintaining confidentiality of patient-related information, enhancing patient-provider 
relationship, use of reminders including SMS text messages, and engagement of PLHIV in 
adherence improving interventions through peer support, and providing regular health 
education to the PLHIV to improve adherence of patients to ART. 
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CHAPTER 1 
ORIENTATION TO THE STUDY 
1.1 INTRODUCTION 
This chapter of the study provides the general overview of the research problem, research 
purpose and objectives, significance of the study, demarcation of field of study, foundations 
of the study, research design and method, scope and limitation of the study, and ethical 
considerations. 
1.1.1 Global status of HIV/AIDS epidemic 
The emergence of the HIV epidemic is one of the biggest public health challenges the 
world has ever seen in recent history. In the last three decades HIV has spread rapidly and 
affected all sectors of society: young people and adults, men and women, and the rich and 
the poor (FHAPCO 2012:1). Globally, a total of 35.3 (32.2-38.8) million people were 
estimated to be living with HIV in 2012. This increase was partly related from the increased 
number of people receiving life-saving antiretroviral therapy. During the year, around 2.3 
(1.9-2.7) million new HIV infections occurred, showing a 33% decline in the number of new 
infections from 3.4 (3.1–3.7) million in 2001. At the same time the number of AIDS deaths 
is also declining with 1.6 (1.4–1.9) million AIDS deaths in 2012, down from 2.3 (2.1–2.6) 
million in 2005 (UNAIDS 2013:4). The decline in mortality has been related to the 
increased availability of antiretroviral therapy, as well as care and support, to people living 
with HIV, particularly in middle- and low-income countries. Besides, it results from the 
decreasing tendency in the incidence of HIV infection starting in the late 1990s. The effects 
of antiretroviral therapy are by large evident in Sub-Saharan Africa, where an estimated 
320,000 (or 20%) HIV infected people died of AIDS-related causes in 2009 than in 2004, 
when antiretroviral therapy began to be dramatically expanded (UNAIDS 2010:19). 
 
1.1.2   HIV/AIDS epidemic in Sub-Saharan Africa 
Sub-Saharan Africa continues to bear a disproportionate share of the global HIV burden. 
Recent reports indicated that about 68% of all people living with HIV resided in Sub-
Saharan Africa in mid-2010. The total number of people living with HIV in sub-Saharan 
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Africa increased to 22.9 million in 2010 which was 12% more than in 2001. Reports 
indicate that more women than men are living with HIV in 2010, in which women comprised 
59% of the people living with HIV in the region (WHO/UNAIDS/UNICEF 2011:24). Although 
the epidemics seem to vary considerably in different parts of the continent; HIV/AIDS 
severely affected the southern Africa countries (UNAIDS 2010:28).  
In general, the HIV incidence rate in SSA seems to decline progressively comparing to the 
earlier period. Reports indicated only 1.9 million people were HIV infected in 2010 which 
was 16% fewer than the estimated 2.2 million people newly infected with HIV in 2001 and 
27% fewer than the annual number of people newly infected between 1996 and 1998, 
when the incidence of HIV in sub-Saharan Africa peaked overall (WHO/UNAIDS/UNICEF 
2011:11). This trend reflects a combination of factors, including the impact of HIV 
prevention efforts and the natural course of HIV epidemics (UNAIDS 2010:16). However,  
still enormous effort and needs required to further curb the incidence of HIV and its public 
health impact in the future especially in SSA. 
With regards to the mortality, AIDS has claimed the lives of a large number of nations in 
Sub-Saharan Africa since 1998. Data showed that the estimated number of people dying 
from AIDS related illnesses was 1.2 million in 2010 which was 29% fewer than in 2005. 
The number of people dying from AIDS-related causes has steadily decreased due to 
wider availability of free antiretroviral therapy in the region (WHO/UNAIDS/UNICEF 
2011:25). 
 
1.1.3   HIV/AIDS epidemic in Ethiopia 
Ethiopia is one of the countries significantly affected by HIV and AIDS epidemic in Sub- 
Saharan Africa. HIV infection was initially recognized in the early 1980s with the first two 
AIDS cases reported in 1986. Since then, the epidemic has rapidly spread throughout the 
country and peaked in the mid-1990s (FHAPCO/FMOH 2010:2). According to HIV/AIDS 
estimates and projections in Ethiopia, the national adult HIV prevalence was estimated at 
1.3% in 2012. This revealed that around 759,268 people were estimated to be living with 
HIV in the country. For the same period, there were an estimated 41,444 deaths occurred 
due to AIDS in 2012 (HIV/AIDS estimates & projections... 2013). The number of AIDS-
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related deaths would have been much higher had it not been for the free Anti-Retroviral 
Therapy (ART) program which has been scaled-up in an accelerated manner since 2005. 
With the current status, it is evident that HIV and AIDS remains a formidable development 
challenge to the country (FHAPCO/FMOH 2010:2). 
Similar to other SSA countries, the epidemic tends to be heterogeneous. There has been 
wide variation in HIV prevalence among different administrative regions, and between 
urban and rural settings. For instance, according to the Ethiopian Demographic and Health 
Surveys HIV prevalence in the country ranges from 0.9% in SNNPR and 1.0% in Oromiya 
region to 5.2% in Addis Ababa and 6.5% in Gambella region in 2011 (FHAPCO 2012:14). 
 
1.2     BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
1.2.1 The source of the research problem  
Free antiretroviral treatment has been provided to people living with HIV in many of the 
health facilities in Ethiopia since 2005. The number of patients receiving ART has 
remarkably increased from time to time with rapid scale up of ART program throughout the 
country. It has been emphasized that for patients on antiretroviral therapy to benefit 
maximally at least 95% of adherence to their prescribed medications needs to be achieved. 
This indicates that adherence of patients is very crucial element in the scale up and 
implementation of ART program in resource limited settings like Ethiopia. In a routine 
clinical practice of ART clinics in Ethiopia maintaining high level of adherence to 
antiretroviral treatment has been a challenge to health care providers as well as the ART 
program. Besides, in many areas of the country the number of lost to follow up patients is 
high in the health facilities and it is commonly observed that patients do not adhere to their 
prescribed antiretroviral medications for different reasons. According to the report of 
FHAPCO, the total number of ever started clients on antiretroviral treatment had reached to 
52,585 in Addis Ababa by the end of February 2010. Among these 32,279 clients were 
found to be currently receiving antiretroviral treatment (Monthly HIV care and ART update 
2010). The level of adherence to antiretroviral therapy of HIV infected patients and 
determinant factors affecting their adherence have not been well studied in health facilities 
in Addis Ababa.  
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1.2.2 Background of the research problem 
With the introduction of ARV drugs, AIDS has been changed in to a treatable chronic 
disease. Even in a resource constrained setting with increasing people with AIDS 
accessing services, a decline in death rates has become clearly visible.  In Ethiopia, the 
public health approach has been an overarching principle of the ART program which is 
actually recommended by WHO for resource-poor settings. By this approach, large 
numbers of people has been able to access ART and survival is maximized (FMOH 
2008:46-47). Free access to antiretroviral therapy was launched in Ethiopia in January 
2005 in hospitals and rapidly expanded to the health centres in 2006 (FMOH 2007:10). In 
order to ensure universal access great effort has been made in decentralization of 
comprehensive HIV care and treatment services including antiretroviral therapy to hospitals 
and health centres throughout the country. However, with rapid expansion of ART service 
the issue of adherence of patients has increasingly become a serious challenge. 
1.2.2.1 Adherence to ART 
The WHO (2006:78) states that adherence to ART has been recognized as an essential 
component of individual and programmatic treatment success. Higher level of adherence 
greater than 95% is necessary to get the best outcome out of antiretroviral treatment. 
Studies on drug adherence in the developed world demonstrated that higher levels of drug 
adherence are associated with improved virological, immunological and clinical outcomes. 
Adherence to antiretroviral therapy has also been documented as the second strongest 
predictor of progression to AIDS and death, after CD4 count in PLHIV receiving treatment 
(Machtinger & Bangsberg 2006). Nonetheless, adherence creates a special challenge and 
requires commitment from the patient and the health care team since HIV treatment is a 
lifelong endeavour and patients may be initiated on treatment while they are healthy and 
even they get better with treatment (Panel on antiretroviral guideline... 2009:111).  
Although near perfect adherence is required for better and long term clinical benefits, 
incomplete adherence prevails in all groups of treated individuals. The average rate of 
adherence to ART remains approximately 70% (Machtinger & Bangsberg 2006). The 
concern of suboptimal adherence especially was recognized as a major obstacle to scale 
up of antiretroviral therapy in resource limited settings due to the risk of development of 
drug resistant strains and transmission to the population (Sarna, Pujari, Sengar, Garg, 
Gupta & Van Dam 2008:28-29).  The continuity of HIV treatment is also emphasized in 
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terms of maximizing the efficacy, extending the period patients spend on the first-line ART 
regimen, and reduce the risk of developing drug resistance and treatment failure 
(Nakanjako, Colebunders, Coutinho & Kamya 2009:185-186). For instance, since the 
inception of large scale ART access early in this decade, ART programs in Africa have 
retained about 60% of their patients at the end of two years, with loss to follow-up as a 
major cause of attrition, followed by death. The percentage of loss to follow-up varies 
widely across programs and ranges from 3.7 to 44% in resource limited settings 
(Nakanojako et al 2009:185). Therefore, greater attention should be given to ensure 
improved patient retention in ART programs as well as enhancing their adherence 
behaviour for ultimate benefit of the population in general and HIV infected patients in 
particular. 
1.2.2.2 Factors affecting adherence 
A number of factors have been identified to be associated with non adherence to ART. The 
factors associated with medication adherence are categorized in to five: patient related 
variables, treatment related factors, disease characteristic, patient-provider relationship 
and clinical setting. Understanding these factors help to identify adherence at risk 
individuals as early as possible and inform the development of interventions to improve 
adherence (Machtinger & Bangsberg 2006). 
 
Various studies have been conducted about adherence of patients to ART both in 
developed and developing countries. In the meta-analysis of adherence to antiretroviral 
therapy in Sub-Saharan Africa and North America indicated a pooled estimate of 55% of 
the populations in North America and 77% of the populations in Africa found to achieve 
adequate levels of adherence (Mills, Nachega, Buchan, Orbiniski, Attaran, Singh, Rachlis, 
Wu, Cooper, Thabane, Wilson, Guyatt & Bangsberg 2006a:679). In Ethiopia there have 
been few studies conducted to assess the magnitude of adherence to ART and its barriers. 
The level of adherence to ART seems to vary across different settings and contexts. The 
literature review section discussed the findings of the studies in different contexts in detail. 
There have been limited studies conducted on the magnitude of adherence and 
determinant factors that affect adherence to antiretroviral therapy in Adult patients in Addis 
Ababa. 
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1.2.3 Statement of the problem 
Adherence to antiretroviral therapy has been found as a major challenge in the treatment of 
HIV infected patients both in developed and developing countries. The rate of adherence of 
patients to ART varies in different settings. A meta-analysis of adherence levels found that 
a pooled estimate of only 77 percent of people taking antiretroviral medications in sub-
Saharan Africa adhered to the regimen (Mills et al 2006a:679). Studies suggested that sub-
optimal adherence to antiretroviral therapy will lead to increased risk of dug resistance, 
treatment failure and clinical deterioration with increased risk of death (Enriquez & 
Mckinsey 2011:46). Adherence of patients may be affected by various factors as 
mentioned in the literature. People living with HIV on antiretroviral therapy in Ethiopia may 
also suffer from multiple factors that could compromise their adherence as in other 
resource limited settings. There have been limited studies conducted in Addis Ababa to 
reveal the magnitude of adherence of HIV infected adult patients receiving antiretroviral 
therapy and determinant factors that could influence their adherence.  Besides, the 
variation in the level of adherence overtime may necessitate evaluating about adherence of 
patients periodically in order to inform adherence interventions. In light of this, this 
particular study was conducted to investigate the determinant factors affecting adherence 
to antiretroviral therapy among adult patients infected with HIV in Addis Ababa. 
1.3   AIM OF THE STUDY 
The aim of this study was to contribute to existing body of knowledge with regard to the 
magnitude of adherence of HIV infected adult patients to antiretroviral treatment and 
determinant factors affecting adherence in the context of Ethiopian setting. 
1.3.1 Research purpose 
The purpose of this study was to explore and describe the determinant factors affecting 
adherence to antiretroviral therapy among HIV infected adult patients in Addis Ababa, 
Ethiopia. 
1.3.2 Research objectives 
The objectives of the study were to: 
 describe the level of adherence of HIV infected adult patients to antiretroviral  
therapy in Addis Ababa; 
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 explore the determinant factors that could affect patients‟ adherence to their 
antiretroviral therapy; 
 identify the association of socio-demographic and other patient related factors with 
the level of adherence; and 
 recommend appropriate interventions with regards to ways of improving adherence 
of patients based on the research finding. 
1.4 SIGNIFICANCE OF THE STUDY 
Different studies in African context indicated that there is a deficit in the level of adherence 
of patients to ART and multiple factors have been mentioned to contribute to the existing 
gap. This study provides knowledge on the level of adherence of HIV infected adult 
patients and understand the potential barriers to optimal adherence in Ethiopian context. 
Moreover, it provided important information with regard to aspects of adherence and 
forwarded recommendations to health care providers, health facilities and policy makers in 
enhancing the implementation of ART program and development of evidenced-based 
interventions to improve adherence to antiretroviral therapy. This study benefits the clients 
directly or indirectly through provision of appropriate and relevant information to the 
patients and their health care providers about the pervasiveness of non adherence and 
contribute to help them understand the need for patients to play active role in achieving the 
maximum required adherence level with due emphasis on the focus areas of improving 
adherence. 
1.5 DEMARCATION OF FIELD OF STUDY 
The research was conducted in Addis Ababa, which is a capital city of Ethiopia. Ethiopia is 
the tenth largest country in Africa, bordered by Eritrea in the north and northeast, by 
Djibouti and Somalia on the east, by Kenya in the south, and by Sudan in the west and 
southwest. It is a country with great geographical diversity and its topography shows a 
variety of contrasts ranging from high peaks of 4,550m above sea level to a low depression 
of 110m below sea level (FMOH 2010:1).  
 
The Federal Democratic Republic of Ethiopia is composed of nine Regional States: Tigray, 
Afar, Amhara, Oromia, Somali, Southern Nation Nationalities and Peoples Region 
(SNNPR), Benishangul-Gumuz, Gambella, and Harari; and two City Administrations 
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council of Dire Dawa and Addis Ababa (FMOH 2010:2). The administrative regions of 
Ethiopia are clearly demarcated in the following map. 
 
 
(Source: Adapted from: http://www.mapsofworld.com ) 
Figure 1.1 Map of administrative regions of Ethiopia 
According to the projections from the 2007 population and housing census the total 
population of Ethiopia for the year 2010 is estimated to be 79.8 million. The country is 
among the least urbanized countries in the world with 83.6% of the total population living in 
rural areas whilst 16.4% living in urban areas. And, Addis Ababa which is the largest city in 
the country estimated to have a total population of 2.7 million, accounting for nearly 4% of 
the entire population (FMOH 2010:1). The pyramidal age structure of the population has 
remained predominately young with 44% under the age of 15 years, and over half (52%) of 
the population lies in the age group of 15 and 65 years. The population in the age group of 
over 65 years accounts for only 3% of the total. While the sex ratio between male and 
female is almost equal, women in the reproductive age group constitute 24% of the 
population (FMOH 2010:1).  
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1.6 DEFINITIONS OF TERMS 
1.6.1 Adherence 
Adherence is defined as „‟the extent to which a person‟s behaviour – taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider‟‟ (WHO 2003:3). In the context of this study 
optimal adherence to antiretroviral therapy refers to taking at least 95% of ARV 
medications at appropriate schedule and in accordance with instructions of dietary 
requirement in the past three days as prescribed by health care providers. While, sub 
optimal adherence to antiretroviral therapy refers to taking less than 95% of prescribed 
ART medications by people living with HIV/AIDS and/or not taking the medications at the 
right time and/or not following instructions to dietary requirements provided by health care 
providers in the past three days. 
 
1.6.2 Highly active antiretroviral therapy (HAART)  
It refers to the complex medical regimens of therapies directed against HIV that are likely to 
stop its replication and mutation (Bartlett & Finkbeiner 2006:349). In the context of the 
study the HAART entails a combination of ARV drug regimen used to treat patients 
infected with HIV based on the Ethiopian national guideline recommendations. 
 
1.6.3 Determinant factors  
It refers to correlates and predictors of adherence and non adherence. These include 
aspects of the complexity and duration of treatment, characteristics of the illness, iatrogenic 
effects of treatment, costs of treatment, and characteristics of health service provision, 
interaction between practitioner and patient, and socio-demographic variables (WHO 
2003:137). In the context of this study the determinant factors referred to those inter-
connected patient related variables, treatment related factors, disease characteristics, 
aspects of patient-provider relationship and clinical setting that may affect the adherence of 
HIV infected adult patients receiving antiretroviral therapy. 
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1.7 FOUNDATIONS OF THE STUDY 
1.7.1 Metatheoretical assumptions 
The researcher opted to conduct the study under the metatheoretical assumptions of 
positivism. The assumption of positivism is that there is a reality out there that can be 
studied and known. It values objectivity and attempt to hold personal beliefs and biases in 
check to avoid contaminating the phenomena under study. This scientific approach 
involves using orderly, disciplined procedures with tight controls of the research situation to 
test researchers‟ hunches about the phenomena being studied and relationships among 
them (Polit & Beck 2012:12). 
The researcher conducted the study with an assumption that all HIV infected adult patients 
taking antiretroviral therapy are not able to achieve >95% adherence level in resource 
limited settings like Ethiopia. Various factors have been mentioned to interfere with proper 
adherence of patients to their medications. Thus, this study empirically measured the level 
of adherence and explored the determinant factors affecting adherence of HIV infected 
patients receiving antiretroviral treatment. 
1.7.2 The conceptual framework 
A framework is the overall conceptual underpinnings of a study. If a study is based on a 
theory, the framework is referred to as the theoretical framework; while a study that has its 
roots in a specified conceptual model, the framework is often called the conceptual 
framework although the terms conceptual framework and theoretical framework are 
frequently used interchangeably (Polit & Beck 2012:128).  
The factors associated with medication adherence are commonly divided into five 
intersecting categories. These include patient related variables, factors related to treatment 
regimen, disease characteristic, patient-provider relationship and clinical setting 
(Machtinger & Bangsberg 2006). In view of these inter-related factors the researcher 
adopted a conceptual framework developed by Gellad, Grenard and McGlynn (2009:5-6) 
for reviewing barriers to medication adherence. The conceptual framework helped to guide 
the literature review and the accomplishment of the research. The model constitutes the 
interaction of patient related factors, health system related factors and providers factors to 
influence the adherence behaviour of patients. The conceptual framework of the study was 
illustrated in the diagram depicted below. 
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Figure 1.2 Conceptual framework of the study 
(Source: Adapted from Gellad et al (2009:6)) 
Patient Factors: Patients are influenced by each of the following factors as demonstrated in 
the above figure. Illness representation includes important elements of health beliefs, 
including beliefs about medications (both positive and negative) and knowledge about 
illness and treatment.  
Cognitive function includes comprehension and memory. Demographics include age, 
gender, and ethnicity, as well as health literacy, and unstable living situations. Coexisting 
illness includes medical and psychiatric conditions, as well as alcohol use and smoking. 
Medication characteristics include regimen complexity, number of medications, and side-
effect profiles (Gellad et al 2009:5). 
Health-System Factors: In addition to cost (specifically, the effect of cost-sharing and out-
of-pocket costs on patient adherence), health-system factors include formularies, prior-
authorization requirements and benefit caps, fragmentation of care, and access to care 
(Gellad et al 2009:6). 
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Provider Factors: These include patient-provider trust and satisfaction; time spent 
discussing medications, and other communication issues (Gellad et al 2009:6). Also 
confidentiality issue and support in helping patients in taking their medications was also 
addressed. 
 
The determinant factors that influence adherence of patients were discussed in detail in the 
literature review section. 
1.8 RESEARCH DESIGN AND METHOD 
1.8.1 Research design 
According to Joubert and Ehrlich (2007:77) a study design refers to the structured 
approach followed by researchers to answer a particular research question. It has been 
called the „architecture‟ of the study, because the choice of the study design determines 
how we sample the population, collect measurements and analyse the data. Burns and 
Grove (2005:40) also describes a research design as a blue print for the conduct of a study 
that maximizes control over other factors that could interfere with the study‟s desired 
outcome. There are numerous types of research design that are appropriate for the 
different types of research projects. The choice of which design to apply depends on the 
nature of the problems posed by the research aims. Each type of research design has a 
range of research methods that are commonly used to collect and analyse the type of data 
that is generated by the investigations (Walliman 2011:9). 
The researcher followed an observational, analytic, cross-sectional study design to conduct 
this particular study.  
1.8.1.1 Quantitative study 
Quantitative research is a formal, objective, systematic process in which numerical data 
are used to describe variables, examine relationships among variables, and determine 
cause and effect interactions between variables (Burns & Grove 2005:747).  
Fouché and Delport in De Vos et al (2005:73) also describe quantitative approach as 
follow: 
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 The researcher‟s role is that of an objective observer whose involvement with the 
phenomena being studied is limited to what is required to obtain necessary data. 
 Studies are focused on relatively specific questions or hypotheses that remain 
constant throughout the investigation. 
 Plans about the research procedures – design, data collection methods, types of 
measurement and so on – are developed before the study begins. 
 Data collection procedures applied in a standardised manner 
 Data collectors are expected to obtain only the data called for and to avoid adding 
their own impressions or interpretations. 
 Measurement is normally focused on specific variables that are, if possible, 
quantified through rating scales, frequency counts and other means. 
 Data analysis proceeds by obtaining statistical breakdowns of the distribution of 
variables and by using statistical methods to determine associations (or differences) 
between variables. 
1.8.1.2 Analytical study design 
The analytical study design is used to figure out the causes of or risk factors for a disease 
by assessing whether particular exposures are related to diseases and other health 
outcomes. Thus, it entirely focuses on examining associations rather than just describing 
how much outcome of interest available (Joubert & Ehrlich 2007:78). In this study the 
researcher carried out statistical analysis to determine a relationship between dependent 
and independent variables. 
1.8.1.3 Cross-sectional study design 
Cross-sectional designs involve the collection of data at one point in time: the phenomena 
under study are captured during one period of data collection. They are appropriate for 
describing the status of phenomena or for describing relationships among phenomena at a 
fixed point in time. They are relatively easy and economical to conduct (Joubert & Ehrlich 
2007:87; Polit & Beck 2012:184). In this study the researcher used a cross-sectional 
design to describe the level of adherence of adult HIV infected patients on antiretroviral 
therapy and explore factors that affect adherence to treatment during the specified data 
collection period. 
14 
 
1.8.2 Research method 
Research methods are the techniques that researchers use to structure a study and to 
gather and analyze information relevant to the research question (Polit & Beck 2012:12). 
The researcher systematically described about the research methods that were applied 
during conduct of the study. These included defining the study population and selecting 
sample, determining the sample size, data collection process and data analyses. 
 
1.8.2.1 Study population and sample selection 
When conducting a study, it is important to define clearly the group about which we want to 
gather information and draw conclusions. This group, called the study population, should 
be clearly defined in respect of person, place and time, as well as other factors relevant to 
the study (Joubert & Ehrlich 2007: 94). 
The study population for this study were eligible HIV infected adult patients on antiretroviral 
therapy attending ART clinic in the selected health facility in Addis Ababa. Eligible patients 
were screened by the inclusion criteria of age >18 years, on antiretroviral therapy for at 
least three months, be able to provide consent and not involved in the pilot study.  
1.8.2.2 Sample  
Sampling defines the process for selecting a group of people with which to conduct a study 
(Burns & Grove 2005:41). The researcher used systematic sampling which is one of the 
probability sampling methods to determine the sample selection process. Probability 
sampling methods have been developed to ensure some degree of precision in estimation 
of the populations parameters, thus reduce sampling error (Burns & Grove 2005:365). In 
this research the study participants were selected using the ordered list patients on ART 
based on their unique ART identification numbers which was generated from computer 
data base.  
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1.8.2.3 Sample size 
Using a precision of 5% and 95% confidence interval the sample size was determined by 
the formula,  
N= p (1-p) z2 / d2;  
Where, p = estimated proportion of patients adherent to ART,  
 z = the cut off value of the Normal distribution and  
 d = the precision required on either side of the proportion.  
Considering lost to follow up, transfer out, death and non-willingness, 10% of the sample 
size was added to the total sample size. A pooled estimate of adherence to antiretroviral 
therapy in Sub-Saharan Africa was found to be 77% (Mills et al 2006a:679). Therefore, the 
total sample size for this study was 300 using a precision of 5% and 95% confidence 
interval. 
1.8.2.4 Data collection  
The researcher proceeded to data collection process after securing ethical clearance and 
permission from the health studies department at UNISA, Addis Ababa regional health 
bureau and the management of the health institutions. A data collection is the precise, 
systematic gathering of information relevant to the research purpose or the specific 
objectives, questions or hypothesis of a study (Burns & Grove 2005:42). In this particular 
study data were collected by interviewing study participants using a structured 
questionnaire. The questionnaire was piloted in a small group of HIV positive individuals on 
antiretroviral therapy before commencing on actual data collection. A pilot study is a small-
scale version or trial run designed to test the methods to be used in a larger, more rigorous 
study (Polit & Beck 2012:195). 
Data collectors were trained and deployed to gather data by interviewing the selected study 
participants attending ART clinic in Zewditu Memorial hospital and Bole 17 health centre. 
So they carried out a structured interview using the questionnaire. In structured interviews, 
the interviewers are supposed to follow a clearly structured format to prevent them from 
placing their own interpretation of the questions. They ask questions in a standard way, 
with the same probes and clarifications for each respondent, and they also record verbal 
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responses of the participants in a uniform way. This standardization increases the reliability 
of the information obtained (Joubert & Ehrlich 2007:107). The principal investigator closely 
followed and supervised the data collection process to ensure and guide proper data 
collection. This also helped to minimise the occurrence of variations and errors in the data 
during data gathering. 
1.8.2.5 Data collection tool 
The researcher used a questionnaire (see annexure F) as a data collection tool. It was 
developed by reviewing different literature in such a way to gather relevant information on 
measurement of the level of adherence to antiretroviral therapy and its various determinant 
factors. The questionnaire comprised of questions related to the level of adherence, 
demographic, socio-economic, psychosocial, health related, clinical setting, and patient-
provider relationship factors. A statistician was consulted and reviewed the questionnaire 
before starting data collection. 
1.8.2.6 Validity and reliability of data collection instrument 
The quality of the information collected in conducting a study is necessary to produce a 
valid research finding. The first way of checking data quality is to review issues concerning 
the data collection process and the respondents. The second is a more formal evaluation 
of measurement error. Thus, the measurement instruments are usually evaluated for 
validity and reliability (Joubert & Ehrlich 2007: 116).  
1.8.2.6.1 Validity of data collection instrument 
Validity: refers to the extent to which a measurement instrument actually measures what it 
is meant to measure (Joubert & Ehrlich 2007: 117). Although various ways of evaluating 
the validity of a measurement instrument have been mentioned in literatures the 
questionnaire was evaluated for face and content validity by experts in the field and the 
research supervisor and a statistician to ensure greater degree of accuracy of the 
measurement. 
1.8.2.6.2 Reliability of data collection instrument 
According to Joubert and Ehrlich (2007: 117) reliability refers to the degree of similarity of 
the results obtained when the measurement is repeated on the same subject or the same 
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group. The reliability of the instrument was enhanced by deploying appropriately selected 
and well trained data collectors with strict supervision of data collection process. A 
statistician was also consulted for his assistance on evaluating the instrument for its 
reliability. 
 
1.8.2.7 Data Analysis 
Data was cleaned, coded and entered in to a computer. The data was analysed using 
SPSS 20.0 statistical software package. Descriptive statistics such as means, median and 
standard deviations were calculated to describe the basic participants‟ characteristics. 
Odds ratio, chi-square test and their 95% confidence interval were computed to identify the 
presence and strength of associations between the categorical independent variables and 
dependent variable. Independent t-test was also computed to examine relationship 
between continuous independent variables and dependent variable. A P-value of less than 
0.05 was considered for an association to be considered as statistically significant. 
Multivariate regression analysis was also carried out to identify independent factors 
associated with low level of adherence to antiretroviral therapy. A statistician was involved 
in the entire data analyses process. 
 
1.9 ETHICAL CONSIDERATIONS 
Ethical clearance and approval was ascertained from the Research Ethics Committee of 
the University of South Africa (see annexure A) and the regional health bureau of Addis 
Ababa city administration (see annexure C). Permission to conduct the study was 
requested and obtained from the management of the health institutions where the study 
was undertaken. The researcher took in to consideration the fundamental principles of 
ethical research which include justice, beneficence and respect for human dignity. 
 
1.9.1The principle of justice:  
Right to fair treatment: means that researchers must treat people who decline to participate 
(or who withdraw from the study after initial agreement) in a non prejudicial manner; that 
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they must honor all agreements made with participants (including payment of any promised 
stipends); that they demonstrate respect for the beliefs, habits, and lifestyles of people from 
different backgrounds or cultures; that they give participants access to research staff for 
desired clarification; and that they afford participants courteous and tactful treatment at all 
times (Polit & Beck 2012:155-156). Every effort was made to treat participants fairly. 
Participants were treated properly whether they consent or not, even if they withdraw from 
participating in the study. The data collectors were strictly explained not to be judgmental 
with any aspect of the study participants. 
Right to privacy: Participants have the right to expect that any data they provide will be kept 
in strictest confidence (Polit & Beck 2012:156). The researcher and the data collectors 
made every effort to comfort and maintain the privacy of the participants. 
Confidentiality: According to Fain (2009:34) confidentiality refers to protecting data by not 
divulging information that is gathered or learned in caring for a patient without that 
individual‟s permission to do so. Various efforts were made to maintain confidentiality of 
information provided by the study participants in this study. There were no circumstances 
that information related to the participant was shared with others. The field workers were 
strictly informed on keeping confidentiality of information of the participants. Data was 
collected in a private room. They used codes rather than any identifiable information on the 
questionnaire. They did not give any access to the participants‟ information to other 
individuals except the principal investigator. The completed questionnaires were kept 
secured in a lockable cabinet till collected by the researcher. They also signed 
confidentiality pledge forms to strictly maintain confidentiality of information. 
Anonymity: refers to keeping individuals nameless and limiting access to information that is 
gathered about a subject. Anonymity can be facilitated by using code numbers for subjects‟ 
identity to prevent others from linking reported information with them (Fain 2009: 33-34). 
Polit and Beck (2012:162) also describes anonymity as the most secure means of 
protecting confidentiality, and occurs when the researcher cannot link participants to their 
data. In this study, the participants were assured that there could no names or other 
identifier in the questionnaire, so that there was no means to link any information with a 
particular participant. Only codes were used in the questionnaire during data collection. 
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1.9.2 Principle of beneficence: 
Freedom from harm: the research participants were not exposed to any physical or 
psychological harm. The ethical principles were strictly followed not to infringe the 
participants‟ rights and humanity. Participants were informed on their right to withdraw from 
the study at any time when they consent for participation in the study. 
Freedom from exploitation: Participants were treated fairly and they were not at any 
disadvantage because of participation in the study. 
Benefits from the research: Different studies in African context indicated that there is a 
deficit in the level of adherence of patients to ART and multiple factors have been 
mentioned to contribute to the existing gap. This study helped to gain knowledge on the 
level of adherence of HIV infected adult patients and understand the potential barriers to 
adherence. Moreover, it provided important information with regard to adherence and make 
recommendations for health care providers, health facilities and policy makers in 
enhancing the implementation of ART program and development of evidenced-based 
interventions to improve adherence to antiretroviral therapy. 
Risk/benefit ratio: Participants having problems with their adherence were referred to 
adherence counsellors and other psychosocial support organizations as necessary. 
Participants were also explained about the benefits with regard to the recommended 
adherence interventions that resulted from the research findings. Since, the participants 
may have risks such as physical discomfort, emotional distress and fear of stigma, every 
effort was made to comfort and lessen the risks. Even the participants were clearly 
explained that they had the right to withdraw from the study at anytime they felt like. 
 
1.9.3 Principle of respect for human dignity: 
The right to self-determination: According to Polit and Beck (2012:154) self determination 
implies that prospective participants can voluntarily decide whether to take part in a study, 
without risk of prejudicial treatment. It also points out that people have the right to ask 
questions, to refuse to give information, and to withdraw from the study. The research 
participants were fully autonomous whether to volunteer to participate or not, to ask 
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questions and to refuse providing information. They were not coerced or subjected to any 
penalty for refusal to participate in the study. 
Informed Consent: means that participants have adequate information about the research, 
comprehend that information, and have the ability to consent to or decline participation 
voluntarily (Polit & Beck 2012:157). The study participants were requested to provide a 
written informed consent before data collection. They were clearly explained about the 
purpose of the study, the data collection procedure and the potential risks and benefits that 
may occur up on participation in the study.  The participation in the study was voluntary 
and a decline to participate did not result in any penalty or loss of benefit. They were 
informed that even after consenting they have the right to withdraw from the study and to 
refuse to provide any specific piece of information. 
The right to full disclosure:  Full disclosure means that the researcher has fully described 
the nature of the study; the person‟s right to refuse participation, the researcher‟s 
responsibilities, and likely risks and benefits (Polit & Beck 2012:154). The study 
participants and the health institutions were fully explained about the purpose and nature of 
the study, the data collection process and the potential risks and benefits of participation in 
the study. 
The right of vulnerable subjects: vulnerable subjects such as those who were below 18 
years of age, severely ill and mentally handicapped individuals did not participate in the 
study. 
1.10 SCOPE AND LIMITATIONS OF THE STUDY 
The researcher anticipated and acknowledged the following potential limitations in 
conducting the study: 
 The generalizability of the research findings may be compromised as the study was 
conducted in only few health facilities. 
 Since there were no standardized methods for measurement of adherence, accurate 
assessment of adherence could not be possible. The researcher used „self report‟ 
as a measure of adherence to patients‟ treatment which could overestimate the 
actual rate of adherence to treatment. 
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 Social desirability and recall biases of patients may affect the reliability of the data 
with respect to adherence. 
 Lost to follow up, transfer out and death of patients may limit to find the 
systematically selected study participants. 
 
1.11 STRUCTURE OF THE DISSERTATION 
This dissertation was structured in such a way that the research processes be presented 
and discussed in chapters separately. The chapters of the dissertation included:- 
Chapter 1: Orientation to the study: provides overview of the research problem, research 
purpose and objectives, significance of the study, demarcation of field of study, foundations 
of the study, research design and method, and ethical considerations. 
Chapter 2: Literature review: provides in-depth review of various literatures to understand 
the existing body of knowledge on the prevalence of adherence to antiretroviral therapy, 
importance of adherence, measurement of adherence and factors associated with non 
adherence both in developing and developed countries. 
Chapter 3: Research design and method:  describes the overall process of the research 
methodology carried out to undertake the study. 
Chapter 4: Analysis, presentation and description of the research findings: include the 
statistical analysis, results of the study and summary of the research findings 
Chapter 5: Conclusion and recommendation: include the recommendations and conclusion 
made based on the research findings 
 
1.12 CONCLUSION 
This chapter introduced the research problem, the purpose, the objectives and the 
methodologies of the research to be conducted. It also highlighted the ethical principles 
that the researcher followed in conducting the research. Each component of the research 
process was further elaborated in detail in the next chapters of the dissertation. Chapter 
two discussed about the literature review in the next section. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 INTRODUCTION 
The literature review refers to the process of taking stock of existing knowledge in order to 
make informed choices about policy, practice, research direction and resource allocation 
(Joubert & Ehrlich 2007:66). It involves identification and analysis of relevant publications 
that contain information pertaining to the research problem. The major purpose of 
reviewing the literature is to discover what is already known about the problem. It also 
provides the understanding and insight necessary to develop a logical framework. In 
general, the literature review provides important information regarding what has been done 
and what needs to be done in relation to the research problem(Fain 2009:53). 
According to Polit and Beck (2003:88) literature reviews can serve a number of important 
functions in the research process. For researchers, acquaintance with relevant research 
literature and the state of current knowledge can help with the following: 
 Identification of a research problem and development or refinement of research 
questions or hypotheses 
 Orientation to what is known and not known about an area of inquiry, to ascertain 
what research can best make a contribution to the existing base of evidence 
 Determination of any gaps or inconsistencies in a body of research 
 Determination of a need to replicate a prior study in a different setting or with a 
different study population 
 Identification or development of new or refined clinical interventions to test through 
empirical research 
 Identification of relevant theoretical or conceptual frameworks for a research 
problem 
 Identification of suitable designs and data collection methods for a study 
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 For those developing research proposals for funding, identification of experts in the 
field who could be used as consultants 
 Assistance in interpreting study findings and in developing implications and 
recommendations 
Moreover, a literature review helps to lay the foundation for a study, and can also inspire 
new research ideas. A literature review also plays a role at the end of the study, when 
researchers are trying to make sense of their findings (Polit & Beck 2003:88). 
The literature review in the current study guided the researcher to conceptualize the 
research problem adequately and understand the current body of knowledge related to the 
magnitude of adherence problems and determinant factors for non adherence. The 
researcher underwent a systematic and thorough identification and review of different 
literatures that were believed to be relevant to the research topic. Literature search was 
carried out using libraries and the internet sources (from pubmed, medline and google). A 
number of studies were obtained and reviewed to gain existing knowledge on the 
prevalence of adherence to antiretroviral therapy, importance of adherence, measurement 
of adherence and factors associated with non adherence both in developing and developed 
countries.  
 
2.2 TREATMENT OF HIV/AIDS 
Antiretroviral treatment (ART) provides relief to HIV infected individuals by reducing the risk 
of developing opportunistic infections, but cannot cure HIV infection yet. Antiretroviral 
treatment was first  introduced in 1996, since then it has brought significant improvement in 
the life span and quality of life for people living with HIV (Wasti, van Teijlingen, Simkhada, 
Randall, Baxter, Kirkpatrick & GC 2012:71). Currently, the antiretroviral therapy has been 
improved steadily and new drugs with new mechanisms of action, improved potency and 
activity even against multidrug-resistant viruses, dosing convenience, and tolerability 
became approved and availed for use (Panel on antiretroviral guidelines... 2011:1). The 
primary goals of  antiretroviral therapy (ART) include reduction of HIV-associated morbidity 
and prolong the duration and quality of survival, restoration and preservation of 
immunologic function, maximal and durable suppression of plasma HIV viral load, and 
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prevention HIV transmission (Panel on antiretroviral guidelines... 2012:D1). This treatment 
definitely requires a combination of drugs from at least two, and preferably three active 
drugs, from two or more drug classes to achieve maximal and sustainable suppression of 
viral replication. Accordingly, the WHO recommends the preferred first-line regimens to 
include two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside 
reverse transcriptase inhibitor (NNRTI). For second-line regimens, preference would be 
given to a combination of two NRTIs (at least one of which is new) and a protease inhibitor 
boosted with ritonavir (Panel on antiretroviral guidelines... 2012:D1; Panel on antiretroviral 
guidelines... 2011:24; UNAIDS 2008:138). 
The ART treatment guideline was adopted from the public health approach which is 
recommended by WHO for resource-poor settings. It helps to standardise and simplify the 
initiation and monitoring of ART in the country. The guideline recommends to use two 
NRTIs and NNRTI as a standard first-line treatment, reserving PIs for second-line 
(FHAPCO/FMOH 2008:47). Hence, as demonstrated in figure 2.1either TDF or ZDV should 
be used as preferred first line NRTI drug in the treatment naïve patients in combination 
either with 3TC or FTC. While, D4T and ABC can used as alternative to TDF or ZDV in 
selected patient, such as renal impairment or adverse effects of ZDV. The NNRTIs (NVP or 
EFV) are used in equal preference depending on the patient condition (FHAPCO/FMOH 
2008:47). 
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3TC/FTC
EFV
NVP
Preferred:
1) TDF
2) AZT
Alternatives:
1) d4T
2) ABC
FIRST LINE REGIMEN: ETHIOPIAN
ART PROGRAM 2008
REGIMENS:
PREFERRED
1. TDF+FTC+EFV
2. ZDV+3TC+EFV
3. ZDV+3TC+NVP
ALTERNATIVES
1. D4T+3TC+NVP
2. TDF+3TC+NVP
3. D4T+3TC+EFV
4. ABC+3TC+NVP
5. ABC+3TC+EFV
6.ABC+3TC+ZDV
 
Figure 2.1 First - line antiretroviral regimen in Ethiopia 
(Source: FHAPCO/FMOH 2008:52) 
 
26 
 
2.3 ACCESS TO ANTIRETROVIRAL THERAPY 
Antiretroviral therapy used to be unaffordable and could not be available in resource limited 
countries for decades, despite its benefit of reducing HIV related morbidity and mortality in 
high income countries (UNAIDS 2008:136). In fact, this was mainly related to concerns of 
suboptimal adherence to ART in African patients, which could in turn lead to the 
development and spread of drug resistance (Mills et al 2006a:680). However, current 
evidences revealed that patients in resource-limited settings can achieve levels of 
adherence and virologic suppression that are equivalent to or possibly better than, those 
seen in resource-rich settings (Machtinger & Bangsberg 2006; Mills et al 2006a:682). Poor 
infrastructure, inadequate logistic and human capacity, and cost-effectiveness were also 
incriminated as major contributing factors to delay access to treatment (Assefa, Jerene, 
Lulseged, Ooms & Van Damme 2009:1). 
 
2.3.1 Expanding access to antiretroviral therapy in SSA 
Following the declaration of WHO 3-by-5 initiative in 2003, antiretroviral medications 
became widely accessible to people living with HIV in resource-constrained settings (WHO 
2006:7). Since then, several enabling factors have been created for the rapid scale-up of 
ART in resource-limited settings, for instance, increased funds, mainly through global 
initiatives such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United 
States President‟s Emergency Plan for AIDS Relief (PEPFAR) and a dramatic reduction in 
prices of antiretroviral drugs through considerable negotiation (Assefa et al 2009:1). 
Expanding access to ART has brought changes in the global HIV epidemic in momentous 
ways. The scaling up of ART averted an estimated 4.2 million deaths in low- and middle-
income countries in 2002–2012. Moreover, the average life expectancy of people living 
with HIV who adhere to effective treatment now approaches the life expectancy in the 
general population (WHO 2013:43-45). 
The rapid growth in antiretroviral therapy coverage represents one of the great success 
stories in recent global health history (UNAIDS 2008:136). According to the 
WHO/UNAIDS/UNICEF (2011:90), around 6.6 million people living with HIV were receiving 
antiretroviral therapy globally by the end of 2010 which showed a 17-fold increase from the 
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approximately 400,000 people recorded in December 2003. (WHO/UNAIDS/UNICEF 
2011:21). 
Despite the unprecedented efforts of national governments and international partners, the 
estimated global coverage of antiretroviral therapy in low- and middle-income countries 
remains still less than 50% in 2010 (WHO/UNAIDS/UNICEF 2011:90). The ART coverage 
in Sub-Saharan Africa, where 73% of the estimated treatment need in low and middle-
income countries and 76% of the total number of people receiving treatment are living has 
reached only 49% in 2010. Only few countries such as Botswana, Namibia and Rwanda 
have already achieved universal access to antiretroviral therapy which is commonly 
understood as providing antiretroviral therapy to at least 80% of the people who need it 
(WHO/UNAIDS/UNICEF 2011:99). This clearly indicates that there is unmet need that calls 
for further strengthening the collaborative efforts of the international community and 
national governments to close the existing gap to achieve the universal access target in 
SSA. 
 
2.3.2 Access to antiretroviral therapy in Ethiopia 
In Ethiopia, around 759,268 people were estimated to live with HIV by the end of 2012, and 
336,106 of them were in need of antiretroviral treatment (HIV AIDS estimates & projection 
...2013). The ART program was started in 2003 on fee basis mainly in the largest urban 
countries. But, later on a free ART roll out program was launched by the FMOH in 
collaboration with different global health initiatives in 2005. By mid 2006, health centres in 
different parts of the country started to provide treatment as part of decentralization and 
scaling up ART program. Hence, currently ART services have been provided both at the 
health centers and hospitals in the country (Assefa et al 2009:2; Kloos, Assefa, Adugna, 
Mulatu, & Haile Mariam 2007: [S.a]; Tiyou, Belachew, Alemseged & Biadgilign 2010:2). 
Reports from FHAPCO demonstrated 246,347 patients had been ever started on ART and 
among which 179,183 patients were receiving ART by the end February 2010. The ART 
coverage also reached 53% which showed significant progress compared to the baseline 
of 13,000 in 2005/06 (FMOH 2010:13). This results from the collaborative effort of the 
government of Ethiopia with its development partners towards achieving universal access 
to chronic HIV care and treatment services. Nonetheless, there still remains a gap to reach 
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to those who are in need of ART and the FMOH has planned to further expand the service 
in its strategic plan II (2010/11 – 2014/15). 
Addis Ababa, the capital city of Ethiopia, was one of the pioneer cities to launch free 
antiretroviral treatment in 2005. The ART service has been provided both in public and 
private health facilities. The number of facilities providing HIV care and treatment services 
has increased gradually. Till February 2010, the total number of ever started HIV positive 
clients on antiretroviral treatment has reached to 52,585 in Addis Ababa. Among which 
32,279 clients were found to be currently on treatment (Monthly HIV care and ART report 
update 2010). 
 
2.3.3 Retention of patients on ART 
Apart from continuous support in the scale up of ART services, greater attention should 
also be given to enhance retention of patients in the ART program. Once people start ART, 
the retention rates are initially high and then decline gradually. For instance, data reported 
in 2013 from 18 countries with cohorts of at least 2000 people on ART indicate that the 
average retention rates decreased from about 86% at 12 months to 82% at 24 months and 
72% at 60 months (WHO 2013:11). Similarly, studies demonstrated ART programs in 
Africa have retained only about 60% of their patients at the end of two years since the 
inception of large scale ART access early in this decade, with loss to follow-up as a major 
cause of attrition, followed by death. The percentage of loss to follow-up ranges from 3.7% 
to 44% which varies widely across programs in resource limited settings (Nakanojako et al 
2009:185). In support of this, a recent cohort study in Kenya also reported as high as 29% 
of patients  dropped out from the ART program and the probabilities of remaining on care 
and treatment in the program at 6, 12, and 24 months were 0.83, 0.74, and 0.65, 
respectively (Unge, Södergård, Ekström, Carter, Waweru, Ilako, Ragnarsson & Thorson 
2009:399-400). This indicates a progressive decline in the number of patients in HIV care 
could happen along with time. Therefore, close support and improvements in the 
infrastructure and systems of HIV care are required to improve the quality of care as well 
as proper monitoring of treatment adherence and retention as programs are scaled up 
(UNAIDS 2010:29). 
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2.4 ADHERENCE TO ANTIRETROVIRAL THERAPY 
 
2.4.1 Importance of adherence to antiretroviral therapy 
A high level of adherence to antiretroviral therapy is required to achieve sustainable viral 
suppression and better clinical outcomes in HIV-infected persons (Beer, Heffelfinger, 
Frazier, Mattson, Roter, Barash, Buskin, Rime & Valverde 2012:123). Studies have 
demonstrated that higher levels of drug adherence are associated with improved 
virological, immunological and clinical outcomes (WHO 2006:78). Along with this, 
adherence has been found to be the most valuable and potentially alterable factor to 
determine treatment outcomes of patients living with HIV (Panel on antiretroviral 
guidelines... 2006:20; Matchtinger & Bangsberg 2006).  
Although previous studies indicated that 95%–100% adherence was necessary to sustain 
viral suppression and prevent drug resistance, more-recent findings demonstrated the 
existence of different relationships between adherence, viral suppression, and drug 
resistance with different antiretroviral drugs (Bangsberg 2008:275). The studies 
emphasized that reliable virologic suppression is possible at moderate levels of adherence 
in majority of patients receiving more potent non nucleoside reverse transcriptase inhibitors 
(NNRTI) and ritonavir boosted PI therapy (Parienti, Das-Douglas, Massari, Guzman, 
Deeks, Vedon & Bangsberg 2008:1). Despite the fact that viral suppression may be 
possible with moderate levels of adherence, every increase in the adherence level 
increases the probability of viral suppression and, more importantly, reduces disease 
progression and mortality (Bangsberg 2006:941).  This was supported by a study which 
revealed the decrease in the risk of virologic rebound  with each 10% increase in average 
adherence (OR = 0.56; 95% confidence interval (CI) [0.37, 0.81], P=0.002) (Parienti et al 
2008:3). Another study in Mozambique also revealed that the relationship between >95% 
treatment adherence and a final viral load <1000 copies/mL is closer than that between 
>90% treatment adherence and a viral load <1000 copies/mL in both the group that 
received 15–27 months of NNRTI based HAART and the group that received >27 months 
of HAART (San Lio, Carbini, Germano, Guidotti, Mancinelli, Magid, Narciso, Palombi, 
Renzi, Zimba & Marazzi 2008:1613). This implies that health care providers should strive to 
provide ongoing counselling and support to patients to get near perfect adherence to the 
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prescribed doses for all antiretroviral regimens (Panel on antiretroviral guidelines... 
2011:121). 
Optimal adherence to antiretroviral therapy has also brought a significant change in the 
quality of life of PLHIV. For instance, a study in China found a better score in the 
dimensions of physical function (P=0.001), general health (P=0.009), vitality (P=0.016), 
social function (P=0.001), and mental health (P=0.023) in consistent adherers than non 
adherers (Wang, Zhou, He, Luo, Li, Yang, Fennie & Williams 2009:759). With optimal 
adherence, ART may also result in significant improvement in population health, reduction 
of the number of premature deaths, and lowering of health care costs. Studies indicate that 
adherence to ART is one of the important factors in reducing HIV transmission by 
suppressing HIV viral load (Beer et al 2012:123).   
 
2.4.2 Consequences of non adherence 
2.4.2.1 Clinical implications of non-adherence 
Failure to adhere to recommended medication regimens is a serious problem that has 
negative consequences for patients, providers, health plans, employers, industry, and 
society (Gellad et al 2009:1). Patients with suboptimal adherence are generally more 
vulnerable to the development of drug resistance, and subsequent treatment failure. They 
tend to develop poor health outcomes with increased morbidity and mortality as a result of 
disease progression (Enriquez & Mckinsey 2011:46; Vriesendorp, Cohen, Kristanto, 
Vrijens, Rakesh, Anand, Iwebor & Stiekema et al 2007:1116). Even the new second line 
regimen may be more complex than the initial regimen, thereby creating an additional 
barrier to adherence. The same pattern of gradual decline in adherence may necessitate 
an even more complex third-line regimen. Thus, failure to detect and address risky 
adherence patterns prior to the first viral rebound can lead to a continuous loop of less-
effective, poorly tolerated therapies that require even higher levels of adherence to sustain 
viral suppression (Bangsberg 2008:272). 
Various studies demonstrated that suboptimal adherence has been correlated with the 
development of drug resistance and treatment failure. For instance, a study in Zambia 
indicated the risk for virologic failure was higher among patients with suboptimal [adjusted 
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RR (ARR): 1.7; 95% CI: 1.0, 1.6] and poor adherence (ARR: 1.8; 95% CI: 1.3, 2.4) than 
those with optimal adherence. Based on MPR adherence categories, the risk of detectable 
VL increased from optimal [118/531 (22%)], suboptimal [89/306 (29%)], to poor [31/76 
(41%) (Goldman, Cantrell, Mulenga, Tambatamba, Reid, Levy, Limbada, Tylor, Saag, 
Vermund, Stringer & Chi 2008:1032). A recent cohort study in South Africa which followed 
154 women receiving NNRTI based ART regimen for 24 weeks, found out that patients 
with adherence level below 80% were at high risk of developing viremia (El-Khatib, 
Ekstrom, Coovadia, Abrams, Petzold, Katzenstein, Morris & Kuhn 2011a:6-8). Another 
study in Mozambique also demonstrated the increased risk of viremia in patients with 
suboptimal adherence.  
In this study, of the 284 patients who had treatment adherence >95%, 274 (96.5%) had a 
viral load <1000 copies/mL at the end of the observation period; of the 110 patients who 
had treatment adherence ≤95%, 92 (83.6%) had a viral load <1000 copies/mL at the end of 
the observation period (San Lio et al 2008:1613). A recent US study indicated non 
adherence to multiple measures (i.e non adherence to dose, schedule and instruction) was 
also associated with increased odds of a detectable viral load (Beer et al 2012:216). A 
study conducted in South Africa demonstrated the association of poor adherence to drug 
refill with virologic and immunologic failure (El-Khatib, Katzenstein, Marrone, Laher, 
Mohapi, Petzold, Morris & Ekström 2011b:3). A prospective cohort study also revealed that 
non continuous adherence and treatment interruptions are strongly related to treatment 
failure (Knobel, Urbina, González, Sorli, Montero, Carmona & Guelar 2009:366). 
The impact of poor adherence on immunologic and other clinical outcomes has been also 
well established. Patients with suboptimal adherence have impaired clinical and 
immunologic outcomes. A study in Zambia observed an association between level of 
adherence and CD4 lymphocyte response. Individuals with adherence of <80% had an 
attenuated response at 18, 24, 30 and 36 months when compared with those at or above 
this MPR threshold (Chi, Cantrell, Zulu, Mulenga, Levy, Tambatamba, Reid, Mwango, 
Mwinga, Bulterys, Saag & Stringer 2009:751-752). Another study conducted in China found 
a better mean growth of CD4 count in patients with consistent adherence. The mean 
growth of CD4 count was 72 cells per micro litre in consistent adherers and 27 cells per 
micro litre in non adherers (P=0.03). The study also demonstrated that patients with good 
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adherence were more likely to be free from OIs, had lower hospital expenses and shorter 
hospital stay, and less likely be hospitalized or re-hospitalized as compared to non 
adherent participants (Wang et al 2009:760). In Kaplan–Meier analysis, individuals with 
<80% adherence had a significantly higher risk of death when compared with those in other 
adherence categories (log rank P=0.0001). In unadjusted proportional hazards regression, 
the relative hazard for death was 1.7 (95% CI: 1.4–2.1) among those with poor adherence, 
when compared with those with optimal adherence (Chi et al 2009:751). 
2.4.2.2 Public health impact of non-adherence 
Non-adherence has also imposed additional public health impact beyond individual health. 
The financial burden of non adherence has been substantial. As HIV-infected individuals 
fail ARV regimens, each subsequent medication regimen becomes not only more complex 
but also more costly (Enriquez & Mckinsey 2011:46). Non adherence also has negative 
influence on general health care system including waste of medication, increased health 
care costs, and increased use of medical resources such as nursing homes, hospital visits 
and hospital admissions (Jimmy & Jose 2011:155). Last but not least, non adherence to 
HAART can result in serious health impact with risk of transmission of resistant viral strains 
to the general population as well (Machtinger & Bangsberg 2006). 
 
2.5 MEASUREMENT OF ADHERENCE 
A variety of adherence measurement methods have been used for clinical practice and 
research purpose. However, none of the measurements can be used as a gold standard 
(Panel on antiretroviral guidelines... 2012:K2). These methods are categorized as direct 
and indirect measures of adherence. The direct measures include directly observed 
therapy, measurement of the level of a drug or its metabolite in blood or urine and 
detection or measurement of a biological marker added to the drug formulation, in the 
blood. The indirect ones include self reports, electronic drug monitoring (EDM), pill counts, 
pharmacy refill records, measurement of physiologic markers and patient diaries. Each of 
the adherence measurements has its own strengths and limitations (Jimmy & Jose 
2011:157). The following section discussed in brief the most commonly used methods for 
assessment of adherence. 
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2.5.1 Self report 
Patient self-report of adherence is a routine method used in assessing adherence both in 
clinical trials and in routine clinic settings (Steel, Nwokike & Joshi 2007: 7). Evidences 
indicated that self report adherence has been correlated well with clinical and virologic 
outcomes and other objective measures of adherence (Amico, Barta, Konkle-Parker, 
Fisher, Cornman, Shuper & Fisher 2009:69; Reda & Biadgilign 2012:1-2; Steel et al 2007: 
7). Self report adherence was validated in various studies. For instance, a recent meta-
analysis demonstrated a moderate correlation between adherence measured by MEMS 
and self reported questions ranging from 0.24 to 0.87 for 11 articles (Shi, Liu, Fonseca, 
Walker, Kalsekar & Pawaskar 2010:4). Another study in Uganda also validated self report 
adherence with serum level of stavudine, and the researchers found in multivariate model 
patients who reported 95% and above S-RA were almost eight times more likely (Adjusted 
Odds Ratio: 7.7, 95% CI: 3.5 to 7.0, P < 0.0001) to have within or above therapeutic 
plasma stavudine concentrations, compared to those who reported less than 95% S-RA. 
(Balikuddembe, Kayiwa,  Musoke, Ntale, Baveewo, Waako & Obua 2012:4). Self report of 
adherence offers the primary advantages of ease of administration, flexibility and low cost 
(Glass, Geest, Hirschel, Battegay, Furrer, Cavassini, Vernazza, Bernasconi, Rickenbach, 
Weber, Buche 2008:78). However, it tends to overestimate adherence due to its 
vulnerability to fabrications and to the dynamics of provider-patient relationship (Steel et al 
2007:7-8). Self report is also subjected to measurement biases such as social desirability, 
recall bias, and response bias (Shi et al 2010:2). Despite the fact that patient self-report of 
adherence can predictably overestimate adherence by as much as 20%, a patient‟s report 
of suboptimal adherence is a strong indicator of non adherence and should be taken 
seriously (Panel on antiretroviral guidelines... 2012:K2).  
 
2.5.2 Pill count 
Pill count is also a common method to measure adherence. Although clinic-based pill 
counts generally perform poorly, unannounced pill counts conducted in the home have 
been closely associated with viral suppression, the development of drug resistance, and 
progression to AIDS (Bangsberg 2008:274). This method is simple to use, but  has many 
disadvantages including switching of medicines between bottles and  discarding pills 
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before hospital visits in order to appear to be following the regimen (Jimmy & Jose 
2011:157). Besides, it can overestimate adherence as the use of pills is assumed if not 
counted in the bottle, and also cannot give any information about timing or pattern of doses 
taken (Gellad et al 2009:25-26).  
 
2.5.3 Pharmacy refill records 
Pharmacy-dispensing information is another potential approach to routine adherence 
monitoring. Pharmacy refill information can be used to calculate the drug-possession ratio, 
which represents the maximum possible adherence for a patient over a defined refill period 
(Bangsberg 2008:274). The relationship of pharmacy refill adherence and clinical outcomes 
has been well established. For instance, a study in South Africa found out a significant 
association between cumulative adherence of > 95% to drug-refill visits and virologic and 
immunologic failure (p= 0.01). The researchers suggested that adherence to drug-refill 
visits can work as an early warning indicator for both virologic and immunologic failure (El-
Khatib et al 2011b:3-5). Another study in Cameroon also demonstrated pharmacy refill 
adherence had even greater accuracy, with higher sensitivity and similar specificity to CD4 
count changes at 6 months for predicting virological treatment failure. In this study 
pharmacy refill irregularity was found to be the most powerful predictor of virologic failure 
(Rougemont, Stoll, Eia & Ngang 2009: [S.a]).  
The rates of refilling prescriptions can be used as an accurate measure of overall 
adherence particularly in a closed pharmacy system since refills are measured at several 
points in that time (Jimmy & Jose 2011:158). The limitation of this approach is that multiple 
pharmacies can be used by the same person, which actually complicates data collection. 
(Bangsberg 2008:274). 
 
2.5.4 Electronic drug monitoring (EDM) 
Electronic devices to monitor medication adherence consist of medication event electronic 
monitoring system (MEMS), which electronically record the date and time when patients 
open a pill bottle. This method uses a micro switch, a battery, and flash memory to detect 
and record the date and time when a medication bottle is opened. These time/date stamps 
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create an electronic record of pill bottle–opening behaviour that is closely associated with 
viral suppression and drug resistance (Bangsberg 2008:274; Gellad et al 2009:25). MEMS 
entails the advantages of obtaining data in a computer accessible format and allowing 
more detailed view of non adherence patterns. It also seems to be more reliable adherence 
measure and less prone to respondent bias (Reda & Biadgilign 2011:2; Steel et al 2007:7). 
The limitation of this method includes inaccurate measure of adherence as the patients 
could open the container and not necessarily take the medication, take the wrong amount 
of medication or take multiple doses out of the container at the same time (or place multiple 
doses in another container), patients decanting pills, measuring only one medication at a 
time, and being unavailable for blister packs (Jimmy & Jose 2011:158; Steel et al 2007:7). 
The use of advanced technology, high cost, and logistic requirements have also precluded 
their wider application in Sub-Saharan Africa (Reda & Biadgilign 2011:2). However, a 
recent study in Tanzania indicated the feasibility and acceptability of using MEMS-bottles 
to monitor adherence to ART in resource limited settings (Lyimo, Boogaard, Msoka, 
Hospers, Ven, Mushi, D & Bruin 2011:6). 
In general, the use of a single isolated method of adherence assessment seems to be 
inadequate and impractical. Use of more than one ART adherence measures to capture 
more accurate information to determine adherence levels have been recommended at 
recent times (Sahay, Reddy & Dhayarkar 2011:837; Steel et al 2007: 54). 
 
2.6 RATES OF ADHERENCE TO ANTIRETROVIRAL THERAPY 
Adherence to antiretroviral treatment has been recognized as a major problem for patients 
receiving treatment. Studies evaluating adherence have been conducted both in developed 
and developing countries. The following section highlighted the status and variation in rate 
of adherence in developed and developing settings. 
 
2.6.1 Adherence in developed countries 
Adherence to ART in HIV infected patients is estimated closer to 70% despite the variation 
of the methods used to assess adherence and the group studied (Machtinger & Bangsberg 
2006). Review of the literature indicated that adherence has been found to be sub optimal 
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in most developed countries. In a study conducted among 154 HIV positive patients in 
Deep South, Missisipi, an optimal adherence rate of 81% was reported, as adherence was 
measured by self report (Amico et al 2009:70). A cross sectional study in United States 
also investigated the rate of adherence among 9088 participants from the Supplement to 
HIV and AIDS Surveillance (SHAS) Project. The result indicated only 84% of the 
participants were found to be adherent to ≥ 95% of the prescribed doses of ART in the past 
48 hours before the interview (Sullivan, Campsmith, Nakamura, Begley, Schulden & 
Nakashima 2007:3). Similarly, an overall two-day adherence rate of 89% was reported, in a 
study conducted in persons living with HIV/AIDS who are homeless or unstably housed, in 
three US states (Royal, Kidder, Patrabansh, Wolitski, Holtgrave, Aidala, Pals & Stall 
2009:451). Another study was conducted among 110 participants who were identified from 
the Research on Access to Care in the Homeless (REACH) cohort, a systematic sample of 
HIV-positive adults recruited from San Francisco, California, homeless shelters, free meal 
programs, and low-income, single-room-occupancy hotels.  The Average rate of adherence 
to therapy was found to be 70% as measured by unannounced pill count and electronic 
medication monitoring (Bangsberg 2006:940).  
In contrast, other studies showed low level of adherence in resource rich settings. A meta-
analysis of adherence studies by Mills et al (2006:682) demonstrated a pooled adherence 
estimate of 55% in North America. This study indicated that adherence to antiretroviral 
treatment in resource rich setting was relatively lower despite the fact that majority (71%) of 
the studies used self report method which is known to overestimate adherence. Other 
studies conducted in Europe also demonstrated comparable findings. In a study of 
adherence among patients who have received antiretroviral therapy for more than ten 
years in Spain, only 67.5% of the study participants were adherent to ≥95% of their 
prescribed medications. The investigators assessed adherence through self report and 
serum drug concentration (Fumaz, Muñoz-Moreno, Moltò, Ferre, Lòpez-Blázquez, 
Negredo, Paredes, Gómez & Clotet 2008:798). Similarly, a recent meta-analysis of 
adherence studies in Spain revealed the average adherence to HAART under the random 
effects model was 0.54 (95%CI: 0.49-0.59), showing wide heterogeneity (I2 = 91.20; 
95%CI: 88.75-93.13) under the fixed-effects model (Ortego, Huedo-Medina, Vego & Liorca 
2011:286). Adherence rate of 43% was also reported in a study conducted in United States 
among 272 patients with alcohol problems (Parsons, Rosof & Mustanski 2007:364). This 
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may reflect the influence of alcohol consumption on adherence to medications. Overall the 
above studies revealed that achieving optimal level of adherence to antiretroviral therapy 
seems to be even challenging in resource-rich settings. 
 
2.6.2 Adherence in developing countries 
A growing number of studies have been also conducted to investigate the rate of 
adherence to antiretroviral therapy in resource limited settings. Mills et al (2006:682) 
demonstrated that a relatively higher level of adherence could be achieved in developing 
than developed countries; although, there were some concern of sub optimal adherence in 
African settings. In this meta-analysis of 27 adherence studies, which were from 12 Sub-
Saharan African countries, the researchers found out that a pooled estimate of adherence 
in SSA was 77%.  
A plethora of studies conducted in Sub Saharan Africa have reported even a higher level of 
adherence among HIV infected patients to their treatment. A recent cross sectional study 
conducted in Uganda found out that among 234 patients, 194 (82.9%) patients had a self 
report adherence of 95% and above (Balikuddembe et al 2012:3). A study conducted in 
Tanzania among 340 patients assessed adherence to self report of four day and one 
month duration, and revealed that 320 (94.1%) patients were adherent to at least 95% of 
their prescribed medications (Watt, Maman, Golin, Earp, Eng, Bangdiwala & Jacobson 
2010: 383-384). However, another study in Tanzania reported adherence rate of 78.2% 
among 897 study participants using a combination of self report and pill count methods 
(Abaasa, Todd, Ekoru, Kalyango, Levin, Odeke & Karamagi 2008: [S.a]).Another research 
in Botswana also found a mean adherence level of 85% and 98% using MEMs and self-
reporting of medication intake respectively (Vriesendorp et al 2007:1117-1118).  A 
prospective study conducted in HIV infected patients in Cameroon also found out that 78% 
of patients were adherent to their prescribed ARV medications. However, the self report 
data indicated that the proportion of patients with full adherence declined from 83% at the 
first month to 57% at the six months (Rougemont et al 2009: [S.a]). A study conducted in 
Rwanda reported an overall adherence rate of 73% taking correct use of doses, on the 
schedule and dietary recommendation in to consideration (Jean-Baptiste 2008:15). A study 
in rural Zambia also assessed the rate of adherence using self-report among 518 study 
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participants. The investigators found that 88% of the participants had never missed ARVs 
in the past four days (Nozaki et al 2011:832). In a cross-sectional study in Nigeria, 80.6% 
of HIV positive pregnant women reported adherence level of greater or equal to 95% using 
3 day recall method (Ekama, Herbertson, Addeh, Gab-Okafor, Onwujekwe, Tayo & Ezechi 
2012:3). 
Although majority of the adherence studies in SSA revealed a higher rate of adherence 
among HIV infected patients, some studies demonstrated remarkably lower adherence. For 
instance, a large programmatic cohort study across 18 primary care centres providing ART 
in Lusaka, Zambia assessed adherence by medication possession ratio (MPR). The 
researchers revealed, among 27,115 treatment-naïve adults initiated and continued ART 
for at least 12 months only 17,060 (62.9%) had optimal adherence of ≥ 95% ( Chi et al 
2009:748). Similarly, other studies in Zambia showed comparable results; Goldman et al 
(2008:1032) reported only 58% of patients had optimal adherence as measured by MPR. 
Birbeck, Chomba, Kvalsund, Bradbury, Mang'ombe, Malama, Kaile, Byers, & Organek 
(2009:670-671) also indicated that only 59.2% were found to be adherent among 255 study 
participants. A study conducted in 125 HIV infected out patients in Benin using self report 
and pill count, also demonstrated adherence level of 58.1% ± 2.4% which was significantly 
lower than those reported in many other sub-Saharan African countries (Erah & Arute 
2008:146-150).  
Studies conducted in resource limited settings other than SSA indicate comparable rate of 
adherence. A longitudinal study in China reported an average rate of adherence of 89% in 
89 HIV infected patients, as measured by 7 day visual analogue scale. The researchers 
also demonstrated a slight decline in adherence across time; adherence rate was found 
91%, 89% and 88% at baseline, month 3 and month 6 respectively (Wang et al 2009:759). 
A study on adherence among 412 study subjects in Brazil showed about 74.3% of the 
patients were adherent to > 90% their prescribed treatment in the past five days (Silva et al 
2009:136). A cross-sectional study in Cuba also indicated 70.6% of the study participants 
were highly adherent to > 95% of their prescribed medications (Aragonés, Sánchez, 
Campos & Pérez 2011:19). A cross-sectional study conducted in India among 310 HIV 
positive patients receiving ART revealed 93% of patients had > 90% adherence to their 
treatment in the past 4 days (Sarna et al 2008: 31-32). However, other studies in India 
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demonstrated lower rate of adherence. For instance, another study conducted by 
Cauldbeck, O'Connor, O'Connor, Saunders, Rao, Mallesh, Kotehalappa, Kumar, Mamtha, 
McGoldrick, Laing & Satish (2009:3) found out an overall medication adherence rate of 
60.4% in adult HIV infected patients in India. A cross sectional analysis of 198 HIV-infected 
Indian patients also found about 50% of the participants had >95% adherence to ART 
(Venkatesh, Srikrishnan, Mayer, Kumarasamy, Raminani, Thamburaj, Prasad, Triche, 
Solomon & Safren 2010:799). 
 
2.6.3 Adherence in Ethiopia 
Some studies have investigated the level of adherence to antiretroviral treatment and 
factors associated with non adherence in Ethiopia. Literature review demonstrated the rate 
of adherence to antiretroviral therapy in Ethiopia seems to be comparable to the findings in 
most of the SSA countries, and even better than those cited in some developed countries. 
A cross-sectional study investigated the level of adherence among 291 PLHIV taking 
antiretroviral medication in Yirgalem hospital, Southern Ethiopia. The investigators used 
self patient report and pill counts as a measure adherence. The findings showed that 
72.8% of the study participants were found to be adherent in the week before the 
assessment and 26.1% did not follow treatment schedule and 5.5% did not follow 
instructions (Markos, Worku, & Davey 2008:176). Another cross-sectional study that 
evaluated adherence among 504HIV infected patients on in North West Ethiopia in Gonder 
Univesity and Felege Hiwot hospitals, revealed 82.7% of the patients reported taking >95% 
of their prescribed doses of treatment (Tessema, Biadglegne, Mulu, Getachew, Emmrich & 
Sack 2010:5). A prospective study conducted in Jimma University hospital, South West 
Ethiopia demonstrated the rate of self reported adherence based on the combined indicator 
of the three adherence errors (dose, time and food adherence) was 79.3% at baseline and 
75.7% at follow up visit at third month (Amberbir, Woldemichael, Getachew, Girma & 
Deribe 2008: [S.a]). This also suggested that adherence behaviour is dynamic and can 
vary over time. 
Similarly another cross-sectional study conducted among 319 adult PLHIV in the same 
setting with self report adherence in a one week recall based on combined indicator. The 
combined indicators include self reported missed doses, self reported schedule/time 
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adherence and self reported food adherence. Accordingly, 303(95%) of the study subjects 
were adherent based on self report of missed doses (dose adherence) in a one-week 
recall. Two hundred fifty five (79.9%) of the study subjects always follow the schedule/ time 
restrictions (time adherence) agreed upon with their providers and 286(89.7%) follow 
dietary instruction (Food Adherence). Hence, the overall rate of self reported adherence in 
the study area based on the combined indicator of the dose, time and food adherence 
measurement was 231(72.4%) (Tiyou et al 2010:3-4). 
Although studies demonstrated a comparable finding in the rate of adherence to 
antiretroviral therapy, the adherence definition and the methods used in measurement of 
adherence in various studies both in developed and developing settings have been 
variable and pose challenges in appropriate comparison of adherence rates.  
 
2.7 FACTORS THAT INFLUENCE ADHERENCE TO ANTIRETROVIRAL THERAPY 
A number of factors have been associated with non adherence to ART. Adherence is 
increasingly understood as a dynamic behaviour influenced by a matrix of interrelated 
factors that change over time. Understanding these factors can increase a clinician's 
attention to adherence when working with particularly susceptible patients and can inform 
the development of interventions to improve adherence. These factors are commonly 
divided into 5 intersecting categories: patient variables, treatment regimen factors, disease 
characteristics, patient-provider relationships and clinical setting. Many of these factors are 
modifiable, or at least partially modifiable, with appropriate interventions (Enriquez & 
Mckinsey 2011:46; Machtinger & Bangsberg 2006). 
 
2.7.1 Patient factors 
Patient related variables include socio-demographic factors (age, gender, race/ethnicity, 
income, education, literacy, housing status, insurance status, HIV risk factors) and 
psychosocial factors such as mental health, substance use, social climate and support, 
knowledge and attitudes about HIV and its treatment (Machtinger & Bangsberg 2006). 
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Socio-demographic factors: 
Studies revealed inconsistent findings about the association of adherence behaviour with 
various socio-demographic factors. Some studies have demonstrated significant 
association of non adherence with certain socio-demographic factors such as low literacy 
or education, lower individual or family income, unemployment, not participating in any 
religious activities, poor living conditions and not having any health insurance plan (Bonolo, 
César, Acúrcio, Ceccato, Pádua, Álvares, Campos, Carmo & Guimarães 2005:S9; 
Campos, Guimarães & Remien 2010:293-294; Hegazi, Bailey, Ahadzie, Alabi, & Peterson 
2010: 1342; Protopopescu, Raffi, Roux, Reynes, Dellamonica, Spire, Leport & Carrieri 
2009: 602; Sullivan et al 2007:3; Tiyou et al 2010:4; Venkatesh et al 2010:800; Wasti et al 
2012:72). Another study showed non adherence was associated with completing 
secondary school (Hansana, Sanchaisuriya, Durham, Schareun, Chaleunvong, 
Boonyaleepun, & Schelp 2013:5). However, a study conducted by Cauldbeck et al (2009: 
[S.a]) showed no association between literacy and individual or family income with 
adherence.  
Studies also demonstrated variable results on the association of age and sex with 
adherence behaviour. Some studies revealed that younger age and female sex were 
significantly associated with low level of adherence (Beer et al 2012:218; Fumaz et al 
2008:799; Nozaki, Dube, Kakimoto, Yamada & Simpungwe 2011:834; Ortego et al 
2011:287; Sullivan et al 2007:3; Tapp, Milloy, Kerr, Zhang, Guillemi, Hogg, Montaner & 
Wood 2011:3-4; Wasti et al 2012:72). Another study also documented the difference in 
adherence between young and old cohorts (Barclay, Hinkin, Castellon, Mason, Reinhard, 
Marion, Levine & Durvasula 2007:45). But, other studies did not support any association of 
adherence with age and sex (Aragonés et al 2011:19; Birbeck et al 2009:672; Sarna et al 
2008: 32; Sharma, Khadga, Dhungana, Chitrakar 2013:51; Venkatesh et al 2010:800). 
Other variables such as marital status, religion, education and occupational status were 
also not found to be associated with adherence (De & Dalui 2012:251). This indicates that 
it would be difficult to predict the adherence behaviour of patients based on the socio-
demographic characteristics of patients. 
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Psychosocial factors: 
Psychosocial factors that are consistently associated with adherence include psychological 
distress, active drug or alcohol use, social support, knowledge and beliefs about HIV and 
its treatment (Machtinger & Bangsberg 2006). Depressive symptoms and stress have been 
correlated significantly with non adherence (Achappa, Madi, Bhaskaran, Ramapuram, Rao, 
& Mahalingam 2013:222; Amberbir et al 2008: [S.a]; Beer et al 2012:218; Protopopescu 
2009:602; Royal et al 2009:452-453). Studies also indicated that the severity of depression 
and anxiety have significant influence on adherence to medications. Patients with severe 
depression were found four times more likely to report lower adherence than patients with 
minimal depression (Sarna et al 2008:32). A multivariate analysis in another study 
indicated that symptoms of severe anxiety were independently associated with non-
adherence (RH=1.87, 95% CI=1.14–3.06; p < .05). But, there was no indication of 
statistical association between severe depression and non adherence (Campos et al 
2010:293). 
The use of illicit drugs and alcohol consumption has also been significantly associated with 
low levels of adherence (Achappa et al 2013:222; Braithwaite & Bryant 2010:285; Campos 
et al 2010:293; Do, Dunne, Kato, Pham & Nguyen 2013:5; Fumaz et al 2008:799; Hansana 
et al 2013:7; Ortego et al 2011:287). A study identified the level of alcohol consumption as 
most important alcoholic factor to affect adherence (Parsons et al 2007:365). Another study 
also demonstrated significant association between daily alcohol consumption and non 
adherence (Protopopescu 2009:602). Smoking and alcoholic habits were also found to be 
associated with non adherence to ART (Bonolo et al 2005; Sharma et al 2013:51). 
Therefore, addressing issues related to substance abuse would have significant influence 
in the management of HIV infection and adherence to treatment. 
Various studies have documented that inadequate knowledge and negative beliefs about 
HIV disease and treatment effectiveness present an important barrier to ART adherence 
(Amberbir et al 2008: [S.a]). Some other studies documented the association of knowledge 
about ART and adherence, benefits of ART and importance of adherence with adherence 
of patients to ART (Markos et al 2008:176; Gari, Doig-Acuňa, Smail, Malungo, Martin-
Hilber & Merten 2013:7). Moreover, a study conducted in India revealed the association of 
information on the importance of HAART with adherence of patients (Lal, Kant, Dewan, Rai 
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& Biswas 2010:181). It indicated that those who were not told about the importance of 
HAART were 9.2 times more likely to be non adherent compared to those who reported 
having being told about its importance. But, studies revealed that adherence-related 
information about one's regimen was related to adherence behavioural skills but not 
significantly directly associated with 3-day self reports of dose adherence. Thus, it appears 
that being well-informed did not necessarily imply high levels of adherence, but did relate to 
one's fund of behavioural skills, which was directly related to levels of ART adherence 
(Amico et al 2009:73). In support of this, a study by Do et al (2013:5) indicated the 
association of perceived quality of information with non adherence. Another study by 
Fumaz et al (2008:800), however, revealed lack of association between level of information 
and level of adherence.  
The presence of social support from family members and/or friends has been repeatedly 
associated with better adherence. Patients with supportive friends and/or families tended to 
have better adherence to HAART than those without supportive friends (Aragonés et al 
2011:19; Amberbir et al 2008: [S.a]; Jean-Baptiste 2008:19; Nozaki et al 2011:834; 
Protopopescu et al 2009:602; Tiyou et al 2010:4). On the contrary, social networks have 
been found to affect adherence due to spontaneous social activities or as a result of issues 
complicated by stigma, disclosure and non-supportive others in the patient‟s environment 
(Parsons et al 2007:359-360). A number of studies consistently demonstrated that fear of 
disclosure and social stigma and discrimination have significant association with non 
adherence (Achappa et al 2013:222; Birbeck et al 2009:672; Mills et al 2006b:2056; Nozaki 
et al 2011:834; Waite, Paasche-Orlow, Rintamaki, Davis & Wolf 2008:1369-70; Wasti et al 
2012:75). Nonetheless, only few studies were unable to show significant association 
between adherence and social support (Sarna et al 2008:32). 
 
Cognitive factors:  
Accurate medication adherence has a number of cognitive components including 
comprehension of medication instructions, organization of the individual medication 
instructions into a medication plan and temporal sequence that integrates multiple 
medications and doses; retention of the medication plan, and, remembering to take the 
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medication at the planned time (Reynolds 2004:209). Forgetfulness has been found as the 
most common factor that affects adherence of patients in a number of studies (Achappa et 
al 2013:221; Ekama et al 2012:3; Markos et al 2008:176; Mills, Nachega, Bangsberg, 
Singh, Srachlis, Wu, Wilson, Buchan, Gill & Cooper 2006b:2056). Difficulty in 
understanding instructions has also been reported to affect adherence. Requirements 
and/or restrictions on the intake of food and water, or the temporal sequences of dosing 
can be confusing for patients (WHO 2003:100). A lack of understanding of treatment 
benefits was also found to be one of the consistent barriers to adherence both in 
developed and developing countries (Mills et al 2006b:2056). 
 
2.7.2 Treatment related factors 
Treatment related factors consists of number of pills prescribed, the complexity of the 
regimen (dosing frequency and food instructions), the specific type of antiretroviral drugs, 
and the short- and long-term medication side effects (Machtinger & Bangsberg 2006). A 
number of studies have indicated the association of non adherence with increased number 
of ARV drugs (Aragonés et al 2011:19; Beer et al 2012:218; Protopopescu et al 2009:602; 
Sarna et al 2008:32; Sullivan et al 2007:3). However, Fumaz et al (2008:176) reported no 
difference between adherences of patients taking between once- or twice-daily regimens. 
The frequency of ARV doses and treatment schedule are also important factors related 
with adherence behaviour. Taking drug regimen more than twice a day was significantly 
associated with poor adherence (De & Dalui 2012:251). Patients taking fixed dose 
combination drugs also tended to have better adherence than those taking multiple 
combined ARV drugs (Jean-Baptiste 2008:19). Schedule fitting to daily routine (Markos et 
al 2008:176) and switching of ARV regimen (Bonolo et al 2005:S9) were also found to be 
associated with adherence to medication.  
Antiretroviral drug adverse reactions have also been significantly associated with non 
adherence (Cauldbeck et al 2009: [S.a]; Markos et al 2008:176; Ortego et al 2011:287; 
Protopopescu et al 2009:602; Tessema et al 2010:5). The commonest side-effects causing 
non-adherence were metabolic reasons (66%) and GI symptoms (50%) (Cauldbeck et al 
2009: [S.a]). The experience of side effects and its influence on daily activities and quality 
of life is known to have led to treatment fatigue and ART non adherence in many other 
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studies. Gastrointestinal adverse events of ART were the most frequently cited reason for 
discontinuation of ART. It is important to note that not all side effects are seen immediately 
after ART initiation. Long term side effects like lipoatrophy or dystrophy leading to central 
obesity and thinning of limbs due to prolonged use of stavudine may arouse community 
suspicion leading to stress and non adherence among patients who might be otherwise 
stable on ART (Sahay et al 2011:840). 
 
2.7.3 Disease characteristics 
Disease characteristics include the stage and duration of HIV infection, associated 
opportunistic infections, and HIV-related symptoms (Machtinger & Bangsberg 2006).  
Studies demonstrated patients with baseline CD4 count of greater than 200 cells per micro 
litre had an increased risk of non adherence to ART (Beer et al 2012:216; Campos et al 
2010:293; Sarna et al 2008: 32). Few studies did not found significant difference in CD4 
cell count between different adherence levels (Fumaz et al 2008:799). 
Inconsistent findings have been demonstrated on the association of clinical staging and 
adherence. The WHO clinical stage was found as an independent predictor of adherence 
in a study conducted in Ethiopia (Tiyou et al 2010:4). Another study demonstrated that 
patients with asymptomatic WHO clinical stages tend to have poor adherence (Campos et 
al 2010:293). In contrast, Ortego et al (2011:287) revealed patients with stage A tend to 
have greater adherence than patients with stage B or C. But, a study in Zambia showed 
WHO clinical stage at baseline not predictive of non adherence (Chi et al 2009:751). 
Duration of time since knowing HIV status is also an important factor influencing 
adherence. A study in Rwanda revealed that adherent patients had known their HIV status 
for a short period of time than non adherent patients (Jean-Baptiste 2008:13). Another 
study also showed that increased number of years since HIV diagnosis to be independently 
associated with non adherence (Beer et al 2012:218). However, few studies demonstrated 
the absence of association between adherence and time of HIV diagnosis (Aragonés et al 
2011:19; Lal et al 2010:181). Another factor that may influence adherence included 
duration of antiretroviral treatment. A study by Lal et al (2010:181) demonstrated significant 
association between times elapsed since starting HAART and adherence. For instance, a 
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study by Venkatesh et al (2010:799) showed patients who experienced HAART for more 
than two years tend to have lower adherence. In the contrary, a systematic review of 
studies, taking ART for more than two years was positively associated with adherence in 
high income countries (Gari et al 2013:7). 
 
2.7.4 Patient-provider relationships 
The interpersonal dynamics of the physician–patient relationship play an important role in 
determining a variety of patient outcomes including patient adherence to their treatment 
recommendations. Cohesive partnerships and effective interpersonal communication, 
encouragement of participation of patients in their own care, trusting relationship between 
patients and physicians are important components of patient-provider relationship which 
promote greater patient satisfaction with medical care, which in turn foster higher levels of 
adherence (Martin, Williams, Haskard & Di Matteo 2005:192-193). Moreover, the patient's 
opinion of the provider's competence, the affective tone of the relationship (warmth, 
openness, cooperation, etc), the concordance of race/ethnicity between patient and 
provider, and the adequacy of referrals may affect treatment adherence (Machtinger & 
Bangsberg 2006). Studies indicated lack of trust in their medical provider was a barrier for 
adherence (Curioso et al 2010:5). A study done by De and Dalui (2012:251) also 
emphasized the influence of negative attitude of health care providers on adherence 
behaviour of patients. This implies that smooth and effective interaction between patients 
and providers has been essential in supporting patients to achieve optimal adherence. 
Supportive communications, agreement with positive opinions on confidence in health care 
providers, and perceived quality of patient-provider relationship were also associated with 
better adherence (Aragonés et al 2011:19; Watt et al 2010:384). 
 
2.7.5 Clinical setting 
Aspects of the clinical setting that may influence adherence include access to ongoing 
primary care, involvement in a dedicated adherence program, availability of transportation 
and childcare, pleasantness of the clinical environment, convenience in scheduling 
appointments, perceived confidentiality, and satisfaction with past experiences in the health 
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care system (Machtinger & Bangsberg 2006). In a Meta analysis of adherence studies 
issues of access, including financial constraints and a disruption in access to medications 
were identified as a more common barrier to adherence in developing countries (Mills et al 
2006b: 2056).  
Although access to medication is essential for continuation of treatment, free access to 
medication was found to negatively affect adherence. On multivariate analysis patients 
receiving free ARVs were 4.4 times more likely to report lower adherence than patients 
paying out-of-pocket for ART (Sarna et al 2008:32). Patients‟ follow up status in relation to 
adherence needs also worth mentioning. Regular clinic follow up was found to be 
significantly associated with good adherence (Cauldbeck et al 2009: [S.a]). In another 
study, respondents who missed a clinic appointment were almost three times more likely to 
report poor adherence, compared with those who never missed a clinic appointment (Watt 
et al 2010:385). A study by Chalker, Andualem, Gitau, Ntaganiara, Obua, Tadeg, Waako, 
Ross-Degnan & INRUD-IAA (2010: [S.a])   also revealed attendance of patients within 
three days of appointment was associated with adherence to ART. 
Several studies have also evaluated the reasons for non adherence to antiretroviral 
therapy. The most commonly cited reasons were forgetfulness, being away from home and 
being busy with other things (Hansana et al 2013: 5; Jean-Baptiste 2008:16; Markos et al 
2008:176; Sullivan et al 2007:3; Tiyou et al 2010:4; Wang et al 2009:759; Wasti et al 
2012:73-75; Watt et al 2010:384). Transport costs and financial problems were also 
mentioned in some studies as a reason for non adherence (Mills et al 2006b:2056; Wasti et 
al 2012:75). Studies also identified running out of medications (Wasti et al 2012:75; Tiyou 
et al 2010:4), avoiding side effects (Sullivan et al 2007:3; Tessema et al 2010:5; Wang et al 
2009:759) and felt sick (Amberbir et al 2008: [S.a]) as barriers to adherence. 
2.8 CONCLUSION 
This chapter discussed the literature review section which focused on access to 
antiretroviral therapy, adherence importance and consequences of non adherence, 
measurement of adherence, rates of adherence in various settings and complex of 
determinant factors to adherence. The next chapter described the research methodology 
section. 
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CHAPTER THREE 
RESEARCH METHODOLOGY 
3.1 INTRODUCTION  
This chapter discusses the entire process and procedures of the research methodology 
used to undertake this study. It clearly described the research design and method used to 
conduct the study, the study population, sampling and sample selection techniques, data 
collection instrument and procedure, data analysis, the validity and reliability of the study, 
ethical considerations and limitations of the study.  
 
3.2 RESEARCH SETTING 
According to Polit and Beck (2003:164), research settings are the specific places where 
data collection takes place. This study was conducted in respective ART clinics of two 
randomly selected health facilities (Zewditu hospital and Bole 17 health center) in Addis 
Ababa. Zewditu Memorial Hospital was one of the pioneer public hospitals that started free 
ART service in Addis Ababa. With the decentralization of ART services to the health centre 
level, Bole 17 Health Centre launched ART program later. These two health facilities had 
enrolled a large number of people living with HIV receiving antiretroviral therapy in 
comparison to other hospitals and health centres. They provide comprehensive HIV 
prevention, care and treatment services. The study subjects were approached and 
recruited to participate in the study when they came to ART clinics for regular follow-up 
visits. The interview was conducted in a private room to make the participants comfortable 
and minimise any anxiety. The level of adherence was measured using self-report 
adherence in the past three days before the interview and assessed the factors affecting 
adherence using a questionnaire. In this study 20% of the study participants were found to 
be non-adherent to their anti-retroviral therapy. 
 
3.3 RESEARCH DESIGN 
A research design is described as a blue print for the conduct of a study that maximizes 
control over other factors that could interfere with the study‟s desired outcome (Burns & 
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Grove 2005: 40). A quantitative, cross-sectional, analytical study design was used to 
conduct this study. This design was found suitable to investigate the research questions in 
the study population. A quantitative data related to level of adherence in the past three 
days and factors affecting adherence was collected using structured questionnaire from 
study participants during the specified data collection period. Descriptive and analytic 
statistical analyses were computed to describe, summarize and analyse quantitative data 
and assess relationship between level of adherence and various determinant factors. 
 
3.4 RESEARCH METHOD 
Research methods are the techniques used by researchers to structure a study and to 
gather and analyze information relevant to the research question (Polit & Beck 2012:12). In 
this study, the researcher clearly described the research methods that were used to 
conduct the study. These include defining the study population, the sample and sampling 
procedure, the sample size, the data collection process, and data analyses. 
 
3.4.1 Population 
A population is the entire aggregation of cases in which a researcher is interested. The 
accessible population is the aggregate of cases that conform to the designated criteria and 
that are accessible as a pool of subjects for a study. The target population is the aggregate 
of cases about which the researcher would like to make generalizations (Polit & Beck 
2012:273-274). Babbie (2007:190) also describes a study population as that aggregation of 
elements from which a sample is actually selected. The population of this study consists of 
HIV infected adult patients who were receiving antiretroviral therapy in selected health 
facilities in Addis Ababa and who fulfilled the eligibility criteria for the study. The eligibility 
(inclusion) criteria included those who were older than 18 years, those who had been 
receiving antiretroviral therapy for at least three months, those who gave their consent to 
participate in the study, and those who were not involved in the pilot study. The accessible 
population were also those adult HIV infected adult patients who met the eligibility criteria 
and attended follow-up visits in the ART clinic of the selected health facilities during the 
period of data collection. 
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3.4.2 Sample, Sampling, and sampling procedures 
3.4.2.1 Sample and sampling 
A sample is referred to as a subset of population elements (Polit & Beck 2012:275). In this 
study, the sample for each health facility was drawn from the sampling frame of HIV 
infected adults receiving antiretroviral therapy who met the inclusion criteria. The samples 
were supposed to refill their ARV medications in the data collection period. The researcher 
used a systematic sampling technique to select the samples for the study. Accordingly, 
with the assistance of the staff in charge of the data in the ART clinics, a sampling frame 
was prepared from a list of eligible adult HIV infected patients on antiretroviral therapy 
using their unique ART number from computer data base. Then, the first sample and the 
sample interval were used to eventually establish the list of the sample of participants 
before data collection started. The sampling procedure is described in the next section. 
 
3.4.2.2 Sampling procedure 
The sampling procedure was described as follows; 
 At the beginning, the list of health facilities providing ART service in Addis Ababa 
was obtained from the national AIDS resource centre website. The two health 
facilities (Zewditu Memorial Hospital and Bole 17 Health Centre) were chosen 
randomly on convenience, since they had a large number of patients from the 
respective list of hospitals and health centres.  
 A sample of participants in each of the health facilities was selected using a 
systematic sampling technique.  And, a sampling frame for each facility was 
established from the list of HIV infected adults receiving ART fulfilling the eligibility 
criteria. The study participants were sampled from a sampling frame of a list of 
eligible adult HIV infected patients on ART based on their unique ART identification 
numbers, which were generated from a computer data base. Medical record 
numbers were used in some patients transferred from other health facilities who did 
not have unique ART numbers. 
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 The first sample, as a starting point, was selected randomly from the first ten eligible 
patients from the ordered list of sampling frame. A proportionate number of the total 
sample size was determined for each of the facility depending on the number of 
ART clients receiving treatment in these facilities. With this, from a total of 300 
sample size, the proportionate number allocated for the hospital and health centre 
was 240 (80%) and 60 (20%), respectively. Then, the sampling interval was 
calculated by dividing population size by the sample size for each facility. Finally, 
every 26th HIV infected adults on ART from the sampling frame was identified and 
selected for participation in the study in the respective health facilities. 
 
3.4.2.3 Sample size 
The researcher determined the sample size of this study using a precision of 5% and 95% 
confidence interval by the following formula,  
                       N= p (1-p) z2 / d2;  
                       Where     p = estimated proportion of patients adherent to ART,  
                                       z = the cut off value of the Normal distribution, and  
                                       d = the precision required on either side of the proportion.  
A pooled estimate of adherence to antiretroviral therapy in Sub-Saharan Africa was found 
to be 77% (Mills et al 2006:679). Therefore, assuming an adherence rate of 77%, the total 
sample size for this study was calculated to be 300, using a precision of 5% and 95% 
confidence interval. Considering loss to follow-up, transfer, death, and non-willingness, 
10% of the sample size was added to the total sample size. 
 
3.4.3 Data collection Procedures  
The procedure followed during the data collection process was described as follows. The 
researcher obtained ethical clearance from UNISA and Addis Ababa City Administration 
Health Bureau. A support letter from the health bureau was submitted to the management 
of the health facilities and permission was granted to collect data in the ART clinics. The 
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researcher approached the staff in charge of the data in the ART clinics to access the data 
of ART users in the computer with their direct assistance. As previously mentioned, the list 
of potential study participants was sampled from each health facility.  
The researcher trained and deployed two data collectors to gather data from the study 
participants. The data collectors were trained on the objective of the study, applying the 
ethical aspects, obtaining informed consent, ethically treating the study participants based 
on their willingness, and how to complete the questionnaires and keep the completed 
questionnaires confidential. The data collectors also signed a confidentiality pledge form 
(See annexure D) to ensure confidentiality of the data. The researcher provided the 
consent form and the questionnaire prepared in Amharic and the necessary stationary 
materials to the data collectors. 
With the assistance of the staff, the researcher found a room in each of the facilities for the 
data collectors to interview the study participants in private. The list of study participants 
was used to identify the patients when they came to the ART clinic to pick up their ARV 
medications during the data collection period. The nurses facilitated the referral of the 
study participants who were willing to participate in the study to the data collectors. The 
data collectors explained the purpose of the study and read the written consent form to the 
study participants, and then a written informed consent was obtained from a participant 
when he/she was willing for participation. However, those study participants who can write 
and read were given the consent form and they were allowed to complete it by themselves. 
Following this, the data collectors interviewed the participants within the allocated 
schedule. The average time utilized for the interview was 25 minutes for each participant. 
Since the researcher wanted to minimize biases, as the data collection took place in the 
health facilities, the data collectors were told not to wear gowns so that the participants 
could provide genuine responses during the interview. The researcher close supervised the 
process and provided support to the data collectors to ensure the data collection was done 
properly. Finally, the completed questionnaires were collected and reviewed in a timely 
manner by the researcher. 
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3.4.3.1 Data collection approach and method 
The data collectors gathered data by interviewing the study participants using a pre-tested 
structured questionnaire. But some participants preferred to complete the questionnaires 
themselves with the assistance of the data collectors. The interview was conducted in 
Amharic, which is the national local language widely spoken in Ethiopia. Joubert and 
Ehrilch (2007:107) state that in a structured interview, the interviewers follow a clearly 
structured format to prevent themselves from placing their own interpretation of the 
questions. They ask questions in a standard way, with the same probes and clarifications 
for each respondent and record their verbal response in a uniform way. This 
standardization increases the reliability of the information obtained. 
 
3.4.3.2 Development and testing of the data collection instrument 
The researcher developed the structured questionnaire after thoroughly reviewing the 
literature aiming to gather relevant information to assess adherence to antiretroviral 
therapy and its various determinant factors. A supervisor, three experts on the field of 
study, and a statistician had assisted in the development and refinement of the 
questionnaire. Most of the items of the questionnaire were adapted from the widely used 
the Adult AIDS Clinical Trial Group (AACTG) adherence questionnaire and the Life 
Windows Information-- Motivation -- Behavioural Skills ART Adherence Questionnaire (LW-
IMB-AAQ) with some modifications to fit the context of the research setting. The rest of the 
items were synthesized through reviewing other relevant literature. Most of the questions 
were closed-ended. The questionnaire was initially prepared in English and then later 
translated into Amharic, which is a commonly used local language in Ethiopia. 
The questionnaire consisted of eight sections: 
Section 1: Questions on demographic variables of respondents  
These included age, sex, marital status, literacy status, occupation, religion, ethnicity and 
average family income. 
Section 2: Questions related to the clinical condition of the patient 
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These included baseline and latest CD4 counts of patients, WHO clinical stage, duration of 
antiretroviral treatment, time since HIV diagnosis, and whether the patient was sick in the 
past one month or not. 
Section 3: Questions related to the type of ARV regimen and level of adherence of the 
respondent 
This section consisted of 9 items, most of which were adapted from AACTG adherence 
questionnaire. The respondents were asked to respond to the type of ARV regimen and 
frequency; and the number of missed doses in the past 3 days, in the past week and in the 
past month. The reviewed literature suggested that adherence can be assessed in the past 
three days, and modification on the number of days for recall of missed ARV doses was 
made. Patients were also asked whether they took their pills on specified times and in 
accordance with recommended food requirements by physicians. Besides, they were 
asked if they had a change of treatment regimen. Patients who missed their medications in 
the past one month were also asked about the possible reasons for missing doses of HIV 
medications. 
Section 4: Questions related to knowledge about HIV disease and antiretroviral therapy 
This section consisted of 10 items from 4.1 to 4.10. The items were adapted from the LW-
IMB-AAQ adherence questionnaire. The respondents were asked to explain how HIV 
medications were supposed to be taken, what to do if a dose of HIV medication was 
missed, the problems with skipping HIV medications, the side effects of medications, if they 
thought skipping medications was okay as long as the patient felt healthy, how HIV 
medications worked in the body, if they knew medications would fail to cure if not taken as 
prescribed, if they felt they could live longer by taking HIV medications as prescribed, and 
the interaction of HIV medications with alcohol and other substances. 
Section 5: Questions related to social support  
The respondents were asked about disclosing their HIV status, having support from friends 
and/or family members, the frequency of support provided by their friends and/or family 
members in taking medications, and their satisfaction with the overall support provided by 
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their friends and/or family members. They were also asked if they used reminders for 
taking their medications. 
Section 6: Questions related to their perception on patient-provider relationships 
The respondents were asked whether they got appropriate information about HIV 
medications from health care providers, discussed problems related to taking HIV 
medications, were easily understood by HCPs on their problems, obtained help to solve 
their problems, and were satisfied with the overall support from HCPs. 
Section 7: Questions related to the clinical setting 
The respondents were asked about their belief on the confidentiality of their information, 
convenience with appointment schedules, missed clinic appointment frequently, shortage 
of ARV supply, and overall satisfaction with the health care service.  
Section 8: Questions pertaining to the use of substances by respondents 
The respondents were asked if they had ever used alcohol, cigarette or „khat‟, and whether 
they had used substances in the past one month or not. 
3.4.3.3 Characteristics of the data collection instrument 
The researcher used a structured questionnaire to collect data. A questionnaire is a list of 
questions which are answered by the respondent and which give indirect measures of the 
variables under investigation (Joubert & Ehrlich 2007:107). Structured questionnaires are 
those questionnaires in which there are definite, concrete and pre-determined questions. 
The questions are presented with exactly the same wording and in the same order to all 
respondents. Resort is taken to this sort of standardization to ensure that all respondents 
reply to the same set of questions. The form of the question may be either closed or open 
but should be stated in advance and not constructed during questioning. They may also 
have fixed alternative questions in which responses of the informants are limited to the 
stated alternatives. Thus, a highly structured questionnaire is one in which all questions 
and answers are specified and comments in the respondent‟s own words are held to the 
minimum. They are simple to administer and relatively inexpensive to analyse (Kothari 
2004:101). 
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3.4.3.4 Pre - testing of the data collection instrument 
The questionnaire was piloted in a small group (5% of the sample size) of HIV positive 
individuals on antiretroviral therapy before the actual data collection began. A pilot study is 
a small-scale version or trial run, designed to test the methods to be used in a larger, more 
rigorous study (Polit & Beck 2012:195). The purpose of pre-tests includes determining how 
much time it takes to administer the entire instrument package and whether participants 
find it burdensome. It also helps to identify parts of the instrument package that are difficult 
to read or understand or that may have been misinterpreted by them, to identify any 
instruments or questions that participants find objectionable or offensive, to determine 
whether the sequencing of instruments is sensible, and to determine if the measures yield 
data with sufficient variability (Polit & Beck 2012:296). 
The data collection instrument was refined by incorporating constructive inputs from the 
pilot study. One problem observed during pilot study was that responses to some 
questions, especially those referring to the patient-provider relationship and clinical setting, 
were positively skewed as the data collectors were in white coat during the interview. The 
second one was that some patients were unable to provide data related to their clinical 
stage and CD4 counts. 
3.4.3.5 Ethical considerations related to data collection 
In this study, the researcher took the necessary steps to ensure that ethical aspects were 
maintained during data collection. These include procedures to keep the privacy and 
dignity of the study participants and maintain the confidentiality of the data. Before the data 
collection started, a private room was arranged for interviewing the study participants. The 
data collectors explained the purpose of the study and obtained a written informed consent 
from the study participants. The consent form was translated into Amharic to make the 
study participants understood the purpose of the study. Participation in this study was 
completely voluntary, and data were collected from those study participants who were 
willing to participate in the study. The study participants were allowed to ask questions any 
time and they were told they could withdraw from the interview in case they were not 
comfortable. The questionnaires were anonymous with no personal identifiable information 
recorded. The interview took not more than 25 minutes per participant. While conducting 
the interview, psychological reassurance was provided to some patients who suffered from 
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different psychosocial problems, and some were referred to the ART providers when they 
were willing to get further counselling and support.  
The researcher also emphasised on the confidentiality of the data. The data collectors 
were trained and made to sign a confidentiality pledge form to keep the data confidential. 
All the completed questionnaires were kept locked in filing cabinets, and the researcher 
gathered the completed questionnaires from the data collectors in time. No one was 
allowed to access the data. 
 
3.4.4 Data analysis 
Quantitative data analysis is the numerical representation and manipulation of observations 
for the purpose of describing and explaining the phenomena those observations reflect 
(Babbie 2007:405). Before data analysis, the data were cleaned, coded and entered into a 
computer. A statistician did the analysis of all the data using the latest version of SPSS 
statistical software. The data analysis incorporated both descriptive and inferential 
statistics.  Descriptive statistics helps to describe data in more manageable forms. 
Inferential statistics assists researchers in drawing conclusions about a population from the 
study of a sample drawn from it (Babbie 2007:450).  
Univariate analysis was made to describe and summarize basic characteristics of the 
participants using descriptive statistics such as percentages, means, median and standard 
deviations. The researcher also conducted bivariate analysis such as odds ratio, chi-
square test and 95% confidence interval to examine the relationship between levels of 
adherence and the independent variables of categorical data. But for continuous variables 
independent t-test was computed to examine the relationship with the dependent variable. 
According to Babbie (2007:419), bivariate analysis refers to the analysis of two variables 
simultaneously for the purpose of determining the empirical relation between them. A P-
value of less than 0.05 was considered for an association between dependent and 
independent variables to be statistically significant. 
In addition, multivariate regression analysis was carried out to identify factors that are 
independently associated with low level of adherence to antiretroviral therapy. Multivariate 
analysis encompasses a range of statistical techniques which, on the basis of 
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mathematical models, can evaluate the inter-relationship of more than two variables, for 
example more than one dependent variable and/or more than one independent variable 
(Joubert & Ehrlich 2007:153). In binary logistic regression the dependent variable is a 
dichotomous one. The dependent variable is typically coded 1 to represent an event or a 
characteristic, and 0 to represent the absence of the event or characteristic (Polit & Beck 
2012:449). 
 
3.5 VALIDITY AND RELIABILITY OF THE STUDY 
According to Joubert and Ehrlich (2007:116), good quality of information is essential in 
order to ensure the soundness of study results. Although data quality can be checked by 
reviewing issues related to data collection process and respondents, a measurement 
instrument needs to be evaluated formally for its validity and reliability. 
 
3.5.1 Validity 
Validity refers to the extent to which a measurement instrument actually measures what it 
is meant to measure (Joubert & Ehrlich 2007: 117). Morgan et al (2005:50) also state that 
validity is concerned with establishing evidence for the use of a particular measure or 
instrument in a particular setting with a particular population for a specific purpose.  The 
most common and useful classification schemes attempting to categorise the 
measurement of the underlying validity are content validity, face validity, criterion validity, 
and construct validity (Delport in De Vos et al 2005:160). 
Face validity deals with the superficial appearance or face value of a measuring instrument 
(Delport in De vos et al 2005:161). The face value of the questionnaire was evaluated by 
professionals in the field of the research topic for its relevance to the area of interest and 
clarity for easy administration in data collection. 
Construct validity involves the validity of inferences from the observed persons, settings, 
and cause-and-effect operations included in the study to the constructs that these 
instances might represent. One aspect of construct validity concerns the degree to which 
an intervention is a good representation of the underlying construct that was theorized as 
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having the potential to cause beneficial outcomes. Another concern was whether the 
measures of the dependent variable are good in the operationalization of the constructs for 
which they are intended (Polit & Beck 2012:237). 
Content validity is concerned with the representativeness or sampling adequacy of the 
content of an instrument. In other words, a valid measuring device would provide an 
adequate or representative sample of all content, or elements, or instances of the 
phenomenon being measured. Content validity is established on the basis of judgement; 
that is, researchers or other experts make judgements about whether the measure covers 
the universe of facets that make up the concept (Delport in De Vos et al 2005:161). 
Although data collection instruments can be validated with any of the above-mentioned 
criteria, the researcher used face and content validity to enhance the quality of the 
questionnaire in this study. To ensure the content validity of the research instrument, the 
researcher designed the questionnaire by reviewing relevant literature to get a better 
understanding of the concepts in the area of interest. The questionnaire was also reviewed 
by a professional statistician, three senior experts in the area of the field, and the 
researcher supervisor for face and content validity. The researcher incorporated the 
valuable feedbacks to refine and enrich the questionnaire. All these people evaluated to 
what extent the items in the questionnaire measured adherence, how adequate and 
representative they are to indicate the factors that may affect adherence of patients to ARV 
medications and to what degree the phrasing of the items is free from ambiguity. 
3.5.2 Reliability 
According to Joubert and Ehrlich (2007: 117), reliability implies the degree of similarity of 
the results obtained when the measurement is repeated on the same subject or the same     
group. Delport in De Vos et al (2005:162) also defines reliability of a measurement 
procedure as the stability or consistency of the measurement. The reliability of the research 
questionnaire was enhanced by pretesting the instrument to ensure clarity, and by 
appropriately selecting and training data collectors to create a similar understanding of the 
questionnaire. Besides, data collection was undertaken with a strict supervision of the 
principal investigator. A statistician was also consulted for his assistance on evaluating the 
instrument for its reliability. In this study, the reliability coefficients (Cronbach‟s Alpha) of 
items for measuring knowledge about HIV disease and ART and patient-provider 
60 
 
relationship were found to be 0.75 and 0.82, respectively. The authors of LW-IMB-AAQ 
also demonstrated internal consistency for the information scale of adherence 
questionnaire to be 0.59. Amico et al (2009:71) in their study also revealed a moderate 
internal consistency to the same instrument as the items are expected to assess diverse 
aspects of ART information. 
3.5.3 External and internal validity of the study 
External validity refers to the extent to which it can be inferred that relationships observed 
in a study hold true over variations in people, conditions, and settings, as well as over 
variations in treatments and outcomes (Polit & Beck 2012:250). Whereas, internal validity 
refers to the extent to which it is possible to make an inference that the independent 
variable, rather than another factor, is truly causing variation in the dependent variable 
(Polit & Beck 2012:244). To ensure the external validity of the research, the researcher 
used a probability sampling technique so that the selected participants were representative 
of the study population. Besides, adequate sample size was calculated to enhance the 
representativeness of the sample. Also, inferential statistics were calculated to draw 
conclusions about a population from the study of a population drawn from it. 
 
3.6 ETHICAL CONSIDERATION  
The researcher took into consideration the fundamental principles of ethical research, 
which include justice, beneficence and respect for human dignity while conducting this 
study. The ethical consideration in respect to this particular research was discussed 
thoroughly in the first chapter. The data collectors clearly explained to the study 
participants what is expected from them and what to do if they decided not to proceed with 
the study. Whether to participate or not from the very beginning was the decision of the 
study participants, and they were assured that their refusal to participate in the study would 
have no consequences. The written informed consent form described very well what is 
needed and how study participants could respond. They were also told that they had the 
right to ask questions at any time and withdraw from the study under any circumstances. 
(Chapter One discussed this in more detail.) 
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3.7 CONCLUSION 
This chapter discussed thoroughly the methodology of the research including the study 
design, sample and sampling technique, developing a questionnaire, data collection 
procedure, data analyses, validity and reliability of the study and ethical considerations. 
The next chapter discussed the data presentation and discussion of the research findings. 
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CHAPTER 4 
ANALYSIS, PRESENTATION AND DESCRIPTION OF THE RESEARCH FINDINGS 
4.1 INTRODUCTION  
The previous chapter thoroughly discussed the research design and the research 
methodology used to undertake this study. This chapter focuses on the data management 
and statistical analysis performed to summarize and present the research findings. The 
purpose of this study was to explore and describe the determinant factors affecting 
adherence to antiretroviral therapy among HIV-infected adult patients in Addis Ababa, 
Ethiopia. 
The objectives of the study were to: 
 describe the level of adherence of HIV infected adult patients to antiretroviral  
therapy in Addis Ababa; 
 explore the determinant factors that could affect patients‟ adherence to their 
antiretroviral therapy; 
 identify the association of socio-demographic and other patient-related factors with 
the level of adherence; and 
 recommend appropriate interventions with regard to the ways of improving 
adherence of patients based on research findings. 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
The data collection was carried out from March to April 2013.  A proportionate number of 
samples in relation to the number of HIV positive patients receiving antiretroviral therapy 
were allocated at the beginning of the data collection, thus 240 and 60 study participants 
were sampled in Zewditu Memorial Hospital and Bole 17 Health centre, respectively. The 
data was gathered by trained data collectors using a structured interview questionnaire in 
the two health facilities. Among a total sample size of three hundred participants, 290 
(96.6%) were interviewed and these participants responded fully to the questionnaires after 
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they had been informed about the purpose of the research. The data was anonymous and 
kept with confidentiality in a secure place where no one was able to access it.  
The questionnaire consisted of the following sections: 
Section 1: Demographic characteristics of respondents  
Section 2: Information on the clinical condition of patients 
Section 3: The current type of ARV regimen and level of adherence of the respondent 
Section 4: Respondents‟ knowledge about HIV disease and antiretroviral therapy 
Section 5: Aspects related to social support  
Section 6: Aspects of patient-provider relationships 
Section 7: Aspects of the clinical care setting 
Section 8: The use of substances by respondents 
The data analysis was carried out using SPSS version 20.0 with the assistance of a 
statistician. The data was cleaned, coded and entered into the SPSS database. In the data 
analysis, descriptive statistics such as percentages, frequency distributions, mean, median 
and standard deviation were computed. Besides, bivariate analysis was performed using 
chi-square test and P-value to determine significance of association between adherence 
and independent categorical variables. For the continuous variables, independent t-test 
was calculated to examine the presence of statistically significant difference in the mean of 
the variable. Multivariate logistic regression analysis was computed to determine 
independent factors associated with adherence to antiretroviral therapy. 
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4.3 RESEARCH RESULTS 
4.3.1 Demographic characteristics of the respondents 
This section of the study presented the research findings on the socio-demographic 
characteristics of the respondents including age, sex, marital status, occupation, religion, 
ethnicity and average monthly family income. 
 
4.3.1.1 Age distribution of study participants 
The age distribution of the study participants was illustrated in the following figure. 
 
Figure 4.1 Age distribution of study participants 
The age distribution of the respondents as displayed in Figure 4.1 indicates that 38.6% 
(n=112) of the participants were in the age group of 25-34 years, 34.8% (n=101) were 
between 35-44 years of age, 16.9% (n=49) were between 45-54 years of age, 7.2% (n=21) 
were 55+ years of age, and 2.4 % (n=7) were in the range of 18-24 years of age. This 
showed that the majority of the respondents in this study were comprised of younger age 
groups. The mean age of the respondents was 38 years and the range extends from 19 
years to 71 years. 
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Table 4.1 Association of age of study participants and combined adherence (N=290) 
Age group of study participants Combined adherence Total 
 Optimal Suboptimal 
18 – 24 Count 
% within age of participants 
7 
100.0 
0 
0.0 
7 
100.0 
25 – 34 Count 
% within age of participants 
93 
83.0 
19 
17.0 
112 
100.0 
35 – 44 Count 
% within age of participants 
79 
78.2% 
22 
21.8% 
101 
100.0 
45 – 54 Count 
% within age of participants 
38 
77.6% 
11 
22.4% 
49 
100.0 
55+ Count 
% within age of participants 
15 
71.4% 
6 
28.6% 
21 
100.0 
Total Count 
% within age of participants 
232 
80.0 
58 
20.0 
290 
100.0 
 
Table 4.1 shows the association between the age of the participants and their combined 
adherence. In this study, there was no statistically significant association found between 
the age of respondents and their adherence to antiretroviral therapy (P=0.447). This finding 
was in agreement with other similar studies which indicated lack of association between 
age and adherence (Aragonés et al 2011:19; Birbeck et al 2009:672; Sarna et al 2008: 32; 
Sharma et al 2013:51; Venkatesh et al 2010:800). In contrast, some other studies 
demonstrated a statistically significant association between age and adherence; that is, 
younger people tended to have lower adherence (Beer et al 2012:218; Fumaz et al 
2008:799; Nozaki et al 2011:834; Ortego et al 2011:287; Sullivan et al 2007:3; Tapp et al 
2011:3-4; Wasti et al 2012:72). A study conducted in Tanzania by Watt et al (2010:384) 
also revealed the association of age (being 19-30 years old or older than 51 years) with 
poor adherence. Barclay et al (2007:45) also compared the difference in the adherence 
rate of young and older participants, and the result showed that there was a statistically 
significant difference in the rate of adherence between the two cohorts. 
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4.3.1.2 Gender distribution of study participants 
 
 
Figure 4.2 Distribution of study participants, by sex (N=290) 
 
The gender distribution of the participants in this study, as depicted in Figure 4.2, shows 
that 37.2% (n=108) of the participants were males and 62.8% (n=182) were females. This 
indicated that the majority of the participants interviewed in this study were females. 
The relationship of gender status of study participants was shown in the following table. 
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Table 4.2 Association of gender status of study participants and their combined 
adherence to ART (N=290) 
Gender status of study participants Combined adherence Total 
 Optimal Suboptimal 
Male Count 
% within age of participants 
83 
76.9 
25 
23.1 
108 
100.0 
Female Count 
% within age of participants 
149 
81.9 
33 
18.1 
182 
100.0 
Total Count 
% within age of participants 
232 
80.0% 
58 
20.0% 
101 
100.0 
 
The result in Table 4.2 revealed the relationship between gender and combined adherence 
to antiretroviral therapy. It indicated that among 108 males, 76.9% (n=83) reported optimal 
adherence and 23.1% (n=25) had suboptimal adherence. Of the 182 females who 
participated in the study, 81.9% (n=149) had optimal adherence while 18.1% (n=33) 
reported suboptimal adherence.  
In this study, there was no statistically significant association found between the gender of 
study participants and their adherence to antiretroviral treatment (P=0.302). This result is 
supported by other similar studies that revealed the lack of association between gender 
and adherence (Aragonés et al 2011:19; Birbeck et al 2009:672; Sarna et al 2008: 32; 
Venkatesh et al 2010:800; Sharma et al 2013:52). But, other studies reported  
contradictory findings in which females tended to be less adherent than males (Beer et al 
2012:218; Fumaz et al 2008:799; Nozaki et al 2011:834; Ortego et al 2011:287; Sullivan et 
al 2007:3; Tapp et al 2011:3-4; Wasti et al 2012:72). 
 
4.3.1.3 Distribution of study participants, by marital status 
The study participants were asked to describe their marital status and the result was 
presented in the following table.  
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Table 4.3 Distribution of study participants, by marital status (N=290) 
Marital status of respondents Frequency Percent 
Never married 63 21.7 
Married 148 51.0 
Divorced 28 9.7 
Widowed 32 11.0 
Separated 19 6.6 
Total 290 100.0 
 
Table 4.3 depicts the marital status of the study participants. As can be seen, 51% (n=148) 
were married, 21.7% (n=63) were never married, 11.0% (n=32) were widowed, 9.7% 
(n=28) were divorced, and 6.6% (n=19) were separated. The majority of the study 
participants have been involved in marriage, which may have a vital influence in following 
their treatment properly. 
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Figure 4.3 Marital status of respondents and their adherence to antiretroviral therapy (N=290) 
Figure 4.3 depicts the marital status of the study participants with respect to their 
adherence behaviour. Out of 63 participants who were never married, 82.5% (n=52) and 
17.5% (n=11) were found to have optimal and suboptimal adherence, respectively. Among 
148 participants who were married, 79.1% (n=117) had optimal adherence and 20.9% 
(n=31) had suboptimal adherence. Among 28 participants who were divorced, 75.0% 
(n=21) had optimal adherence and 25.0% (n=7) had suboptimal adherence. Out of 32 
participants who were widowed, 81.2% (n=26) reported optimal adherence and 18.8% 
(n=6) had suboptimal adherence. Among the 19 participants who were separated, 84.2% 
(n=16) and 15.8% (n=3) had optimal and suboptimal adherence, respectively. 
In this study, the bivariate analysis revealed that no statistically significant association 
existed between marital status and self reported combined adherence to antiretroviral 
therapy (P=0.907). This finding was supported by the findings of other similar studies 
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(Birbeck et al 2009: 672; De & Dalui 2012:251). However, Watt et al (2010: 384) found out 
that having never been married was associated with lower rate of adherence. 
 
4.3.1.4 Distribution of study participants, by literacy status  
 
Figure 4.4 Distribution of study participants, by literacy status (N=290) 
As indicated in Figure 4.4, out of 290 study participants, 7.6% (n=22) were illiterate, 12.8% 
(n=37) were able to read and write only, 26.2% (n=76) had an elementary level of 
education (Grades 1-8), 32.8% (n=95) had a secondary level of education (Grades 9-12), 
while 20.7% (n=60) had a tertiary level of education (12+). This indicated that the majority 
of the study participants had formal education and had attained secondary level of 
education. 
In this study, the bivariate analysis showed no statistically significant association between 
the literacy status of participants and their level of adherence to antiretroviral therapy 
(P=0.942). This finding was in agreement with studies conducted by Birbeck et al (2009: 
672) and Cauldbeck et al (2009: [S.a]), which reported that the literacy status of HIV 
infected patients was not statistically associated with their adherence to medication. On the 
contrary, Campos et al (2010: 293) revealed that lower education status was independently 
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associated with non adherence. Similarly, another study conducted in Tanzania also found 
out that patients with a lower level of education tended to have poor adherence (Watt et al 
2010: 384). 
4.3.1.5 Distribution of study participants, by occupation 
The occupational status of the study participants was assessed in this study, and the result 
was illustrated as follows. 
Table 4.4 Distribution of study participants, by occupation (N=290) 
Occupation Frequency Percent 
Unemployed 39 13.4 
Government employee 53 18.3 
Student 20 6.9 
Housewife 76 26.2 
Driver 16 5.5 
Merchant 20 6.9 
Private employee 38 13.1 
Other 28 9.7 
Total 290 100.0 
 
The finding on the occupational status of the respondents presented in Table 4.4 shows 
that out of a total of 290 participants, 26.2% (n=76) were housewives, 18.3% (n=53) were 
government employees, 13.4% (n=39) were unemployed, and 13.1% (n=38) were private 
employees. The rest were merchants (6.9%), students (6.9%), drivers (5.5%), and other 
occupations (9.5%). 
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Figure 4.5 Occupational status of study participants and their adherence to ART (N=290) 
Figure 4.5 depicts the occupational status of the study participants in relation to their 
adherence to antiretroviral therapy. No statistically significant association was found 
between the occupational status of the respondents and their level of adherence to 
antiretroviral therapy (Fisher‟s Exact test=0.630). This implies that adherence behaviour of 
patients might not be influenced by the category of their occupation. However, other 
studies that examined the relationship between employment status and adherence to ART 
revealed that unemployment was associated with non adherence (Bonolo et al 2005:S9; 
Campos et al 2010: 293). 
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4.3.1.6 Distribution of study participants, by religion 
 
 
Figure 4.6 Distribution of study participants, by religion (N=290) 
Figure 4.6 depicts the religion of the study participants. Out of the 290 study participants, 
78.3% (n=227) were Orthodox Christians, 10.3% (n=30) were Protestants, 9.3% (n=27) 
were Muslims, 1.7% (n=5) were Catholics, and only 0.3% (n=1) had no religion. 
The bivariate analysis in this study showed no statistically significant association between 
the religion of study participants and their combined adherence to ART (P=0.183). This 
was consistent with other studies (De & Dalui 2012:251; Erah & Arute 2008:14), which 
indicated that religion was not associated with adherence to ART. However, a longitudinal 
study by Bonolo et al (2005:S9) reported that not participating in any religious activities was 
associated with non adherence. 
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4.3.1.7 Distribution of the study participants, by ethnicity 
The study participants were asked to provide information about their ethnicity and the result 
was illustrated in the following figure. 
 
 Figure 4.7 Distribution of study participants, by ethnicity (N=290) 
Figure 4.7 depicts the ethnic status of study participants. As can be seen, 60.7% (n=176) 
were Amhara, 18.3% (n=53) were Oromo, 9.3% (n=27) were Gurage, and the rest 4.4% 
(n=13) were categorized in other ethnic groups. 
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Figure 4.8 Ethnicity of study participants and their combined adherence to ART (N=290) 
Among the 156 participants from the Amhara ethnic group, 78.4% (n=138) had optimal 
adherence and 21.6% (n=38) had suboptimal adherence. Out of the 53 Oromo participants, 
77.4% (n=41) and 22.6% (n=12) reported optimal and suboptimal adherence, respectively. 
Among the 21 Tigre participants, 81.0% (n=17) had optimal adherence and 19.0% (n=4) 
had suboptimal adherence. Out of the 27 participants from the SNNPR, 88.9% (n=24) 
reported optimal adherence and 11.1% (n=3) had suboptimal adherence. Out of the 13 
participants categorised under „others‟, 92.3% (n=12) and 7.7% (n=1) had optimal and 
suboptimal adherence to ART, respectively. 
In this study, the bivariate analysis showed no statistically significant association between 
the ethnicity of the study participants and their level of adherence (Fisher‟s Exact 
test=0.616). However, some studies in developed countries indicated association between 
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non adherence and ethnicity. In a study conducted in the United States, Blacks and 
Hispanics were found to be less adherent than Whites (Beer et al 2012:218).  
4.3.1.8 Distribution of study participants, by average family monthly income 
 
Table 4.5 Distribution of study participants, by average family income (N=290) 
Average family income (ETB) Frequency Percent 
< 500 38 13.1 
500 – 1499 160 55.2 
1500 – 2499 60 20.7 
2500 – 3499 18 6.2 
3500+ 14 4.8 
Total 290 100.0 
 
Table 4.5 depicts that among the 290 study participants, 55.2% (n=160) earned an average 
monthly family income between 500 and 1499 ETB, 20.7% (n=60) earned in the range of 
1500-2499 ETB, 13.1% (n=38) earned less than 500 ETB, and only 4.8% (n=14) earned 
more than 3500 ETB. This showed that the majority of the study participants (68.0%) had 
an average monthly family income of less than 1500 ETB, which is too low to lead a 
reasonably decent life in the Ethiopian context. 
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Figure 4.9 Average family income of study participants and their adherence to ART (N=290) 
Figure 4.9 depicts the average monthly family income of the study participants with respect 
to their adherence behaviour. It indicated that, among the 38 participants who got less than 
500 ETB/month, 78.9% (n=30) had optimal adherence and 21.1% (n=8) had suboptimal 
adherence. Out of the 160 participants who got 500-1499 ETB per month, 81.9% (n=131) 
reported optimal adherence and 18.1% (n=29) had suboptimal adherence. Among the 60 
participants who got 1500-2499 ETB per month, 76.7% (n=46) had optimal adherence and 
23.3% (n=14) had suboptimal adherence. Out of the 18 participants who got 2500-3499 
ETB per month, 77.8% (n=14) had optimal adherence and 22.2% (n=4) had suboptimal 
adherence. Among the 14 participants who got more than 3500 ETB per month, 78.6% 
(n=11) and 21.4% (n=3) had optimal and suboptimal adherence, respectively. 
In this study, there was no statistically significant association found between average 
monthly family income and level of adherence to ART (Fisher‟s Exact test= 0.893). This 
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was in line with the study conducted by Cauldbeck et al (2009: [S.a]), which showed 
individual or family income was not associated with adherence. Similarly, another study 
undertaken by Sarna et al (2008:32) also showed that adherence was not associated with 
economic status. However, the current finding is inconsistent with that of a study done in 
southwest Ethiopia, which observed that average family income was significantly 
associated with adherence to ART (Tiyou et al 2010: 4). 
 
4.3.2 Information regarding clinical condition of study participants 
This section summarized the findings of the study on attributes related to the clinical 
condition of the study participants. 
 
4.3.2.1 Duration of time since diagnosed with HIV infection 
The study participants were asked about the duration of time since they were diagnosed to 
have HIV infection. The result was depicted in the following figure. 
 
Figure 4.10 Distribution of study participants, by duration of time since HIV diagnosis (in months) 
(N=290) 
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Figure 4.10 shows that out of the total 290 study participants 2.4% (n=7) were diagnosed 
with HIV infection before 12 months, 11.0% (n=32) were diagnosed between 12 and 35 
months before, 26.9% (n=78) were diagnosed between 36 and 59 months before, and 
59.7% (n=173) were diagnosed 60 or more months before. The mean of duration of time 
that elapsed since the participants were diagnosed with HIV infection was 61.4 months and 
the range was 8 to 120 months. Thus, the majority of the study participants knew about 
their HIV status for a relatively long period of time. 
The bivariate analysis of this study showed no statistical significant association between 
the duration of time of HIV diagnosis and combined adherence to ART (t = - 1.146, P = 
0.253). This result was supported by studies conducted by Lal et al (2010:181) and Sarna 
et al (2008:32), which indicated that the length of time since the diagnosis of HIV infection 
was not associated with adherence to ART. On the contrary, Silva et al (2009:136) found 
out that the longer time that elapsed since HIV diagnosis, the greater the risk of non 
adherence. 
 
4.3.2.2 WHO clinical stage of study participants at the time of ART initiation 
The WHO clinical stage of the study participants at the start of antiretroviral therapy was 
illustrated in the following table. 
Table 4.6 WHO clinical stage of study participants at the time of ART initiation 
(N=290) 
WHO clinical stage Frequency Percent 
I 47 16.2 
II 83 28.6 
III 92 31.7 
IV 32 11.0 
Unknown 36 12.4 
Total 290 100.0 
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Table 4.6 showed that, out of a total of 290 study participants, 16.2% (n=47) had stage I, 
28.6% (n=83) stage II, 31.7% (n=92) stage III, and 11.0% (n=32) stage IV HIV disease 
before they started antiretroviral therapy. In other words, the majority of the study 
participants were symptomatic at the time of starting antiretroviral treatment. 
 
Figure 4.11 WHO clinical stage of study participants and their adherence to ART (N=290) 
Figure 4.11 depicts WHO clinical stages of the study participants, dichotomized into 
asymptomatic and symptomatic, in relation to their adherence to antiretroviral treatment. 
The result showed that, among a total of 49 study participants who were asymptomatic at 
the time of ART initiation, 67.3% (n=33) had optimal adherence and 32.7% (n=16) had 
suboptimal adherence. Out of the 207 study participants who were symptomatic, 81.6% 
(n=169) and 18.4% (n=38) demonstrated optimal and suboptimal adherence, respectively. 
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In this study, a statistically significant association was found between WHO clinical stage 
before initiation of antiretroviral therapy and combined adherence to ART (P=0.027). This 
finding was supported by other similar studies conducted in resource-limited countries. A 
study conducted in Ethiopia revealed that WHO clinical stage was an independent 
predictor of adherence (Tiyou et al 2010:4). Similarly, Campos et al (2010:293) 
demonstrated those patients with asymptomatic clinical stage were more likely to have 
poor adherence. Despite the findings of the above studies, a study conducted in Zambia 
(Chi et al 2009:751) emphasized that WHO clinical stage was not predictive of non 
adherence. 
 
4.3.2.3 Baseline CD4 count of the study participants at the time of ART initiation 
 
Table 4.7 Baseline CD4 count of study participants at the time of ART initiation 
(N=290) 
CD4 count at baseline Frequency Percent 
<200 c/mm3 177 64.1 
200 - 350c/mm3 87 31.5 
>350c/mm3 12 4.3 
Unknown 14 4.8 
Total 290 100.0 
 
As depicted in Table 4.7, the current study revealed that, out of the total 290 participants, 
64.1% (n=177) had a baseline CD4 count of below 200 c/mm3, 31.5% (n=87) had a CD4 
count between 200 and 350 c/mm3, 4.3% (n=12) had a CD4 count of greater than 350 
c/mm3, and the other 4.8% (n=14) did not know their CD4 status at the time of ART 
initiation. This indicated that the majority of the study participants had a low level of 
immunological status at the beginning of their antiretroviral treatment. The fact that a 
significant number of the participants were symptomatic at the time of ART initiation may 
be associated with the low CD4 status before starting treatment. 
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Figure 4.12 Baseline CD4 count and adherence to antiretroviral therapy (N=276) 
Figure 4.12 depicts the relationship between baseline CD4 count and adherence to 
antiretroviral therapy. It indicated that, among 177 study participants with a baseline CD4 
count of less than 200 cells/mm3, 78.5% (n=139) had optimal adherence and 21.5% (n=38) 
had suboptimal adherence. And, out of the 99 participants with a baseline CD4 count of 
200 cells/mm3 and above, 83.8% (n=83) and 16.2% (n=16) had optimal and suboptimal 
adherence, respectively. 
In this study, there was no statistically significant association found between baseline CD4 
count and adherence to ART (P=0.286). This finding was in agreement with other studies 
(Fumaz et al 2008:799; Erah & Arute 2008:149), which revealed the absence of statistical 
difference between adherence of patients and their CD4 count. However, there were other 
contradictory findings in some studies which demonstrated a significant association 
between CD4 count of patients and adherence to ART (Beer et al 2012:216; Campos et al 
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2010:293). Another study (Sarna et al 2008:32) also indicated patients with a baseline CD4 
count of 200 cells per mm3 and above tended to have increased the risk of non adherence. 
4.3.2.4 Duration of antiretroviral therapy 
The study participants were asked about the length of time that had elapsed since they 
started antiretroviral treatment, and the result was displayed in the following table. 
Table 4.8 Distribution of study participants by duration of antiretroviral therapy 
(N=290) 
Duration of ART Frequency Percent 
3 - 6 months 12 4.1 
7 – 12 months 21 7.2 
1-2 years 37 12.8 
>2 years 220 75.9 
Total 290 100 
 
Table 4.8 shows, that out of the total 290 participants, 75.9% (n=220) had been on 
antiretroviral therapy for more than two years, while 12.8% (n=37) of the participants had 
received treatment for 1-2 years. It was also evident that 7.2% (n=21) of the participants 
had been on treatment for 7-12 months while the remaining 4.1% (n=12) had been taking 
antiretroviral therapy for 3-6 months. Thus, it can be said that the majority of the study 
participants had been treated for a relatively long period with antiretroviral therapy.  
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 Figure 4.13 Duration of ARV treatment and adherence to ART (N=290) 
Figure 4.13 shows that, among 70 participants who took antiretroviral treatment for two 
years or below, 77.1% (n=54) had optimal adherence and 22.9% (n=16) had suboptimal 
adherence to ART. Among the 220 study participants who took ART for more than two 
years, 80.9% (n=178) and 19.1% (n=42) reported optimal and suboptimal adherence, 
respectively. 
In this study, there was no a statistically significant association found between duration of 
treatment and adherence to antiretroviral therapy (P=0.493). This result was supported by 
Aragonés et al (2011:19), which showed lack of a significant association between number 
of years on ART and adherence. Consistently, Fumaz et al (2008:799) also revealed that 
length of time on treatment was not associated with level of adherence. However, other 
studies reported conflicting findings. Lal et al (2010:181), for instance, showed that duration 
of time on HAART was significantly associated with adherence. Venkatesh et al (2010:799) 
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also reported that participants who had experienced HAART for greater than 24 months 
were more likely to be less adherent than participants who had been on HAART for less 
than 24 months. However, in a systematic review of studies, it was found that taking ART 
for more than two years was positively associated with adherence in high income countries 
(Gari et al 2013:7). 
 
4.3.2.5 Latest CD4 count of the study participants who had been on treatment for a 
minimum of 6 months 
 
Table 4.9 Latest CD4 count of study participants (N=267) 
Latest CD4 count Frequency Percent 
<200 c/mm3 24 9.0 
200 - 350c/mm3 133 49.8 
>350c/mm3 110 41.2 
Total 267 100.0 
 
The latest CD4 status of the participants who had been receiving ART for a minimum of six 
months was assessed, and Table 4.9 revealed that 41.2% (n=110) had a CD4 count of 
greater than 350 c/mm3, 49.8% (n=133) had a CD4 count between 200 and 350 c/mm3, 
and 9.0% (n=24) had a CD4 count of below 200 c/mm3. The remaining 23 participants did 
not know their CD4 status. This finding indicated that the majority of the participants 
(83.8%) had a CD4 count of 200 c/mm3 or more. Of these, 41.2% (n=110) had a CD4 
count of above 350 c/mm3, which may be explained by the significant number of study 
participants having been taking antiretroviral treatment for more than two years. 
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 Figure 4.14 Latest CD4 count and adherence to ART (N=267) 
Figure 4.14 depicts the relationship between the latest CD4 count of study participants and 
their adherence to ART. It indicated that, out of 24 study participants with a CD4 count of 
below 200 cells/mm3, 87.5% (n=21) had optimal adherence and 12.5% (n=3) had 
suboptimal adherence. Among the 243 participants with a CD4 count of 200 cells/mm3 and 
above, 79.4% (n=193) and 20.6% (n=50) demonstrated optimal and suboptimal adherence 
to antiretroviral treatment, respectively. 
In this study, adherence to antiretroviral therapy was not found to be significantly 
associated with the latest CD4 count (Fisher‟s Exact test=0.431). This was in agreement 
with Fumaz et al (2008:799), which showed no difference in CD4 count of patients with 
different levels of adherence. But, Venkatesh et al (201:799) indicated that participants with 
current CD4 count greater than or equal to 500 cells/mm3 were over two times more likely 
to be non adherent compared to participants with lower CD4 cell counts. 
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4.3.2.6 Illness of the study participants during the past one month 
The study participants were asked whether they had been ill during the past one month, 
and the result was depicted in the following table. 
Table 4.10 Description of illness of study participants in the past one month (N=290) 
Illness in the past one month Frequency Percent 
Yes 77 26.6 
No 213 73.4 
Total 290 100.0 
 
Table 4.10 shows that, among 290 study participants, only 26.6% (n=77) suffered from 
illness during the past one month. The remaining 73.4% (n=213) did not complain of illness 
during the past one month. Majority of the study participants did not suffered from illness in 
the past one month which may be explained by progressive improvement in clinical 
condition of the patients with the use of antiretroviral therapy for long time. 
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 Figure 4.15 Illness in the past one month and adherence to ART (N=290) 
Figure 4.15 depicts the relationship between illness of study participants in the past one 
month and adherence to ART. It reveals that, among 77 study participants who reported 
illness in the past one month, 70.1% (n=54) had optimal adherence and 29.9% (n=23) had 
suboptimal adherence. On the other hand, among 213 study participants who were healthy 
in the past one month, 83.6% (n=178) and 16.4% (n=35) reported optimal and suboptimal 
adherence to ART, respectively. 
In this study, there was a statistically significant association between adherence to ART 
and illness in the past one month (P=0.012). This was consistent with Markos et al 
(2008:177), which documented presence of symptoms in the past month was associated 
with non adherence. 
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4.3.2.7 Description of the seriousness of the illness by the study participants who 
were sick in the past one month 
 
Table 4.11 Seriousness of illness among the study participants who were sick in the 
past one month (N=77) 
Seriousness of illness Frequency Percent 
Mild 43 55.8 
Moderate 31 40.3 
Severe 3 3.9 
Total 77 100.0 
 
Table 4.11 shows the seriousness of illness among the study participants who complained 
of illness in the past one month. Among the 77 participants who were ill in the past one 
month, 55.8% described their illness as mild, 40.3% as moderate, and 3.9% as severe. As 
mentioned earlier, the majority of the participants either did not complain of illness in the 
past month or reported the illness to be mild though they were sick. This may be related to 
the fact that most of the participants had been taking antiretroviral therapy for more than 
two years, which may have improved their immunity and clinical condition. 
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4.3.3 Responses related to questions on the type of current ARV regimen and level 
of adherence 
4.3.3.1 The type of ARV regimen taken by the study participants 
 
 
Figure 4.16 Pie chart showing the type of ARV drug regimen (N=290) 
 
As indicated in Figure 4.16, all of the study participants were taking first line ARV regimen. 
The study revealed that, out of the 290 study participants, 25.9% (n=75) were on 
TDF/3TC/EFV, 23.4% (n=68) on TDF/3TC/NVP, 22.1% (n=64) on AZT/3TC/NVP, 21.7% 
(n=63) on AZT/3TC/EFV, 3.8% (n=11) on D4T/3TC/EFV, and 3.1% (n=9) on 
D4T/3TC/NVP. This revealed that the majority of the respondents were receiving the 
preferred first line ARV regimen (either TDF- or AZT-based), which is currently 
recommended by the national treatment guideline.  
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In this study, there was no statistically significant difference in the type of ARV regimen 
taken between those participants who had optimal adherence and those with suboptimal 
adherence (P=0.682). This suggested that the level of adherence of the study participants 
was not influenced by the type of ARV regimen that the patients were taking. This finding 
was supported by Fumaz et al (2008:799), which showed no statistically significant 
difference in antiretroviral drug use and adherence to ART. Contrary to the current finding, 
a study done in India among HIV positive mothers demonstrated a statistically significant 
relationship between Efavirenz based regimen and poor adherence to ART (De & Dalui 
2012:251). 
 
4.3.3.2 Frequency of daily use of ARV medications 
 
Table 4.12 Frequency of daily use of ARV medications (N=290) 
Frequency of daily dose Frequency Percent 
Once 78 26.9 
Twice 212 73.1 
Total 290 100.0 
 
Table 4.12 shows that, out of the 290 study participants, 73.1% (n=212) took a twice-daily 
regimen and the remaining 26.9% (n=78) took a once-daily regimen. This indicated that 
almost all the study participants were receiving a simplified regimen in the form of fixed 
dose combinations. The ARV drugs taken by study participants were available in dual FDC 
(TDF/3TC, D4T/3TC and AZT/3TC) as well as in triple FDC (D4T/3TC/NVP and 
AZT/3TC/NVP). 
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Figure 4.17 Frequency of dosing of ARV medications and adherence to ART (N=290) 
Figure 4.17 depicts the dosing frequency of ARV medications in relation to combination 
adherence to antiretroviral therapy. It indicated that, of the 78 participants who took a once-
daily ARV regimen, 83.3% (n=65) had optimal adherence and 16.7% (n=13) had 
suboptimal adherence. Among the 212 participants who took a twice-daily ARV regimen, 
78.8% (n=167) and 21.2% (n=45) reported optimal and suboptimal adherence, 
respectively. 
The bivariate analysis in this study found no statistically significant association between 
dosing frequency of ARV medications and combined adherence to ART (P=0.389). This 
result was supported by Fumaz et al (2008:176), who reported no statistically significant 
difference in adherence of patients receiving once-daily and twice-daily ARV regimens. De 
and Dalui (2012:251) also indicated that the frequency of taking drugs daily was not 
associated with lower adherence. However, in situations where ARV medications are taken 
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more than twice in a day, studies suggested an association between increased frequency 
of dosing and poor adherence (De & Dalui 2012:251).  
4.3.3.3 Number of pills of ARV drugs taken daily by the study participants 
 
Table 4.13 Total number of ARV pills taken daily by study participants (N=290) 
Number of pills taken per day Frequency Percent 
Two 149 51.4 
Three 141 48.6 
Total 290 100 
 
Table 4.13 depicts the number of ARV pills taken per day by the study participants. It 
showed that 51.4% (n=149) took two pills per day and the remaining 48.6% (n=141) took 
three pills per day. The formulation of the currently available first line ARV drugs consisted 
of two or three ARV drugs in fixed dose combinations, which contributed to the relative 
reduction of number of pills to be taken daily. Thus, the majority of the participants received 
two ARV pills daily. 
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 Figure 4.18 Number of ARV pills taken per day and adherence to ART (N=290) 
As indicated in Figure 4.18, among 149 participants who took two ARV pills in a day, 
80.5% (n=120) had optimal adherence and 19.5% (n=29) had suboptimal adherence. Out 
of 141 study participants who took three ARV pills per day, 79.4% (n=112) had optimal 
adherence and 20.6% (n=29) had suboptimal adherence. 
In this study, there was no statistically significant association between the number of ARV 
pills taken per day and adherence to ART (P=0.841). This finding is in agreement with 
another study which suggested that adherence did not differ between once- or twice-daily 
regimens (Fumaz et al 2008:799). However, a study conducted in India demonstrated 
taking four or more pills in a day was significantly associated with non adherence (Sarna et 
al 2008:32). 
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4.3.3.4 Adherence level of the study participants 
In this study adherence level of the study participants was assessed by using a self report 
method. The participants were asked to report on the number of missed ARV doses, how 
closely they followed their medication schedules, and dietary instructions agreed with 
health care providers in the past three days. The results of the level of adherence of the 
study participants based on three days‟ recall to dose, schedule, and dietary instructions 
are depicted in Table 4.14. 
Table 4.14 Distribution of participants, by adherence category in the past three days 
(N=290) 
Category Optimal Suboptimal Total 
Frequency Percent Frequency Percent Frequency Percent 
Dose adherence 256 88.3 34 11.7 290 100.0 
Schedule adherence 237 81.7 53 18.3 290 100.0 
Dietary adherence 197 82.8 41 17.2 238 100.0 
Combined adherence 232 80.0 58 20.0 290 100.0 
 
Self report dose adherence was measured by asking participants the number of missed 
doses of ARV pills in the past three days. Missing at least one dose of ARV pills in the past 
three days resulted in adherence level of less than 95%. Table 4.14 shows that the majority 
(88.3% (n=256)) of participants reported no missed doses of prescribed ARV pills in the 
past three days, which resulted in an optimal adherence of >/= 95%. The remaining 11.7% 
(n=34) of the participants reported missing at least one dose of their HIV medications, 
which meant that they had a suboptimal dose adherence of less than 95%. This adherence 
rate is found to be relatively higher than those reported in Ethiopia by Markos et al 
(2008:176) and Amberbir et al (2008:[S.a]). But it is lower than the adherence rate of 95% 
reported by Tiyou et al (2008:3-4). A similar finding was reported by Beer et al (2012:216). 
With respect to schedule adherence, among the 290 study participants, the majority 
(82.4%) reported to have closely followed their ARV medications to the specific schedule in 
the past three days. This shows that a remarkable percentage of the participants took their 
medications at appropriate times according to the schedules agreed with the provider. The 
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result was found to be slightly higher than those in other similar studies in the country 
(Markos et al 2008:176; Tiyou et al 2008:3-4). 
In this study, out of the 290 study participants, 82.0% (n=238) reported that they received 
special instructions in taking their HIV medications, and the remaining 18.0% (n=52) did not 
have such instructions. Out of the 238 participants who had special instructions related to 
dietary requirements from clinicians, 82.8% (n=197) reported to have followed the 
instructions all of the time in the past three days and they reported good adherence to 
instructions. However, the remaining 17.2% (n=41) of the participants did not often follow 
the instructions from clinicians in the past three days, which suggested that they had poor 
adherence to dietary instructions. 
In this study the overall level of combined adherence to antiretroviral therapy in the past 
three days was measured taking dose adherence, schedule adherence, and dietary 
instruction adherence into account. The result showed that, out of the 290 study 
participants, a combined optimal adherence rate of 80.0% (n=232) was reported. This 
means the participants fulfilled an optimal adherence criteria of taking >/= 95% of the 
prescribed ARV pills at the specified time schedule, and always conformed to the agreed 
dietary instructions. And, the non adherence rate was 20.0%.  
The level of combined adherence in this study seems to be relatively higher than that of a 
study conducted in South West Ethiopia (Tiyou et al 2008:3-4) and other studies in Africa 
(e.g. Jean-Baptiste 2008:15). However, the finding of this study is found to be comparable 
to the findings of other studies conducted in Ethiopia, Zambia, Nigeria, Uganda and 
Tanzania (Abaase et al 2018:[S.a]; Amberbir et al 2008 [S.a]; Balikuddembe et al 2012:3: 
Ekama et al 2012:3; Nozaki et al 2011:832; Tessema et al 2010:5), as well as to the 
adherence level reported in the meta-analyses of studies in Sub-Saharan countries (Mills 
et al 2006a:682). 
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4.3.3.5 Response of the study participants on missing doses of ARV medication in 
the past 7 days 
 
Table 4.15 Missed doses of ART in the past 7 days (N=290) 
Missed dose in the past 7 days Frequency Percent 
Yes 45 15.5 
No 245 84.5 
Total 290 100 
 
As depicted in Table 4.15, the research finding on the adherence status of the study 
participants in the past week revealed that 84.5% (n=245) had not missed any of their ARV 
medications, and only 15.5% (n=45) had missed their pills in the past 7 days. Thus, the 
majority of the respondents reported optimal adherence during the week before the 
interview. 
4.3.3.6 Response of the study participants on missing doses of ARV medication in 
the past one month 
Table 4.16 Missed doses of ARV medication by study participants in the past one 
month (N=290) 
Missed doses in the past one month Frequency Percent 
Yes 51 17.6 
No 239 82.4 
Total 290 100 
 
Similarly, the study participants were asked on their adherence behaviour in the past one 
month. The finding depicted in Table 4.16 demonstrates that 82.4% (n=239) of the 
participants had not missed doses of any of their ARV medications, while 17.6% (n=51) of 
the study participants had missed doses of their ARV pills. Again, the majority of the study 
participants reported having taken their prescribed antiretroviral pills properly. 
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4.3.3.7 Change of ARV medication 
The study participants were asked about a change of ARV medication from the initial 
regimen, and the result is depicted in the following table. 
Table 4.17 Distribution of study participants, by change of ARV medication (N=290) 
Change of ARV medication Frequency Percent 
Yes 64 22.1 
No 226 77.9 
Total 290 100 
 
Table 4.17 shows that, out of the total 290 study participants, 77.9% (n=226) had never 
changed their ARV regimen, while 22.1% (n=64) reported having changed their ARV 
medications for different reasons. Thus, the majority of the study participants have been 
put on the same regimen since the initiation of the antiretroviral treatment. 
 
Figure 4.19 Change of ARV medications and combined adherence to ART (N=290) 
The relationship between change of ARV medication and combined adherence to ART is 
depicted in Figure 4.19. The result indicates that, out of 64 study participants who had had 
a change in ARV medication, 70.3% (n=45) reported optimal adherence and 29.7% (n=19) 
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reported suboptimal adherence. Out of the 226 participants who did not change their ARV 
medication, 82.7% (n=187) had optimal adherence and 17.3% (n=39) had suboptimal 
adherence. 
The bivariate analysis in this study revealed a statistically significant association between 
change of HIV medication and combined adherence to ART (P=0.028). The study finding 
pointed out that those participants who had changed their HIV medication tended to have 
suboptimal adherence as compared to those who had not changed ARV medication. This 
is supported by a study conducted in Brazil (Bonolo et al 2005:S9), which revealed that 
switching ARV regimen was significantly associated with non adherence. 
 
4.3.3.8 Reasons for missing ARV medications in the past one month by the study 
participants 
The study participants who missed doses of their ARV medications in the past one month 
were asked about the reasons for missing their medication. In this study, the result showed 
that 17.6% (N=51) participants missed their ARV medication in the past one month. The 
reasons for missing ARV drugs cited by these study participants are depicted in the 
following table. 
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Table 4.18 Reasons for missing doses of ARV medications in the past one month 
Responses Frequency Percent 
Forgetting 20 35.1 
Being busy with other things 10 17.5 
Running out of pills 6 10.5 
Not wanting others to see them taking their medication 5 8.8 
Feeling depressed 5 8.8 
Having too many pills to take 2 3.5 
Feeling good 2 3.5 
Feeling sick or ill 2 3.5 
Feeling like the drug was harmful 1 1.8 
Wanting to avoid side effects 1 1.8 
Being away from home 1 1.8 
Lack of transportation 1 1.8 
Shortage of food 1 1.8 
Total 57 100.0 
 
The most common reason mentioned by the study participants for missing their HIV 
medications in the past one month was forgetfulness (35.1%). This was followed by being 
busy with other things (17.5%), running out of pills (10.5%), feeling depressed (8.8%), and 
not wanting others to see them taking their medications (8.8%). This finding is supported 
by many other similar studies conducted in resource-limited settings. Forgetfulness and 
being busy with other things were frequently identified reasons which were consistently 
observed in various studies (Jean-Baptiste 2008:16; Markos et al 2008:176; Sullivan et al 
2007:3; Tiyou et al 2010:4; Wang et al 2009:759; Wasti et al 2012:73-75; Watt et al 
2010:384). Some studies also suggested that running out of pills was a reason for missing 
ARV medications (Wasti et al 2012:75; Tiyou et al 2010:4). 
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4.3.4 Knowledge about HIV disease and antiretroviral therapy 
The study participants were asked to respond to items related to knowledge of the HIV 
disease and antiretroviral therapy based on a five-point Likert scale ranging from „strongly 
disagree‟ to „strongly agree‟. 
4.3.4.1 You know how each of your current HIV medications is supposed to be taken. 
 
Table 4.19 Response of study participants to the statement that they knew about 
how their current HIV medications are supposed to be taken (N=290) 
Response Frequency Percent 
Somewhat disagree 3 1.0 
Neither agree nor disagree 42 14.5 
Somewhat agree 99 34.1 
Strongly agree 146 50.4 
Total 290 100.0 
 
The study participants were asked to state to what extent they agreed or disagreed to the 
statement that they knew how their HIV medications were supposed to be taken. Table 
4.19 indicates that 50.4 % (n=146) of them strongly agreed, 34.1% (n=99) somewhat 
agreed, 14.5% (n=42) neither agreed nor disagreed, and 1% (n=3) somewhat disagreed to 
the statement. This illustrates that the majority (84.5%) of the study participants agreed that 
they had adequate knowledge on how their HIV medications were supposed to be taken. 
This shows that participants had information about how to take their HIV medication from 
health care providers at the time of ART initiation and during follow-up visits. This is 
important for the participants to properly adhere to their medications as prescribed. 
 
 
 
102 
 
4.3.4.2 You know what to do if you miss a dose of any of your HIV medications. 
 
Table 4.20 Response of study participants on knowledge about what to do if a dose 
of HIV medication is missed (N=290) 
Response Frequency Percent 
Somewhat disagree 6 2.0 
Neither agree nor disagree 26 9.0 
Somewhat agree 78 26.9 
Strongly agree 180 62.1 
Total 290 100.0 
 
Table 4.20 illustrates that, out of the 290 study participants, 62.1% (n=180) strongly 
agreed, 26.9% (n=78) somewhat agreed, 9.0% (n=26) neither agreed nor disagreed, and 
2.0% (n=6) somewhat disagreed to the statement of knowledge on what to do if patients 
missed any of their mediation. Thus, the majority (89.0%) knew what to do if they missed 
their medication. This may indicate that patients are prepared to act appropriately in 
different circumstances where doses of HIV medication might be missed. 
4.3.4.3 Skipping a few of your HIV medications from time to time would not really 
hurt your health. 
Table 4.21 Response of study participants on whether skipping HIV medications 
would not hurt the health of patients (N=290) 
Response Frequency Percent 
Strongly agree 3 1.0 
Somewhat agree 21 7.2 
Neither agree nor disagree 28 9.7 
Somewhat disagree 70 24.1 
Strongly disagree 168 57.9 
Total 290 100.0 
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Table 4.21 shows that the majority of the respondents (57.9%) strongly disagreed and 
24.1% (n=70) somewhat disagreed to the statement that skipping a few of the ARV 
medications would not really hurt the health of the participants. The rest (9.7%, 7.2% and 
1.0%) neither agreed nor disagreed, somewhat, agreed and strongly agreed to the 
statement, respectively. This suggests that the majority of the study participants were not 
likely to take the risk of skipping doses of ARV medications as they acknowledged the 
consequences of missing drugs on their health. 
 
4.3.4.4 You know what the possible side effects of each of your HIV medications are. 
 
Table 4.22 Response of study participants on knowledge about the possible side 
effects of ARV medications (N=290) 
Response Frequency Percent 
Strongly disagree 2 0.7 
Somewhat disagree 7 2.4 
Neither agree nor disagree 56 19.3 
Somewhat agree 93 32.1 
Strongly agree 132 45.5 
Total 290 100.0 
 
The respondents were also asked if they knew the side effects of each of their ARV 
medications. As indicated in Table 4.22, the majority of the participants (45.5%) strongly 
agreed, and 32.1% (n=93) somewhat agreed, while 19.3% (n=56) neither agreed nor 
disagreed to the statement that they had knowledge of the possible side effects of their 
medications. The remaining 3.1% (n=9) of the participants did not have knowledge of the 
side effects of their ARV medications. This indicates that the majority of the study 
participants had appropriate counselling regarding possible adverse events related to HIV 
medications from health care providers while visiting the clinics. 
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4.3.4.5 As long as you are feeling healthy, missing your HIV medications from time to 
time is OK. 
 
Table 4.23 Response of study participants to the statement that missing HIV 
medications is OK as long as they are feeling healthy (N=290) 
Response Frequency Percent 
Strongly agree 4 1.4 
Somewhat agree 37 12.8 
Neither agree nor disagree 24 8.3 
Somewhat disagree 99 34.1 
Strongly disagree 126 43.4 
Total 290 100.0 
 
The responses of the participants to the statement that missing HIV medications from time 
to time was OK as long as they felt healthy is depicted in Table 4.23. The majority of the 
respondents strongly disagreed 43.4% (n=126), and 34.1% (n=99) somewhat disagreed to 
that statement. This may indicate that most of the participants knew an HIV medication is a 
lifelong treatment and should not be interrupted even if the patient is clinically stable and 
well. In contrast, the other 14.2% (n=41) of the participants agreed to the statement, which 
suggests that these patients might not properly adhere to their medication during their 
course of treatment. 
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4.3.4.6 You understand how your HIV medications work in your body to fight HIV. 
 
Table 4.24 Response of study participants on their knowledge about how HIV 
medications work in their body to fight HIV (N=290) 
Response Frequency Percent 
Strongly disagree 1 0.3 
Somewhat disagree 4 1.4 
Neither agree nor disagree 31 10.7 
Somewhat agree 111 38.3 
Strongly agree 143 49.3 
Total 290 100.0 
 
Table 4.24 shows the response of the participants on whether they understood how HIV 
medications work in their body to fight HIV infection. Among the 290 participants, 49.3% 
(n=143) strongly agreed, and 38.3% (n=111) somewhat agreed to the statement. This may 
indicate that most of the patients get enough information in relation to the way that HIV 
medications work to effectively control or suppress the HIV virus in the body. 
4.3.4.7 If you don’t take your HIV medications as prescribed, these medications may 
not work for you in the future. 
 
Table 4.25 Response of study participants to the statement that HIV medications 
may not work for the future if they did not take them as prescribed (N=290) 
Response Frequency Percent 
Somewhat disagree 3 1.0 
Neither agree nor disagree 29 10.0 
Somewhat agree 94 32.4 
Strongly agree 164 56.6 
Total 290 100.0 
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As depicted in Table 4.25, out of the 290 study participants, 56.6% (n=164) strongly agreed 
and 32.4% (n=94) somewhat agreed to the statement that if patients did not take HIV 
medications as prescribed, these medications may not work in the future. This suggests 
that the majority of the participants were informed that unless the medications are taken as 
prescribed, the drugs will tend to fail in the future. 
 
4.3.4.8 Antiretroviral medications eradicate HIV from your body. 
 
Table 4.26 Response of study participants on whether they believe antiretroviral 
medications eradicate HIV from their body (N=290) 
Response Frequency Percent 
Strongly agree 1 0.3 
Somewhat agree 4 1.4 
Neither agree nor disagree 33 11.4 
Somewhat disagree 87 30.0 
Strongly disagree 165 56.9 
Total 290 100.0 
 
As depicted in Table 4.26, the result shows that the majority of the study participants 
(56.9%) strongly disagreed and 30.0% (n=87) somewhat disagreed that antiretroviral 
medications eradicate HIV from the body. Thus, this indicates that most of the participants 
were aware that HIV infection is not yet curable with the currently available antiretroviral 
medications. However, the remaining 38 (13.1%) participants believed or were in doubt 
that antiretroviral medications eradicate HIV from the body. This misinformation or 
misconception may adversely affect adherence behaviour of the patients. 
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4.3.4.9 You believe that if you take your HIV medications as prescribed, you will live 
longer. 
 
Table 4.27 Response of study participants as to whether they believe that if they take 
HIV medications as prescribed, they will live longer (N=290) 
Response Frequency Percent 
Somewhat disagree 1 0.3 
Neither agree nor disagree 21 7.2 
Somewhat agree 78 26.9 
Strongly agree 190 65.5 
Total 290 100.0 
 
As can be seen from Table 4.27, the majority of the study participants (92.4%) believed 
that they could live longer if they took their HIV medications as prescribed. This may be a 
positive reinforcement for the patients to better adhere to their medications to save their 
lives. The remaining 7.5% (n=22) of participants did not believe they would live longer by 
taking their HIV medications as prescribed. 
4.3.4.10 You know how your HIV medications interact with substances such as 
alcohol and ‘khat’. 
Table 4.28 Knowledge on interaction of HIV medications with substances such as 
alcohol and ‘khat’ (N=290) 
Response Frequency Percent 
Somewhat disagree 2 0.7 
Neither agree nor disagree 13 4.5 
Somewhat agree 81 27.9 
Strongly agree 194 66.9 
Total 290 100.0 
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Table 4.28 depicts the responses of the participants regarding their knowledge on the 
interaction of HIV medications with substances such as alcohol and „khat‟. The majority of 
the participants (66.9%) strongly agreed and 27.9% (n=81) somewhat agreed to that 
statement, indicating that the majority were knowledgeable about the interaction of HIV 
medications with the substances. The remaining 5.2% (n=15) did not know the 
consequences of the interaction of HIV medications with substances such as alcohol and 
„Khat‟. This suggests that awareness creation work in this aspect could bring about a 
positive behavioural change to such people.  
On the composite scale measurement the average score of study participants on 
knowledge about HIV disease and antiretroviral therapy was found to be 43.72, ranging 
from a minimum score of 10 to a maximum score of 50 representing „strongly disagree‟ and 
„strongly agree‟. This shows that the majority of the study participants tend to have good 
knowledge on HIV disease and antiretroviral treatment. 
In this study, there was a statistically significant association between having adequate 
knowledge about HIV disease and antiretroviral therapy, and combined adherence to ART 
(t = 4.270, P=0.000). This meant that participants who had adequate knowledge on 
aspects related to HIV disease and antiretroviral therapy had a better level of adherence as 
compared to those who had not. This finding is consistent with various studies conducted 
in developing and developed nations. A study conducted in southern Ethiopia documented 
that knowledge about adherence to ART was associated with adherence (Markos et al 
2008:176). Amico et al (2009:74) also indicated that better adherence was associated with 
greater knowledge about one‟s ARV regimen. Lal et al (2010:3) demonstrated significant 
association between having information about the importance of adherence and adherence 
to ART. It was found that those who reported not having been told about the importance of 
HAART were 9.2 times more likely to be non adherent compared to those who reported 
having been told about its importance (P < 0.001). Similarly, in a systematic review of 
studies, Gari et al (2013:7) reported higher level of treatment information and believing in 
the benefits of ARVs were associated with adherence to ART in high income countries 
(Gari et al 2013:7). Having information about the possible side effects of antiretroviral drugs 
also had influence on the adherence of patients. Evidence emphasized that having 
complaints of the side effects of antiretroviral medications was significantly associated with 
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poor adherence (Achappa et al 2013:222; De & Dalui 2012:251). This had implication on 
the importance of providing adequate information to patients about the adverse effects of 
their HIV medications. In contrast, Sarna et al (2008:32) indicated that knowledge of ART 
was not found to be associated with non adherence. Another study (Markos et al 2008:176) 
also reported that knowledge of patients about the benefit of ART was not associated with 
adherence. 
This finding has a paramount importance in the provision of clinical care and antiretroviral 
therapy to HIV infected individuals, emphasizing on the role of health care providers to 
counsel and educate patients to positively influence their adherence behaviour. The 
education sessions need to address issues related to the nature of HIV disease and 
antiretroviral therapy, including how HIV medications should be taken, the importance of 
ART and adherence, how long HIV medications need to be taken, the possible adverse 
effects of antiretroviral therapy, and their interaction with substances such as alcohol. 
 
4.3.5 Responses to questions related to disclosure and social support 
The study participants were also asked questions related to disclosure and social support. 
The next section presented the findings on items related to disclosure and social support 
as follows. 
 
4.3.5.1 Disclosure of one’s HIV status to friends and/or family members    
The study participants were asked whether they disclosed their HIV status to their friends 
and/or family members or not, and the result is depicted in the following table. 
Table 4.29 Disclosure of one’s HIV status to friends and/or family members (N=290) 
Response Frequency Percent 
Yes 249 85.9 
No 41 14.1 
Total 290 100.0 
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As indicated in Table 4.29, out of 290 study participants, 85.9% (n=249) disclosed their HIV 
status to their friends and/or family members, while the remaining 14.1% (n=41) did not 
disclose their HIV status to any individual close to them. 
 
Figure 4.20 Disclosure of HIV status to friends and/or family members and adherence to ART (N=290) 
Figure 4.20 depicts that, among 249 participants who disclosed their HIV status to their 
friends and/or family members, 82.3% (n=205) had optimal adherence and 17.7% had 
suboptimal adherence. On the other hand, among the 41 study participants who did not 
disclose their HIV status to anyone, 65.9% (n=27) and 34.1% (n=14) had optimal and 
suboptimal adherence, respectively. 
In this study, a statistically significant association was found between disclosure of one‟s 
HIV status to a friend and/or family members and his/her adherence behaviour (P=0.015). 
This result is supported by Birbeck et al (2009:672), who revealed that disclosure of one‟s 
HIV status to his/her spouse was associated with good adherence. Another study (Wasti et 
al 2012:75) also indicated that fear of disclosure of HIV status to the community was found 
to be one of the socio-cultural factors preventing adherence to antiretroviral therapy.  
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Patients may not want to disclose their HIV status due to fear of social stigma. Also, fear of 
social stigma in turn was found to be associated with non adherence (Achappa et al 
2013:222). 
 
4.3.5.2 Do you have family members and/ or friends that support you in taking your 
medications?       
 
Table 4.30 Support provided to study participants on taking HIV medications from 
family members and/or friends (N=290) 
Response Frequency Percent 
Yes 214 73.8 
No 76 26.2 
Total 290 100.0 
              
As depicted in Table 4.30, among the 290 respondents, 73.8% (n=214) claimed they had 
either a friend and/or a family member that supported them in taking their ARV 
medications. However, the remaining 26.2% (n=76) did not have support from their families 
and/or friends in taking their antiretroviral medications. This indicates that the majority of 
the study participants got support from close friends and/or family members to properly 
take their medication. 
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Figure 4.21 Support from family and/or friend in taking HIV medications and adherence to ART 
(N=290) 
As indicated in Figure 4.21, out of the 214 study participants who had support from a family 
member and/or friend in taking their medications, 83.2% (n=178) had optimal adherence 
and 16.8% (n=36) had suboptimal adherence. However, among the 76 participants who did 
not have the support, 71.1% (n=54) had optimal adherence and 28.9% (n=22) had 
suboptimal adherence. 
In this study, there was a statistically significant association found between availability of 
support in taking HIV medications from a family and/or friend and adherence to ART 
(P=0.023). This shows that participants who had support from their friends and/or family 
members tend to have better adherence than those without support. This result is in 
agreement with a study conducted in Ethiopia (Amberbir et al 2008: [S.a]), which reported 
that adherence was more common in patients having social support. Other studies also 
demonstrated similar results in which availability of support from friends and relatives was 
associated with good adherence (Aragonés et al 2011:19; Jean-Baptiste 2008:19; Nozaki 
et al 2011:834; Protopopescu 2009:602; Tiyou et al 2010:4). However, Sarna et al 
(2008:32) did not find association between social support and adherence to HIV 
medications. 
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4.3.5.3 How often do your friends and/or family members help you remember to take 
your medication?       
Table 4.31 Help from friends and/or family members to remember to take HIV 
medications (N=214)      
Response Frequency Percent 
Sometimes 72 33.6 
Most of the time 114 53.3 
Always 28 13.0 
Total 214 100.0 
 
Table 4.31 shows that, out of a total of 214 study participants who had friends and/or family 
member to support them, 33.6% (n=72) sometimes got help from them to remember to 
take HIV medications, 53.3% (n=114) got help most of the time, and 13.0% (n=28) always 
got help. Although the majority of the study participants almost regularly received support 
from their friends and/or relatives to remember to take their HIV medications, some of them 
lacked frequent support, which might contribute to the lower level of adherence for such 
patients. 
4.3.5.4 How satisfied are you with the overall support you get from your friends 
and/or family members? 
Table 4.32 Satisfaction of the study participants with the overall support from friends 
and/or family members (N=234) 
Response Frequency Percent 
Very dissatisfied 2 0.9 
Somewhat dissatisfied 13 5.6 
Neither satisfied nor dissatisfied 64 27.4 
Satisfied 31 13.2 
Very satisfied 124 53.0 
Total 234 100.0 
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Table 4.32 indicates that, out of the 234 study participants, 0.9% (n=2) were very 
dissatisfied, 5.6% (n=13) were somewhat dissatisfied, 27.4% (n=64) were neither satisfied 
nor dissatisfied, 13.2% (n=31) were satisfied, and 53.0% (n=124) were very satisfied with 
the overall support from their friends and/or relatives. A significant proportion of the study 
participants did not seem to be satisfied with the support of their close friends and relatives. 
This may be related to the finding that the frequency of support some patients got in 
remembering to take HIV medications was relatively low. 
The bivariate analysis in this study showed no statistically significant association between 
satisfaction with the overall support of study participants from their friends and/or relatives 
and their combined adherence to ART (P=0.222). This finding is not supported by other 
similar studies. A study conducted in Ethiopia (Markos et al 2008:176) reported that 
satisfaction with social support was associated with adherence. Similarly, a study in 
Vietnam suggested significant association between low satisfaction of received support 
and poor adherence to ART (Do et al 2013:5). 
 
4.3.5.5 Do you use any method to remind you to take your ARV medication?      
The study participants were also asked if they used reminders to take their HIV 
medications. 
Table 4.33 Use of reminders to take ARV medications (N=290) 
Response Frequency Percent 
Yes 242 83.4 
No 48 16.6 
Total 290 100.0 
 
As shown in Table 4.33, among 290 participants, 83.4% (n=242) claimed that they used 
reminders to help them to take their ARV medications properly while the remaining 16.6% 
(n=48) did not use reminders. The majority of the study participants used reminders to 
correctly take their HIV medications as prescribed, which helped them not to miss doses of 
ARV pills. Most of the time, patients may engage in various routine activities and may 
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forget to take their pills appropriately. This is supported by the finding that forgetfulness 
was mentioned as the most common reason for the study participants to miss their ARV 
pills in the past one month. 
 
Figure 4.22 Use of reminders to take HIV medication and adherence to ART (N=290) 
 
Figure 4.22 reveals that, out of 242 study participants who used reminders to take their HIV 
medication, 82.6% (n=200) had optimal adherence and 17.4% (n=42) had suboptimal 
adherence. Out of the 48 participants who did not use reminders, 66.7% (n=32) reported 
optimal adherence and the remaining 33.3% (n=16) had suboptimal adherence. 
The bivariate analysis in this study showed a statistically significant association between 
use of reminders to take HIV medications and adherence to ART (P=0.011). This is 
supported by Nozaki et al (2011:834), which reported that using reminders to take HIV 
medications was associated with better adherence. Similarly, Amberbir et al (2008: [S.a]) 
also indicated that use of memory aids was an independent predictor of adherence to 
antiretroviral therapy. 
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4.3.6 Aspects of patient-provider relationship 
Different aspects of the patient-provider relationship were assessed on a five-point Likert 
scale, in which responses ranged from „strongly disagree‟ to „strongly agree‟. 
 
4.3.6.1 The health care providers give you appropriate information about taking your 
medications. 
 
Table 4.34 Response of study participants on provision of appropriate information in 
taking HIV medications by health care providers (N=290) 
Response Frequency Percent 
Strongly disagree 3 1.0 
Somewhat disagree 11 3.8 
Neither agree nor disagree 38 13.1 
Somewhat agree 97 33.4 
Strongly agree 141 48.6 
Total 290 100.0 
 
Table 4.34 shows that, among the 290 study participants, 48.6% (n=141) strongly agreed 
and 33.4% (n=97) somewhat agreed to the statement that they get appropriate information 
about taking their medications from the health care providers. The majority of the study 
participants reported that they received appropriate information about their medication from 
the health care providers. This was directly linked with the finding that the majority of the 
participants confirmed having adequate knowledge on aspects related to their HIV 
medications. This may in turn serve to alert the patients to properly take their medications 
as prescribed by the health care providers. Of the remaining participants, 13.1% (n=38) 
remained neutral, 3.8% (n=11) somewhat agreed, and 1.0% (n=3) strongly disagree to the 
statement. 
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4.3.6.2 It is easy for you to discuss problems related to your medication with the 
health care providers. 
 
Table 4.35 Response of study participants on whether it is easy for them to discuss 
problems related to HIV medications with their health care providers (N=290) 
Response Frequency Percent 
Strongly disagree 3 1.0 
Somewhat disagree 7 2.4 
Neither agree nor disagree 32 11.0 
Somewhat agree 80 27.6 
Strongly agree 168 57.9 
Total 290 100.0 
 
Table 4.35 reveals that, out of the 290 participants, 57.9% (n=168) and 27.6% (n=80) 
strongly agreed and somewhat agreed, respectively, to the statement that the patients 
were at ease to discuss their problems related to HIV medications with their health care 
providers. This indicates that the majority of the participants were comfortable to discuss 
their problems with health care providers, which can greatly influence adherence behaviour 
of the patients. It is vital for the patients to approach their health care providers openly to 
talk about their health- and medication-related problems without fear and discomfort. This 
may also be a reflection of the positive attitude of health care providers towards their 
patients, treating them with respect and giving them adequate time to talk about their 
problems.  
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4.3.6.3 The health care providers understand the problems you may have in taking 
your ARV medications. 
 
Table 4.36 Response of study participants on whether health care providers 
understand the problems that patients have in taking HIV medications (N=290) 
Response Frequency Percent 
Strongly disagree 5 1.7 
Somewhat disagree 7 2.4 
Neither agree nor disagree 31 10.7 
Somewhat agree 89 30.7 
Strongly agree 158 54.5 
Total 290 100.0 
 
Table 4.36 shows that, out of 290 study participants, 54.5% (n=158) strongly agreed and 
30.7% (n=89) somewhat agreed to the statement that health care providers understand the 
problems that patients may encounter in taking their HIV medications. This may indicate 
the health care providers seem to be ready to help their patients with the problems they 
may face. This result is supported by the finding with respect to feeling easy to discuss 
problems with health care providers. 
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4.3.6.4 The health care providers often help you in solving the problems you may 
have in taking medications. 
 
Table 4.37 Support from the health care providers in solving problems related to 
taking HIV medications (N=290) 
Response Frequency Percent 
Strongly disagree 5 1.7 
Somewhat disagree 13 4.5 
Neither agree nor disagree 31 10.7 
Somewhat agree 88 30.3 
Strongly agree 153 52.8 
Total 290 100.0 
 
Table 4.37 shows that, out of the 290 participants, 52.8% (n=153) strongly agreed and 
30.3% (n=88) somewhat agreed to the statement that they often get help from health care 
providers in solving problems related to taking their medications. Of the remaining 
participants, 10.7% were neutral, 4.5% somewhat disagreed, and 1.7%, strongly agreed to 
the statement. This result was related to the above findings that indicated positive attitudes 
of the study participants about the interaction with their health care providers. 
 
4.3.6.5 You are satisfied with the overall care and support you get from the health 
care providers. 
The overall satisfaction of the participants on the care and support provided by health care 
providers was assessed and the findings are presented in the following table. 
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Table 4.38 Response of study participants on their satisfaction with the overall care 
and support provided by health care providers (N=290) 
Response Frequency Percent 
Strongly disagree 4 1.4 
Somewhat disagree 18 6.2 
Neither agree nor disagree 20 6.9 
Somewhat agree 92 31.7 
Strongly agree 156 53.8 
Total 290 100.0 
 
As indicated in Table 4.38, among the 290 participants, 53.8% (n=156) and 31.7% (n=92) 
were fully satisfied and somewhat satisfied with the overall care and support provided by 
the health care providers. However, only 6.9% (n=20) were neutral and 7.6% (n=22) were 
not satisfied with the overall care and support provided. 
The result on the composite scale of measurement of aspects related to the patient-
provider relationship revealed an average score of 21.56, which ranged from 5 to 25, 
representing extreme results. This denotes that the majority of the study participants tend 
to have a positive interpretation of the aspects of patient-provider relationship. 
In this study, a statistically significant association was found between perception of study 
participants on aspects of patient-provider relationship and adherence to antiretroviral 
treatment (t = 2.551, P=0.011). Participants who had a positive view on the items related to 
patient-provider relationship were found to demonstrate better adherence as compared to 
those with a negative view. Aspects of patient-provider relationship in this study 
emphasized on the provision of appropriate information about HIV medications, 
interactions between patients and health care providers while discussing problems related 
to HIV mediation, and the perceived satisfaction with overall support of health care 
providers. This finding is in agreement with Watt et al (2010:384), which found that 
perceived quality of patient-provider interaction was associated with adherence to ART. 
Other studies also demonstrated supportive evidence for the influence of aspects of 
patient-provider relationship on adherence. A study conducted in Vietnam (Do et al 2013:5) 
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reported that negatively perceived quality of information was significantly associated with 
suboptimal adherence to ART. In addition, De and Dalui (2012:251) indicated a significant 
association between bad attitude of health care personnel and poor adherence to ART. 
 
4.3.7 Aspects of clinical care setting 
Different aspects of the clinical care setting were also assessed using a five-point Likert 
scale with response ranging from „strongly disagree‟ to „strongly agree‟.  
 
4.3.7.1 You believe that health care providers keep your health-related information 
confidential. 
 
Table 4.39 Response of study participants to whether they believed health care 
providers kept their health-related information confidential (N=290) 
Response Frequency Percent 
Somewhat disagree 7 2.4 
Neither agree nor disagree 27 9.3 
Somewhat agree 63 21.7 
Strongly agree 193 66.6 
Total 290 100 
 
As shown in Table 4.39, out of the 290 participants, 88.3% (n=256) believed that the health 
care providers kept patients‟ health-related information confidential. This may indicate that 
patients have trust in their health care providers and protect them against social stigma and 
discrimination by keeping their information confidential, and this may encourage patients to 
freely discuss health-related issues with health care providers.  
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Figure 4.23 Perception of study participants on confidentiality of health-related information and 
adherence to ART (N=290) 
 
As shown in Figure 4.23, among the 258 participants who believed their health-related 
information was kept confidential by health care providers, 82.9% (n=214) had optimal 
adherence and 17.1% (n=44) had suboptimal adherence. However, out of the 32 
participants who did not believe information was kept confidential, 56.2% (n=18) and 43.8% 
(n=14) reported optimal and suboptimal adherence, respectively. 
In this study, there was a statistically significant association between perception of study 
participants on confidentiality of their health-related information and adherence to 
antiretroviral therapy (P=0.000). This is supported by Machtinger and Bangsberg (2006), 
which stated adherence of patients to their HIV medications, was influenced by perceived 
confidentiality of patients‟ clinical status. 
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4.3.7.2 Appointment schedules to your medication refill are convenient to you. 
 
Table 4.40 Response of study participants on the convenience of appointment 
schedules to HIV medication refill (N=290) 
Response Frequency Percent 
Somewhat disagree 9 3.1 
Neither agree nor disagree 26 9.0 
Somewhat agree 62 21.3 
Strongly agree 193 66.6 
Total 290 100.0 
 
As can be seen in Table 4.40, out of the 290 study participants, 66.6% (n=193) strongly 
agreed and 21.3% (n=62) somewhat agreed that appointment schedules to their 
medication refills were convenient. But 9.0% (n=26) remained neutral while 3.1% (n=9) 
somewhat disagreed to the statement. Thus, the majority of the study participants were 
happy about their appointment schedules. This could create an opportunity for the patients 
to collect their medications in time, and patients could avert the risk of interrupting their 
medications.  
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Figure 4.24 Convenience with scheduling appointments to medication refill and adherence to ART 
(N=290) 
 
As depicted in Figure 4.24, among the 255 participants who were happy with appointment 
schedules to medication refill, 82.7% (n=211) had optimal adherence and 17.3% (n=44) 
had suboptimal adherence. On the other hand, out of the 35 participants who were not 
happy with the appointment schedules, 60.0% (n=21) and 40.0% (n=14) reported optimal 
and suboptimal adherence, respectively. 
The bivariate analysis in this study found a statistically significant association between 
convenience with the appointment schedules to HIV medication refill and adherence to 
antiretroviral therapy (P=0.002). This result is in agreement with a study conducted in 
Eastern Africa (Chalker et al 2010: [S.a]), which indicated attendance of clinic within 3 days 
of appointment was significantly associated with self-report adherence. 
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4.3.7.3 You have frequently missed clinic appointments. 
Table 4.41 Response of study participants to whether they have frequently missed 
clinic appointments (N=290) 
Response Frequency Percent 
Somewhat agree 5 1.7 
Neither agree nor disagree 23 7.9 
Somewhat disagree 51 17.6 
Strongly disagree 211 72.8 
Total 290 100.0 
 
As presented in Table 4.41, out of the 290 respondents, 90.4% (n=262) reported that they 
had not frequently missed clinic appointments. This may be related to the finding that most 
of the patients had convenient schedules for their medication refill and had a good 
understanding of the need for timely refill of their HIV medications. 
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Figure 4.25 Encounter of frequently missed clinic appointments and adherence to ART (N=290) 
Figure 4.25 indicates that, among the 262 participants who had frequently missed clinic 
appointments, 81.7% (n=214) reported optimal adherence and 18.3% (n=48) reported 
suboptimal adherence. And among the 28 study participants who had not frequently 
missed clinic appointments, 64.3% (n=18) and 35.7% (n=10) had optimal and suboptimal 
adherence, respectively. 
The bivariate analysis in this study revealed a significant association between frequent 
misses of clinic appointments and adherence to antiretroviral therapy (P=0.029). This 
finding is consistent with that of Watt et al (2010:385), which demonstrated that ever 
missing of clinic appointments was significantly associated with poor adherence. Similarly, 
Claudbeck et al (2009: [S.a]) also showed the association of regular clinic follow-up with 
adherence to ART. 
 
127 
 
4.3.7.4 You have never encountered problems with regard to ARV drug supply. 
 
Table 4.42 Response of study participants to whether they have encountered 
problems related to ARV drug supply (N=290) 
Response Frequency Percent 
Neither agree nor disagree 17 5.9 
Somewhat agree 64 22.1 
Strongly agree 209 72.1 
Total 290 100.0 
 
Table 4.42 depicts the response of study participants to whether they had problems with 
ARV drug supply. The research finding revealed that the majority of the respondents 
(94.2%) had not encountered problems in the refill of their medications related to ARV 
drugs. This can be explained by the provision of free antiretroviral therapy as well as the 
robust and uninterrupted ARV drug supply in the health facilities. 
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Figure 4.26 Occurrence of problems to ARV drug supply and adherence to ART (N=290) 
 
Figure 4.26 reveals that, out of the 273 participants who never had problems with ARV 
drug supply, 80.6% (n=220) had optimal adherence and 19.4% (n=53) had suboptimal 
adherence. Among the 17 participants who had problems with refills of ARV drugs, 70.6% 
(n=12) and 29.4% (n=5) reported optimal and suboptimal adherence, respectively. 
In this study, there was no statistically significant relationship between having problems 
with HIV medication refills and adherence to ART (P=0.317). 
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4.3.7.5 You are highly satisfied with the overall health care services delivered by the 
health facilities. 
 
Table 4.43 Response of study participants about satisfaction with the overall health 
care services delivered by health facilities (N=290) 
Response Frequency Percent 
Strongly disagree 2 0.7 
Somewhat disagree 1 0.3 
Neither agree nor disagree 9 3.1 
Somewhat agree 60 20.7 
Strongly agree 218 75.2 
Total 290 100.0 
 
The study participants were also asked whether they were satisfied with the overall health 
care services delivered by the health facilities. Table 4.43 indicates that 75.2% (n=218) and 
24.8% (n=60) strongly agreed and somewhat agreed to the statement. The remaining 4.2% 
(n=12) were not satisfied or were undecided about the overall health service delivery 
provided by the health facility. The majority of the study participants had a positive attitude 
towards the delivery of different health care services. 
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Figure 4.27 Satisfaction with the overall health care services delivered by health facilities and 
adherence to ART (N=290) 
 
As presented in Figure 4.27, among the 278 participants who were satisfied with the overall 
health care service provided in the facilities, 80.2% (n=223) reported optimal adherence 
and 19.8% (n=55) had suboptimal adherence. Out of the 12 participants who were not 
satisfied with the overall health care service, 75.0% (n=9) and 25.0% (n=3) reported 
optimal and suboptimal adherence, respectively. 
In this study, satisfaction with the overall health care services delivered by health facilities 
was not found to be significantly associated with adherence to ART (Fisher‟s Exact 
test=0.712). However, satisfaction with the past experience in the health care system was 
identified as an influencing factor in adherence to treatment (Machtinger & Bangsberg 
2006). 
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4.3.8 Past and current use of alcohol and drug 
4.3.8.1 Ever use of alcohol 
Table 4.44 Ever use of alcohol by the study participants (N=290) 
Response Frequency Percent 
Yes 72 24.8 
No 218 75.2 
Total 290 100.0 
 
Table 4.44 shows that, out of the 290 study participants, 75.2% (n=218) had never taken 
alcoholic beverages in their life time, while the remaining 24.8% (n=72) had had experience 
in drinking alcohol. This indicates that the majority of the participants had never engaged in 
drinking alcohol. In this study, there was no statistically significant relationship between 
ever use of alcohol and adherence to ART (P=0.118). However, Silva et al (2009:136) 
indicated past use of drugs was associated with risk of non adherence. Similarly, Sharma 
et al (2013:52) observed the association of alcohol addiction with non adherence to ART. 
 
4.3.8.2 Use of alcohol in the past one month 
Table 4.45 Use of alcohol by the study participants in the past one month (N=290) 
Response Frequency Percent 
Yes 10 3.4 
No 280 96.6 
Total 290 100.0 
 
With regard to the use of alcohol in the past one month, Table 4.45 shows that the majority 
of respondents (96.6%) did not drink alcohol in the past one month while only 3.4% (n=10) 
of them were found to have used alcohol in the past one month. 
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In this study, no statistically significant association was found between use of alcohol in the 
past one month and adherence to ART (P=0.108). In contrast, several studies documented 
the association of use of alcohol in the past one month with the risk of non adherence 
(Achappa et al 2013:22; Bonolo et al 2005:S9; Do et al 2013:5). 
 
4.3.8.3 Ever use of cigarette 
Table 4.46 Ever use of cigarette by the study participants (N=290) 
Response Frequency Percent 
Yes 46 15.9 
No 244 84.1 
Total 290 100.0 
 
Table 4.46 shows that, among the 290 participants, 84.1% (n=244) had never ever smoked 
cigarettes, while only 15.9% (n=46) had experienced cigarette smoking in their life time. In 
this study, ever use of cigarettes was not found to be significantly associated with 
adherence to ART (P=0.127). 
 
4.3.8.4 Use of cigarettes in the past one month 
Table 4.47 Use of cigarettes by the study participants in the past one month (N=290) 
Response Frequency Percent 
Yes 9 3.1 
No 281 96.9 
Total 290 100.0 
 
Table 4.47 reveals that, among 290 study participants, 96.9% (n=281) had not smoked 
cigarettes in the past one month while only 3.1% (n=9) reported smoking cigarettes in the 
past one month. 
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In this study, there was no statistically significant relationship between use of cigarettes in 
the past one month and adherence to ART (P=0.866). In contrast, Bonolo et al (2005: S9) 
demonstrated association between current smoking and non adherence. Similarly, Sharma 
et al (2013:52) observed the association of smoking habit with non adherence to ART. 
 
4.3.8.5 Ever use of ‘khat’ 
Table 4.48 Ever use of ‘khat’ by the study participants (N=290) 
Response Frequency Percent 
Yes 47 16.2 
No 243 83.8 
Total 290 100.0 
 
Table 4.48 shows that, of the 290 participants, 83.3% (n=243) had ever chewed „khat‟, 
while the remaining 16.2% (n=47) had never used the stimulant. In this study, no 
association was found between ever use of „khat‟ and adherence to antiretroviral therapy 
(P=0.3). 
4.3.8.6 Use of ‘khat’ in the past one month 
Table 4.49 Use of ‘khat’ in the past one month (N=290) 
Response Frequency Percent 
Yes 12 4.1 
No 278 95.9 
Total 290 100.0 
 
Table 4.49 depicts the use of „khat‟ by the study participants in the past one month. Out of 
the 290 participants, 95.9% (n=278) had not used „khat‟ in the past one month while only 
4.1% (n=12) of them reported to have chewed „khat‟ during the past one month. The result 
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indicates that a great proportion of participants had not been using „khat‟, which may be 
related to better level of awareness in the interaction of the drug with HIV medications and 
the impeding risk of non adherence. 
In this study, there was no statistically significant relationship demonstrated between use of 
„khat‟ in the past one month and adherence to antiretroviral therapy (P=0.768). Although 
there are a limited number of studies to compare this finding with, there are some that 
indicated the relationship between illicit drug use and poor adherence to ART. Fumaz et al 
(2008:799) indicated current substance use was associated with a lower level of 
adherence. Another study also suggested illicit drug use in the past one month was 
associated with suboptimal adherence (Do et al 2013:5). 
 
4.4 OVERVIEW OF THE RESEARCH FINDINGS 
The results of the study indicated that, among the 290 study participants, 88.3% (n=256) 
reported no missed doses of prescribed ARV pills in the past three days, resulting in a self 
report optimal dose adherence of >/= 95%. Moreover, 82.4% (n=230) reported to have 
closely followed their ARV medications to the specific schedule in the past three days and 
82.8% (n=197) reported to have followed the instructions all of the time in the past three 
days. 
In this study the overall level of combined adherence to antiretroviral therapy in the past 
three days was measured taking dose adherence, schedule adherence, and dietary 
instruction adherence into account. Thus, the combined optimal adherence rate was found 
to be 80.0%, fulfilling the optimal adherence criteria of taking >/= 95% prescribed ARV pills 
at a specified time schedule, and always conforming to the agreed dietary instructions. 
And, the non adherence rate was 20.0%.  
The most common reason mentioned by the study participants for missing their HIV 
medications in the past one month was forgetfulness (35.1%). This was followed by being 
busy with other things (17.5%), running out of pills (10.5%), feeling depressed (8.8%), and 
not wanting others to see them taking their medications (8.8%). 
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The bivariate analysis in this study found the following variables to be statistically 
associated with combined adherence to antiretroviral therapy significant at P value < 0.05: 
WHO clinical staging at initiation of ART, illness in the past one month, change of ARV 
medications, knowledge about HIV disease and antiretroviral treatment, disclosure of one‟s 
HIV status, availability of social support from friends and/or relatives, use of reminders in 
taking HIV medications, perception of patient-provider relationship, perceived 
confidentiality of health information, convenience of appointment schedules, and frequent 
missing of clinic appointments. No statistically significant association was demonstrated 
between socio-demographic variables and adherence in this study. 
In multivariate logistic model, only WHO clinical stage, change of ARV medication, 
knowledge about HIV disease and ARV medication, and use of reminders in taking HIV 
medications remained statistically significant at P value < 0.05. 
 
4.5 CONCLUSION 
This chapter presented and described the results of the study in tables and graphs. The 
data were analysed to illustrate the characteristics of the study participants using 
descriptive statistics. Associations of independent factors with adherence to antiretroviral 
therapy were analysed using inferential statistics. The results of the study revealed the 
prevalence of adherence to ART by HIV infected adults. The study explored factors which 
were significantly associated with suboptimal adherence and interpreted the results in 
relation to other studies. 
The following section, Chapter 5, presented the summary of the research findings, the 
limitations of the study, proposed recommendations, and conclusions. 
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CHAPTER 5 
CONCLUSIONS AND RECOMMENDATIONS 
5.1 INTRODUCTION   
This chapter presented the summary and interpretation of the research findings on the 
level of adherence and determinant factors affecting adherence to antiretroviral therapy in 
HIV infected adult patients. It also pointed out the contribution and limitations of the study. 
Finally, recommendations based on the research findings and the conclusions of the study 
are proposed. 
 
5.2 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS 
The research findings were summarized and interpreted in light of the research objectives. 
The objectives of the study were to: 
 describe the level of adherence of HIV infected adult patients to antiretroviral  
therapy in Addis Ababa; 
 explore the determinant factors that could affect patients‟ adherence to their 
antiretroviral therapy; 
 identify the association of socio-demographic and other patient-related factors with 
the level of adherence; and 
 recommend appropriate interventions with regard to the ways of improving 
adherence of patients based on the research findings. 
5.2.1 Adherence to antiretroviral therapy 
It is well documented that the ultimate goal of antiretroviral treatment has been a significant 
reduction in the viral load of HIV and restoration of the immune function of the body, which 
later results in an improved quality of life (Beer et al 2012:123;  Panel on antiretroviral 
guidelines... 2012:D1; Wasti et al 2012:71). However, adherence to treatment has been 
found a crucial and alterable factor that may determine whether patients get maximal 
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clinical benefit from antiretroviral therapy (Panel on antiretroviral guidelines... 2006:20; 
Matchtinger & Bangsberg 2006). 
In this study the level of adherence to a dose of 95% and more, schedule, and instruction 
to dietary requirement in the past three days were found to be 88.3%, 81.7%, and 82.8%, 
respectively. The overall combined level of adherence to all indicators resulted in 80.0%. 
There is documented evidence that a high level of adherence (> 95%) will be required to 
have sustainable viral suppression and improvement in the clinical outcomes (Beer et al 
2012:123; WHO 2006:78) and indeed a significant change in the quality of life of patients 
(Wang et al 2009:759). In comparison, the level of adherence in this study was found to be 
equivalent to the findings of other similar studies in Ethiopia, which reported overall 
adherence of 79.3% to 82.7% (Amberbir et al 2008 [S.a]; Tessema et al 2010:5). However, 
this was higher than the adherence report of 72.4% cited in Tiyou et al (2010:3-4). 
Furthermore, the findings of this study are comparable to different studies carried out in 
developing countries (Abaasa et al 2008:[S.a]; Balikuddembe et al 2012:3; Ekama et al 
2012:3) as well as developed countries (Amico et al 2011:5; Sullivan et al 2007:3). This 
shows that a significant proportion of the study participants were able to demonstrate 
higher level of adherence to their HIV medications in this particular setting as compared to 
those in many other studies. This may be explained by the fact that the majority of the 
patients understood the importance of ART and adherence to it, which is usually addressed 
during adherence counselling sessions while patients get their HIV medication refills. 
However, the adherence rate may have been overestimated due to the use of the self 
report adherence measurement. 
Although a higher level of adherence was reported in the study setting, 20% of the study 
participants were reported to have suboptimal combined adherence. Several studies 
suggested that poor adherence to HIV medications correlated with the emergence of drug 
resistance and subsequent treatment failure with increased morbidity and mortality (Beer at 
al 2012:216; Chi 2009:751-752; Enriquez & Mckinsey 2011:46; Goldman 2008:1032; 
Knobel 2009:366; San Lio et al 2008:1613; Vriesendorp et al 2007:1116). Therefore, these 
patients could be at a higher risk of developing drug resistance and treatment failure, which 
heralds the need to have a strategy that helps to address the foreseeable problems of the 
high risk patients towards better treatment follow-up and adherence. 
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Examining self report adherence to dose, schedule, and instruction may give a clearer and 
wider understanding of the overall level of adherence of patients. As it is widely claimed, 
self report adherence measure correlates with clinical outcomes and other objective 
measures. Nonetheless, it tends to result in a relatively higher adherence rate (Amico et al 
2009:69; Reda & Biadgilign 2012:1-2; Steel et al 2007: 7). The self report combined 
adherence in this study is much higher than those reported by other studies based on more 
objective measures of adherence assessment (Chi et al 2009:748; Erah & Arute 2008:146-
150; Goldman et al 2008:1032).  
 
5.2.2 Factors affecting adherence to ART  
Adherence to antiretroviral treatment has been influenced by multiple factors associated 
with the patient, disease characteristics, patient-provider relationship, and drug-related and 
clinical settings (Enriquez & Mckinsey 2011:46; Machtinger & Bangsberg 2006). This study 
examined the association of such factors with adherence to antiretroviral therapy and 
identified the independent factors that were related to suboptimal adherence and those that 
were not. The discussions below substantiated this claim. 
 
5.2.2.1 Socio-demographic factors 
The study findings suggested that socio-demographic variables such as age, sex, 
educational status, religion, ethnicity, occupation and average family income were not 
associated with adherence to antiretroviral therapy. This is in agreement with different 
studies which documented the absence of statistically significant association between 
socio-demographic variables and adherence to ART (Aragonés et al 2011:19; Birbeck et al 
2009:672; Cauldbeck et al 2009: [S.a]; Sarna et al 2008: 32). This indicates that it may be 
difficult to identify patients at risk of suboptimal adherence based on their demographic 
characteristics. However, some studies reported being female, being young, having low 
educational status, being unemployed, and having lower income to correlate with non 
adherence (Campos et al 2010:293-294; Hegazi et al 2010: 1342; Protopopescu et al 
2009: 602; Sullivan et al 2007:3; Tiyou et al 2010:4; Venkatesh et al 2010:800; Wasti et al 
2012:72). 
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5.2.2.2 Factors related to clinical condition  
The relationship between factors related to clinical condition of the study participants and 
suboptimal adherence was also examined. These factors include duration of time since 
HIV diagnosis, WHO clinical staging, baseline and current CD4 count, duration of 
antiretroviral therapy, change of ART medication, and experience of illness in the past one 
month.  
The findings indicated that WHO clinical stage was significantly associated with adherence 
to antiretroviral therapy. Patients who were asymptomatic (32.7%) at the time of ART 
initiation were more likely to be non adherent as compared to symptomatic ones (18.4%). 
In the multivariate analysis, WHO clinical stage was also found to be an independent factor 
affecting adherence to ART. This can be explained by the fact that the symptomatic 
patients were committed and eager to get better with strict use of ART as prescribed by the 
health care providers. They might also have given due attention to ongoing education and 
counselling sessions provided by health care providers about taking  HIV medications. This 
may not be the case especially for asymptomatic patients. In the study setting patients 
usually had proper adherence counselling sessions in preparation to initiate ART. Other 
studies also presented consistent findings where there was a difference in the level of 
adherence between asymptomatic and symptomatic individuals (Campos et al 2010:293; 
Tiyou et al 2010:4). In contrast, a study done by Chi et al (2009:751) emphasized that 
clinical staging did not affect adherence to ART.  
The current findings also revealed illness in the past one month was statistically associated 
with adherence to ART. Those patients who had illness in the past one month were found 
at a greater risk of suboptimal adherence than those who were healthy. Markos et al 
(2008:177) also reported that having symptoms in the past one month was associated with 
non adherence. This could be associated with unpleasant experience of symptoms of 
illness, such as nausea and vomiting, and difficulty of having proper clinic follow-up. This 
suggests that health care providers should be cautious in evaluating and treating patients 
and should provide them with close support and counselling to help them adhere to their 
treatment. Besides, patients require more psychosocial support from families and/or friends 
especially when they get sick. 
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Other variables such as duration of time since HIV diagnosis, baseline and current CD4 
count, and duration of treatment were not statistically associated with adherence in this 
study. Similar studies also documented consistent findings (Aragonés et al 2011:19; 
Fumaz et al 2008:799). 
 
5.2.2.3 Treatment-related factors 
The study participants were taking first line antiretroviral drugs in line with the national 
guideline. The study finding indicated that the type of ARV regimen, the number of ARV 
pills per day, and the frequency of dosing were not associated with adherence to 
antiretroviral therapy. There was no difference in the adherence of patients taking once- or 
twice-daily regimens, and patients taking a total of two or three ARV pills per day. Although 
there was no association established in variables related to treatment with adherence in 
this study setting, the simplicity of currently available ARV medications has contributed to 
the reduction of the number of pills and the frequency of dosing. This may indirectly 
promote the adherence of patients to their treatment. However, previous studies 
documented that higher number of pills and more frequent dosing schedules had been 
associated with non adherence to treatment. Jean-Baptiste (2008:176) indicated that 
patients taking fixed-dose combination drugs tended to be more adherent than those taking 
multiple combined ARV drugs. 
The study findings also noted that change of ARV medications was found to significantly 
affect adherence to ART. Those patients who had changed their HIV medications tended to 
report poor adherence than those who never changed their treatment. Consistent findings 
were reported by a study conducted in Brazil (Bonolo et al 2005:S9). This may be related 
to the tendency of patients to prefer their initial regimen, inadequate counselling and 
education on the changed regimen, and change in side effect profile of the changed 
regimen. 
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5.2.2.4 Psychosocial factors 
A number of psychosocial factors have been cited to be consistently associated with 
adherence including psychological distress, active drug or alcohol use, social support, and 
knowledge and beliefs about HIV and its treatment (Machtinger & Bangsberg 2006). In this 
study the association of certain psychosocial factors with adherence to ART was also 
examined.  
Disclosure of HIV status: 
Disclosure of one‟s HIV status to either a friend and/or family members was found to be 
significantly associated with adherence to HIV medications in this study. Those patients 
who did not disclose their HIV status were at higher risk of suboptimal adherence. Birbeck 
et al (2009:672) showed that disclosure of HIV status to one‟s spouse was associated with 
better adherence. This finding was supported by other similar studies which reported the 
association of fear of disclosure and social stigma with non adherence (Nozaki et al 
2011:834; Waite et al 2008:1369-70; Wasti et al 2012:75). It has been of paramount 
importance to disclose one‟s HIV status to supportive others from whom patients may get 
the necessary support to properly utilize health care services and appropriate treatment. 
This highlights the need for educating and encouraging patients to disclose their HIV status 
to supportive others as much as possible so that they can help them achieve the goal of 
their treatment. However, disclosure of one‟s HIV status may usually be difficult and 
complicated by the fear of social stigmatization and disruption in social networks. Studies 
indicated that a high level of social stigma concern by itself was found to be a significant 
independent predictor of medication non-adherence in the past four days (Waite et al 
2008:1369).  
 
Social support: 
In addition to disclosure, the importance of social support was also emphasized. In this 
study, the presence of support from friends and/or relatives in taking HIV medication was 
found to be significantly associated with adherence to ART. Consistent findings were also 
documented in other similar studies in which social support was significantly associated 
with adherence (Amberbir et al 2008: [S.a]; Aragonés et al 2011:19; Nozaki et al 2011:834;    
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Tiyou et al 2010:4). Protopopescu et al (2009:602) also reported lack of support from a 
partner was significantly associated with non adherence. This reveals that social support 
from relatives and the community has been essential to deal with not only problems of 
patients in taking their HIV medications and treatment follow-up but also addressing 
multifaceted psycho-social needs of PLHIV. As it has been discussed earlier, this may be 
directly related to disclosing their HIV status to supportive others and discussing their 
medications. Thus, health care providers have to pay closer attention to helping patients 
disclose their HIV status and getting their friends and/or relatives to collaborate with them 
as part of the team in clinical care of the patients.  
 
Use of medication reminders: 
The other finding in this study was the significant association between use of reminders in 
taking HIC medications and adherence to antiretroviral therapy. Patients who used 
reminders in taking their HIV medications were more likely to have better adherence than 
those who did not. In agreement with this study, Amberbir et al (2008: [S.a]) revealed that 
patients who claimed to use memory aids were three times more likely to be adherent than 
those who did not. This suggests that patients should be encouraged to use reminders 
regularly so that they could take their medications strictly as prescribed by their physicians. 
The need to use reminders was also supported by the finding that forgetfulness was one of 
the major reasons stated by patients for missing their ARV pills.  
 
Substance abuse: 
The association of use of substances such as alcohol, cigarette, and „khat‟ with adherence 
behaviour of patients was investigated in this study. No significant association was found 
between use of these substances in the past one month and adherence to antiretroviral 
therapy. It is reasonable to speculate that the majority of the study participants claimed not 
to have used these substances to create a positive impression. In any case, it would be 
quite important to address issues related to substance use in the ongoing counselling of 
patients as it may significantly help patients to take their HIV medications properly. 
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Knowledge about HIV disease and antiretroviral therapy: 
The current study showed that knowledge about HIV disease and antiretroviral therapy was 
significantly associated with adherence to ART. Participants who had adequate knowledge 
about different aspects related to HIV disease and its treatment, reported better adherence 
than those who did not have adequate knowledge. Although the concept of knowledge 
seems to entail wider dimension, certain variables were incorporated to give insight into the 
level of knowledge of the study participants regarding HIV disease and ART. The 
assessment addressed important information about taking HIV medications, possible side 
effects of HIV medications, benefits of antiretroviral therapy, and importance of adherence. 
Consistent findings have been documented on the influence of knowledge about the 
benefits of one‟s HIV medications and importance of adherence on adherence behaviour of 
patients (Gari et al 2013:7; Lal et al 2010:3; Markos et al 2008:176), although Sarna et al 
(2008:32) reported a contradictory finding. In view of the common finding, patients should 
be well informed about their disease and the importance of taking HIV medications properly 
as prescribed. Besides, it would be vital to provide appropriate information about the 
benefits of ART and the importance of adherence in a simplified way so that patients can 
easily understand the concepts. This is necessary to tackle any possible misconceptions 
that may arise about HIV disease and antiretroviral treatment. The health care providers 
should give emphasis to the provision of structured and relevant information to patients 
about their disease before the initiation of ART and throughout the course of their treatment 
on a regular basis. 
 
5.2.2.5 Aspects of patient-provider relationship 
The association between the perception of the study participants on aspects of patient-
provider relationship and adherence to antiretroviral therapy was examined. The majority of 
the study participants positively responded that they got appropriate information about 
taking HIV medications, that they could easily discuss their problems with health care 
providers, that health care providers understood their problems in taking their medication 
and often helped them to solve their problems, and that they were satisfied with the overall 
care and support provided by health care providers. It was found that perception on 
aspects related to patient-provider relationship was significantly associated with adherence 
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to ART. Those patients with a positive perception on items related to patient-provider 
relationship were more likely to have better adherence than those with a negative 
perception. This was supported by a study which illustrated that perceived quality of 
patient-provider relationship was associated with adherence (Watt et al 2012:384). This 
signifies that having a positive relationship with health care providers may lead to better 
adherence as patients could feel free to discuss various problems related to taking their 
medications without any fear and discomfort. Consequently, health care providers may 
develop specific measures to individual patients in addressing problems that may impact 
proper medication adherence. There is evidence that patients‟ overall satisfaction, 
willingness to involve patients in the decision making process, and positive relationship 
significantly affect adherence to HIV medications (Machtinger & Bangsberg 2006). 
 
5.2.2.6 Aspects of clinical settings 
The influence of certain aspects of clinical setting on adherence has been documented in 
some studies. Sahay et al (2011:842) stated that having negative experiences with the 
health care system may be related to unplanned treatment interruption. The current study 
suggested that the extent to which patients believe their medical secrets are kept by health 
providers, the convenience of appointment schedules, and how frequently appointments to 
clinic visits were missed were significantly associated with adherence to antiretroviral 
therapy. 
The study participants who believed health care providers kept health-related information 
of their patients confidential were more likely to have better adherence than those who did 
not. Patients seem to be sensitive to confidentiality of information about their health status, 
and sharing information recklessly may result in stigma and discrimination of patients. 
Thus, this may prevent patients from visiting clinics and taking their HIV mediations 
regularly, and they may eventually become non adherent. 
Another important finding in this study was that participants who had convenient 
appointment schedules to HIV medication refills were more adherent than those who did 
not. This finding was supported by Chalker et al (2010: [S.a]), which pointed out that 
regular attendance of patients (in the past three days of appointments) was associated with 
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adherence. This suggests that health care providers should thoroughly discuss with their 
patients before setting appropriate and convenient schedules for medication refills. Such 
patients require a suitable timing for their clinic follow-ups as they may often engage in 
various routine living activities including daily work and other emergency social events. 
This study also revealed that patients who had frequently missed clinic appointments were 
more likely to have poor adherence as compared to those who had not missed clinic 
appointments. Similarly, some other studies also corroborated the association between 
missing clinic appointments and non adherence (Cauldbeck et al 2009: [S.a]; Watt et al 
2010:385). Unless the patients appropriately follow their clinic visits for medication refills, 
they may run out of pills and this will result in non adherence. One of the reasons for 
missing clinic appointments could be having an inconvenient appointment schedule. 
Therefore, patients should get the opportunity to discuss and set their next visit with their 
health care providers. Additionally, allowing patients to play an active role in the 
management of their disease may promote their adherence to their medication. Even in 
certain circumstances where the patients face serious problems that may impede their 
clinic visit, they have to inform their health care providers in advance to make adjustments 
in their schedule and take adequate quantities of their HIV medications. Understanding 
patients as a whole should be emphasized. 
 
5.2.3 Reasons for missing ARV pills 
Patients may often give various reasons for missing their HIV medications. This study 
revealed that forgetfulness (35.1%), being busy with other things (17.5%), and running out 
of pills (10.5%) were the most common reasons for patients to miss their ARV pills in the 
past one month. Consistent with this finding, a number of studies also mentioned the above 
reasons for missing one‟s ARV pills (Jean-Baptiste 2008:16; Markos et al 2008:176; 
Sullivan et al 2007:3; Tiyou et al 2010:4; Wang et al 2009:759; Wasti et al 2012:73-75; 
Watt et al 2010:384). It might be of importance to look into the influence of being busy with 
various activities and forgetfulness on proper adherence to treatment. This would 
emphasize the need for regular utilization of reminders by the patients to support optimal 
adherence to antiretroviral therapy. This also goes hand in hand with the earlier finding that 
reminders were an independent factor associated with adherence. On the other hand, 
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running out of pills may be interconnected with inconvenience of appointment schedules 
and missing clinic appointments. Thus, having an agreed upon and convenient 
appointment schedule may lessen the chance of missing clinic appointments and running 
out of pills.  
 
5.3 CONCLUSIONS 
Generally, the level of adherence reported in this study was 80%, which is relatively high 
and supports the existing evidence that patients in resource-constrained settings could 
achieve better adherence. But, it also highlights the need to give attention to adherence of 
patients as 20% of the study participants reported suboptimal adherence. A number of 
factors that could affect adherence were analysed. Some of these factors, including WHO 
clinical stage, change of medication, and experience of illness in the past one month were 
associated with adherence of patients to ART. The other important factors related to 
optimal adherence include knowledge about HIV disease and antiretroviral therapy, 
disclosure of one‟s HIV status, social support, and use of reminders. Besides, perception of 
patient-provider relationship and clinical setting aspects such as perception on 
confidentiality of information, convenience with appointment schedules, and missing clinic 
appointments were found to be significantly associated with adherence to antiretroviral 
therapy. Forgetfulness, being busy with other things, and running out of medication pills 
were identified as the most common reasons for the patients to miss their HIV medications. 
Thus, appropriate recommendations are made in the subsequent section to address such 
multiple barriers across different dimensions. 
 
5.4 RECOMMENDATIONS 
This study has come up with important findings on the level of adherence and identified 
factors affecting adherence of adult HIV infected patients to their antiretroviral therapy in 
Addis Ababa. Based on the findings of the study, the following recommendations have 
been made: 
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 Patients should have convenient clinic appointment schedules jointly set by the 
patient and health care providers so that they can get the necessary clinical 
evaluation and timely refills of their HIV medications. It would even be valuable to 
set up electronic-based appointment systems to better facilitate the follow-up of 
patients and to contact those patients who missed their clinic appointments as early 
as possible. 
 Patients should be encouraged to disclose their HIV status at least to someone very 
close to them who would provide support not only in taking medication but also in 
other psychosocial needs of people living with HIV.  
 While health care providers usually counsel and educate their patients before ART 
initiation and later on, special emphasis should be given to those patients who are 
asymptomatic, those who are sick while taking ART, and those who have changed 
their HIV regimen. To this effect, ongoing follow-up, intensive counselling, and 
support should be arranged to help them take their HIV medications properly. 
 Health care providers should enhance their interpersonal interaction with their 
patients to appropriately deliver messages about the HIV disease and HIV 
medications, to build a trusting relationship and encourage patients to ask questions 
about their treatment and discuss challenges of taking ARV medications. This would 
give insights to the health care providers to develop a patient-specific follow-up and 
support to address issues affecting adherence. This should be supported by the 
preparation and dissemination of simplified IEC materials to the patients. 
 The role of media spot messages about the HIV disease, antiretroviral therapy, the 
need for adherence should be intensified. This would give an opportunity to educate 
not only PLHIV but also the community at large, which may also help to reduce the 
possibility of stigma and discrimination. 
 Peer education and adherence support group programmes should be further 
encouraged to help patients learn from one another about their life experiences, 
about breaking barriers of taking medications, and about dealing with common 
problems for treatment follow-up and adherence. Thus, adequate support from 
different levels of the health system would be required. 
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 Patients should be encouraged to use reminders as much as possible starting from 
their initiation to ART. Although it is possible to use various reminders including 
watches and the radio, in recent times applying innovative ways such as MEMS and 
mobile phone technologies (SMS text messages) in the study setting could be 
supportive to improve adherence of patients to ART as well as the ART program. 
 The health care providers should regularly counsel and educate patients before 
initiation and during the course of antiretroviral therapy. The counselling sessions 
should emphasize on the nature of the HIV disease, characteristics of HIV 
medication, benefits of ART, the importance of adherence, the goal of the treatment, 
and the risks of non adherence to antiretroviral therapy. Patients should be 
encouraged to forward questions related to their health condition and HIV 
medications. However, this needs a concerted effort among the multidisciplinary 
team, including adherence counsellors. 
 The management of the health facilities and health care providers should focus on 
maintaining confidentiality of patient-related information as much as possible. This 
should be supported with a code of conduct to help protect the rights of patients and 
promote optimal adherence to treatment. 
 Further research should be conducted focusing on psycho-social issues including 
anxiety and depression among PLHIV. The association of adherence with clinical 
outcomes such as CD4 and viral load parameters as well as other factors should be 
explored using in-depth qualitative methods in various settings. It would also be 
necessary to carry out country-wide adherence studies, preferably with combined 
objective measures of adherence, to better understand the problem and develop 
effective adherence improvement strategies. 
 
5.5 CONTRIBUTIONS OF THE STUDY 
Adherence to antiretroviral medications has been complex and multidimensional in nature. 
This study has documented valuable findings about the prevalence of adherence among 
HIV infected adult patients and factors that affect adherence of patients to antiretroviral 
treatment in Addis Ababa. This study explored amenable factors that may influence 
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adherence behaviour of patients on antiretroviral therapy in resource-limited setting. This is 
of importance in the design and development of targeted interventions to improve 
adherence of patients to achieve better clinical outcomes. It also pointed out important 
areas on which health care providers need to focus in their routine clinical practice to 
identify patients that are at risk of adherence early and provide them with appropriate 
counselling and educational support.  It also provides some important information to policy 
makers, facility managers, and other partners in the development of ART and adherence-
related policies and strategies. Thus, it can assist in drawing feasible and innovative 
adherence interventions and in achieving optimal adherence in the context of resource-
constraint settings. Finally, it may also lay out a platform for other individuals who will be 
interested to work on various scientific endeavours in the field of HIV/AIDS treatment and 
adherence in the future. 
 
5.6 LIMITATIONS OF THE STUDY 
This study was carried out in the face of some limitations. The research findings should be 
interpreted taking the following limitations into consideration.  
 This study was conducted in only two health facilities in Addis Ababa city. This 
means the study findings cannot be generalized to other parts of the country. Thus, 
larger representative health facilities across the country should be involved to get a 
general picture of adherence prevalence in the country. 
 The adherence of patients in this study was assessed with a self report method. 
Since there is no goal standard adherence measurement, self report has been a 
valid measure of adherence. However, self report measure has widely been known 
for its subjectivity and for overestimating adherence of patients. Besides, self report 
measure of adherence has been subjected to recall bias and social desirability bias. 
 Another limitation which may reinforce social desirability bias is the fact that the 
study was conducted in health facility settings where patients may tend to provide 
positive responses on their adherence behaviour, patient-provider interaction, and 
aspects of clinic settings. 
150 
 
 While a cross-sectional study design was used to carry out this study, it was not 
possible to look into the dynamicity of the level of adherence across a period of time. 
It has been repeatedly mentioned that adherence has been a dynamic process and 
patients‟ adherence behaviour may change over time. 
 
5.7 CONCLUDING REMARKS 
The level of adherence in the study setting was found to be 80.0%, which is higher than the 
findings reported in other studies in many other countries. The patients that reported to be 
non adherent should receive greater support with targeted adherence interventions. 
Adherence behaviour has been a challenging and complex phenomenon. It is dynamic by 
its nature and adherence behaviour of patients may vary overtime. This requires periodic 
evaluation of adherence of patients in order to develop appropriate adherence 
interventions in resource-limited settings. In several studies including this one, adherence 
was measured by a self report method due to its low cost and ease of administration. 
However, the tendency to overestimate adherence may obscure the actual circumstances 
in routine clinical practices. Thus, use of more objective measures, preferably in 
combination, has emerged as a better way of measuring adherence (Sahay et al 
2011:837). 
There have been multidimensional factors which may influence adherence behaviour of 
patients which could vary in different settings. Certain important factors affecting 
adherence of patients have been explored and identified in this study so that appropriate 
actions could be taken to resolve adherence problems. 
Eventually, in order to better understand the nature of adherence and its associated 
factors, more quantitative and qualitative studies should be carried out in the context of 
resource-limited settings. 
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Annexure E: Informed consent form 
The purpose of this study will be to explore the level of adherence to antiretroviral therapy 
and its determinant factors among HIV infected adult patients. The study will benefit the 
participants from the recommendations that may result in improving adherence 
interventions based on the result. There will not be significant risks associated with 
participation in the study except minimal physical or psychological stress. Ethical approval 
has been obtained from the institutional review board of health studies department in 
UNISA and Addis Ababa regional health bureau. Permission to conduct the study was 
obtained from the health institution. 
Participants were selected just by chance from computer based data and data will be 
collected by interviewing using a questionnaire. It will take you 20-30 minutes to complete 
the interview. You are allowed to ask questions at any time about the study. Your 
participation in the study will be voluntary; there is no obligation to participate. You have full 
right to withdraw from the study at any time if you feel uncomfortable or stressed. 
The study data will be coded and it will not be linked to your names. The information you 
provide will be kept very confidential and it will not be shared to anyone without your 
permission. 
I have understood this consent form and voluntarily consent to participate in the study. 
 
Date: ____________________________           
 
 Participant‟s signature: ___________________________ 
 
Interviewer‟s signature: ___________________________ 
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Annexure G: Questionnaire 
We would like to appreciate your willingness to participate in the study. The purpose of the 
study will be to explore the level of adherence to antiretroviral therapy and its determinant 
factors among HIV infected adult patients. You are kindly requested to provide genuine 
responses to the questions listed below. We need you to understand that all your 
responses are valuable and will be kept confidential. We need to have your patience as it 
will just take you about 20-30 minutes to respond to the questionnaire. Please do not 
hesitate to ask any question that may not unclear. 
1. Demographic variables: 
1.1. Age (in years):____________ 
1.2. Sex:  1= M                  2= F 
1.3. Marital status: 
1=Never married          2=Married           3=Divorced              4=Widowed               
5=Separated 
1.4. Literacy status: 
1=Illiterate                  2=Read and write      3=Grade 1-8          4=Grade 9-12         
5=Tertiary (12+) 
1.5. Occupation: 
1=Unemployed       2=Government employee    3=Student          4=Housewife      5=driver             
6=Merchant            7= Others, specify _______________ 
1.6. Religion: 
1=Orthodox             2=Protestant       3=Muslim     4=Catholic    5=others, specify ________ 
1.7. Ethnicity: 
              1=Amhara        2=Oromo       3=Tigre         4=SNNPR      5=Others, specify _____ 
1.8. Average family monthly income:_________________________ 
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2. Information regarding the clinical condition of the patient 
2.1. How long has it been since you are diagnosed with HIV infection? __________ 
2.2. What was the clinical stage of the patient at the time of ART initiation? 
          1                       2                        3                         4      5= Unknown 
2.3. What was the baseline CD4 count at the time of ART initiation? 
         1= <200 c/mm3             2= 200 – 350c/mm3        3= >350c/mm3     4= Unknown 
2.4. What is the latest CD4 count after at least 6 months of treatment? 
         1= <200 c/mm3                    2= 200 – 350c/mm3      3= >350c/mm3    4=Unknown 
2.5. How long have you been started on antiretroviral treatment? 
         1= 3 – 6 months    3= 7-12 months   4= 1-2 years    5= > 2 years 
2.6. Were you sick in the past one month?         1=Yes         2=No    
2.7. If yes, how serious was your illness?           1= Mild        2=Moderate     3=Severe 
3. Questions related to the type of current ARV regimen and level of adherence 
3.1. The type of current ARV regimen and frequency 
Name of ARV regimen No. of pills each time 
Morning Evening 
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3.2. The next section of the questionnaire asks about the ARV medications that the patient 
may have missed taking over the last three days. IF HE/SHE TOOK ONLY A PORTION 
OF A DOSE ON ONE OR MORE OF THESE DAYS, PLEASE REPORT THE DOSE(S) AS 
BEING MISSED. 
Names of your ARV 
medications 
HOW MANY DOSES DID YOU MISS . . .? 
Yesterday 2 days ago 3 days ago 
 _____doses _____doses _____doses 
 _____doses ______doses _____doses 
 _____doses ______doses _____doses 
 
3.3. ARV medications need to be taken on a schedule, such as “2 times a day” or “3 times 
a day” or “once a day.” How closely did you follow your specific schedule over the last 
three days? 
1=Never      2=Some of the time     3=About half of the time    3= Most of the time         
4= All of the time 
3.4. Does any of your ARV medication have special instructions from a clinician, such as 
“take with food” or “on an empty stomach” or “with plenty of fluids?”  
  1=Yes •                                             2=No                  
    If „‟no‟‟ please skip to Qn. 3.6. 
3.5 How often did you follow those special instructions over the last four days? 
    1=Never         2=Some of the time          3=about half of the time       4= Most of the time  
    5=All of the time  
3.6. Did you miss taking any of your ART medications in the past 7 days?   1= Yes     2=No 
3.7. Did you miss taking your ART medications in the past one month?       1=Yes    2=No 
3.8. Has your HIV medication been changed?                1=Yes                          2=No 
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3.9. People may miss taking their medications for various reasons. What were your 
reasons for missing any of your ART medications within the past month? (It is possible to 
give more than one response.) 
    1=being away from home 
    2=being busy with other things 
    3=simply forgot 
    4=having too many pills to take 
    5=wanted to avoid side effects 
    6=do not want others to notice taking medication 
    7=a change in daily routine 
    8=felt like the drug was harmful 
    9=felt sick or ill 
  10=felt depressed 
  11=ran out of pills 
  12=felt good 
  13=lack of transportation 
  14=shortage of food 
  15=others, specify ____________________________________ 
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4. Knowledge about HIV disease and antiretroviral therapy 
Questions Strongly 
disagree 
Somew
hat 
disagre
e 
Neither 
agree nor 
disagree 
Some
what 
agree 
Strongly 
agree 
4.1. You know how each of your current HIV 
medications is supposed to be taken. 
     
4.2. You know what to do if you miss a dose 
of any of your HIV medications. 
     
4.3. Skipping a few of your HIV medications 
from time to time would not really hurt your 
health.  
     
4.4. You know what the possible side effects 
of each of your HIV medications are.  
     
4.5. As long as you are feeling healthy, 
missing your HIV medications from time to 
time is OK. 
     
4.6. You understand how your HIV 
medications work in your body to fight HIV.  
     
4.7. If you don‟t take your HIV medications 
as prescribed, these kinds of medications 
may not work for you in the future.  
     
4.8 Antiretroviral medications eradicate HIV 
from your body. 
     
4.9. You believe that if you take your HIV 
medications as prescribed, you will live 
longer.  
     
4.10. You know how your HIV medications 
interact with substances such as alcohol and 
„khat‟.  
     
 
5. The following questions ask about your social support. 
5.1. Have you disclosed your HIV status to your friends &/or family members?  
1=Yes     2=No 
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5.2. Do you have a family/friend that supports taking your medications?  
1= Yes             2=No 
 If „‟no‟‟, please skip to question no. 5.5 & 5.6. 
5.4. How satisfied are you with the support you get from your friends and/or family 
members? 
  1=very dissatisfied   2=somewhat dissatisfied    3=neither dissatisfied or satisfied 
4=somewhat satisfied   5=very satisfied 
5.3. How often do your friends and/or family members help you remember to take your 
medication?             
  1=Never                   2=Sometimes                     3=Most of the time                      4=Always 
5.5. Do you use any method to remind taking your ARV medication? 1=Yes             2= No 
6. Perception on patient provider relationship 
Questions Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
6.1. The health care providers give 
you appropriate information about 
taking your medications. 
     
6.2. It is easy for you to discuss 
problems related to your medication 
with the health care providers. 
     
6.3. The health care providers 
understand the problems you may 
have taking your ARV medications. 
     
6.4. The health care providers often 
help you in solving the problems 
you may have taking medications. 
     
6.5. You are satisfied with the 
overall support you get from the 
health care providers. 
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7. Clinical setting 
Questions Strongly 
disagree 
Somewhat 
disagree 
Neither 
agree nor 
disagree 
Somewhat 
agree 
Strongly 
agree 
7.1. You believe that health care 
providers keep your health related 
information confidential. 
     
7.2. You are convenient with the 
scheduling appointments to your 
medication refill. 
     
7.3 You have encountered frequent 
missed clinic appointments. 
     
7.4 You have never got a problem 
to your medication refill related to 
ARV drug supply. 
     
7.5 You are well satisfied with the 
overall health care services 
delivered by the health facility. 
     
 
8. People have various health habits. The following questions ask about your alcohol 
and drug use, past and current. 
8.1. Have you ever had a drink containing alcohol?               1= Yes                       2= No 
    If yes, have you had a drink within the past 1 month?       1= Yes                        2= No 
8.2. Have you ever smoked cigarette?                                   1= Yes                       2= No 
    If yes, have you smoked within the past 1 month?             1= Yes                      2= No 
8.3. Have you ever chewed „khat‟?                                         1= Yes                       2= No 
   If yes, have you chewed it within the past 1 month?            1=Yes                       2= No 
 
   ---------------------------------- THANK YOU! ------------------------------- 
 
